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IN THE 3’ END MATURATION OF 28S RIBOSOMAL RNA

Stefanie Gerstberger, Ph.D.
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Posttranscriptional gene regulation (PTGR) concerns all processes acting directly upon coding
and non-coding RNAs, regulating and executing their maturation, ribonucleoprotein assembly,
transport, stability and translation. RNA-binding proteins (RBPs) and ribonucleoprotein (RNP)
complexes coordinate these processes. RBPs are central to cellular metabolism and their role in
human diseases has been widely studied. Recent large-scale quantitative methods such as nextgeneration sequencing and modern protein mass spectrometry enabled new approaches to dissect
PTGR networks and renewed interest in investigations of factors involved in PTGR at a genomewide level. A census of all coding and noncoding RBPs has previously not been readily available
and the number of RBPs was estimated based on few selected protein classes. However, for
system-wide analyses of PTGR a comprehensive account of the RBPs is necessary. To address
this need, I developed a census of 1,542 manually curated RBPs and categorized their interactions
with different classes of RNA, defined the number of factors in different regulatory pathways,
and investigated their evolutionary patterns, abundance, and tissue-specific expression. Coregulated gene expression during developmental processes often gives novel insights into
regulatory pathways and components. Furthermore, I showed that by classifying RBPs into their
main regulatory RNA pathways we can start to understand the disease phenotypes of proteins
involved in the same RNA metabolic pathways. These insights are useful for dissecting

dysregulated PTGR pathways in human diseases and finding new therapeutic targets. Finally, I
showed in this chapter that by careful domain analysis, novel RBPs can be predicted and
characterized the previously unknown RG/GG-rich RBP FAM98A. Overall, this analysis
provides a critical step towards the comprehensive characterization of proteins involved in human
RNA metabolism.
In the second part of the thesis I focused on the uncharacterized, highly tissue-specific
RNA exonuclease NEF-sp and characterized its function in pre-28S ribosomal RNA processing.
Ribosomal RNA biogenesis requires a series of endo- and exonucleolytic processing steps for the
production of mature rRNAs. Although the mechanism of 28S 3’ end rRNA maturation remains
largely unknown in higher eukaryotes, it is thought that the 3’ external transcribed spacer (3’ETS)
of the large 47S rRNA precursor, containing 18S, 5.8S, and 28S rRNA, is removed in a precise
endonucleolytic cleavage reaction, guided by U8 snoRNA. Here I show instead that the 3’ETS is
exonucleolytically trimmed by the DEDDh RNA exonuclease NEF-sp in Drosophila
melanogaster. I characterize for the first time in higher eukaryotes a nuclease that is involved in
the removal of the 3’ ETS. Interestingly, NEF-sp shows high tissue-specific expression in gonads.
Gonad development is arrested in dNEF-sp mutants. Our results demonstrate that exonucleolytic
trimming is essential for 28S rRNA maturation in higher eukaryotes and, counterintuitively, the
expression of a factor involved in a core RNA metabolic process can be highly regulated. Our
findings suggest an additional level of posttranscriptional gene regulation in the maturation of
28S rRNA, mediated by the regulated expression of RNA exonucleases.
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1 Introduction
1.1

Principles of posttranscriptional gene regulation

RNA is an essential constituent of all living organisms and central to decoding the genetic
information of every cell. Posttranscriptional gene regulation (PTGR) is a term that refers to the
cellular processes that control gene expression at the level of RNA; it encompasses RNA
maturation, modification, transport, and degradation. Each of these events is regulated by the
formation of different ribonucleoprotein (RNP) complexes with RNA-binding proteins (RBPs) at
their core. Consequently, every RNA molecule independent of its ultimate function is at some
level subject to PTGR (Figure 1.1).
Initially, it was thought that RNA mainly served either as the template in the form of
messenger RNA (mRNA) or as an adaptor or structural component during protein synthesis
provided by transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs). With the discovery of
catalytic RNAs and a multitude of non-coding RNA (ncRNA) species it was recognized that
RNA is a highly versatile molecule carrying out many regulatory functions in the cell, either by
acting as a guide to recognize RNA sequence motifs or RNA recognition elements (RREs)
present in their target RNAs, or by functioning as a scaffold and assembly platform for recruiting
proteins to act synergistically (Cech and Steitz, 2014).
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Figure 1.1 Overview of the main PTGR pathways in eukaryotes. Overview of biogenesis,
decay and function of the most abundant RNAs: rRNAs, tRNAs, mRNAs, snRNAs, snoRNAs,
miRNAs, piRNAs, and lncRNAs. Processes are described from left to right in the diagram. (a)
tRNAs are transcribed by Pol III, 5’ leader and 3’ trailer sequences removed, introns spliced and
end-joined. CCA nucleotides are added to 3’ ends and nucleotide modifications introduced before
tRNA aminoacylation (Maraia and Lamichhane, 2011). (b) 5S rRNA is transcribed by Pol III,
while 28S, 18S, and 5.8S rRNAs are transcribed as one transcript by Pol I. The precursor is
processed by RNA exo- and endonucleases and RNP RNase MRP, guided by U3 snoRNP.
Nucleotide modifications are introduced by snoRNPs. rRNAs are assembled together with
ribosomal proteins into ribosomal precursor complexes in the nucleus and transported to the
cytoplasm, where they mature to functional ribosomes (Granneman and Baserga, 2004;
Lafontaine and Tollervey, 2001; Thomson et al., 2013). (c) Most small nuclear RNAs (snRNAs)
are transcribed by Pol II, capped and processed in the nucleus. Exported to the cytoplasm they
undergo methylation and assemble with LSM proteins to snRNP particles aided by the SMN
complex. Re-imported into the nucleus into the Cajal Body (CB) they undergo final maturation
and snRNP assembly (Kiss, 2004). U6 and U6atac snRNAs are transcribed by Pol III and
alternatively processed in the nucleus/nucleolus (Mroczek and Dziembowski, 2013). Mature
snRNPs form the core of the spliceosome. (d) Small nucleoloar and small cajal body-specific
RNAs (snoRNAs and scaRNAs) are processed from mRNA introns, capped, and modified before
they assemble into snoRNPs/scaRNPs in the CB. snoRNPs/scaRNPs carry out methylations and
pseudouridylations in rRNAs and snRNA or function in rRNA processing (e.g. U3 snoRNA)
(Kiss, 2004). (e) mRNAs are transcribed by Pol II, capped, spliced, edited, and polyadenylated in
the nucleus. Correctly matured mRNAs are exported into the cytoplasm. Regulatory RBPs control
correct translation, monitor stability, decay and localization, and shuttle mRNAs between active
translation, stress granules and P bodies (Buchan and Parker, 2009; Dreyfuss et al., 2002;
Glisovic et al., 2008; Jackson et al., 2010; Müller-McNicoll and Neugebauer, 2013; Parker and
Sheth, 2007). (f) microRNAs (miRNAs) are transcribed from separate genes by Pol II as long primiRNA transcripts, or alternatively, are expressed from mRNA introns (mirtrons), and processed
into hairpin pre-miRNAs in the nucleus. After transport into the cytoplasm, they are processed
into 21-nt double-stranded RNAs. One strand is incorporated into AGO-proteins (miRNPs) and
guides them to partially complementary target mRNAs to recruit deadenylases and repress
translation (Kim et al., 2009). (g) piwi-interacting RNAs (piRNAs) are ~28 nt long, germlinespecific small RNAs. Primary piRNAs are directly processed and assembled from long, Pol IItranscribed precursor transcripts, while secondary piRNAs are generated in the ping-pong cycle
by the cleavage of complementary transcripts by PIWI proteins. Mature piRNAs are 2’-Omethylated and incorporated into PIWI-proteins. The piRNA-PIWI complexes (piRNPs) silence
transposable elements (TEs) either by endonucleolytic cleavage in the cytoplasm or through
transcriptional silencing at their genomic loci in the nucleus (Siomi et al., 2011). (h) Most long
noncoding RNAs (lncRNAs) are transcribed and processed similarly to mRNAs. Nuclear
lncRNAs play an active role in gene regulation by directing proteins to specific gene loci, where
they recruit chromatin modification complexes and induce transcriptional silencing/activation
(Ulitsky and Bartel, 2013). Other ncRNAs, e.g. 7SK RNA, regulate transcription elongation rates
(Peterlin et al., 2011) or induce formation of paraspeckles (PS) (Fox and Lamond, 2010).
Cytoplasmic ncRNAs can modulate mRNA translation (Yoon et al., 2012). (i) Incorrectly
processed RNAs are recognized by a number of complexes in the nucleus and cytoplasm that
initiate and execute their degradation (Doma and Parker, 2007; Houseley et al., 2006).

2

3

Recent advances in RNA sequencing technologies have facilitated the discovery of novel
transcripts and we will soon know the precise composition of most cellular transcriptomes. While
functional annotation for many RNAs is still in progress, the major classes of RNAs have now
been described. The most abundant RNAs, constituting 90% of cellular RNAs by copy number,
are shared by all organisms and required for protein synthesis: rRNAs, tRNAs and mRNAs. The
remaining 10% are noncoding RNAs (ncRNAs) that mainly serve as guides or molecular
scaffolds in a variety of processes including RNA splicing, RNA modification, and RNA
silencing. The structure, length and composition of these RNAs and their RNPs is distinct and
allows their integration into diverse functions (Table 1.1).
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Table 1.1 Classes of RNAs, their sizes and functions. Functional description of the main RNA
classes in humans and their length distribution. Additional reviews on biogenesis pathways and
RBP components interacting with each class of RNA are referenced.
RNA class
messenger RNA
(mRNA)
transfer RNA
(tRNA)
ribosomal RNA
(rRNA)
small nuclear
RNA (snRNA)
small nucleolar
RNA (snoRNA)
and small Cajalbody-specific
RNA (scaRNA)
microRNA
(miRNA) and
small interfering
RNA (siRNA)
piwi-interacting
RNA (piRNA)

Size (nt)
~200100,000
~70-95

long intervening
noncoding RNA
(lncRNA), 7SK
RNA
RNase P and
RNase MRP

>200

Y RNA

~ 80-110

signal recognition
particle RNA
(7SL/SRP RNA)
Vault-associated
RNA (vtRNA)

~300

telomerase RNA
(telRNA)

~500

~1205070
~150
50-450

Biological role (additional reviews on function and biogenesis)
Encode the information for protein coding genes, translated by ribosomes (Dreyfuss et al., 2002;
Glisovic et al., 2008; Müller-McNicoll and Neugebauer, 2013)
RNA adaptor molecules, transport amino acids to ribosome and recognize specific triplet
codons on mRNA (Maraia and Lamichhane, 2011; Simos and Hurt, 1999; Suzuki et al., 2011)
Structural component of ribosomes (Boisvert et al., 2007; Ciganda and Williams, 2011;
Granneman and Baserga, 2004; Woolford and Baserga, 2013)
snRNAs U1, U2, U,4, U5 , U6, U12, U4atac, U6atac are core components of the spliceosome;
U7 snRNA functions in 3’ end maturation of histone RNAs (Kiss, 2004; Matera et al., 2007)
Guide chemical modifications (methylation and pseudouridylation) of rRNAs, snRNAs and
snoRNAs (Filipowicz and Pogacić, 2002; Kiss et al., 2006; Matera et al., 2007)

21-22

Associate with AGO proteins, guide them to target sequences predominantly in the 3’UTRs of
mRNAs; induce degradation and translational repression (Bartel, 2009; Kim et al., 2009)

~28-32

Associate with PIWI proteins, induce transposon silencing in the germline by guiding PIWI
RNP complexes to genomic loci in the nucleus and transposon RNAs in the cytoplasm, leading
to epigenetic silencing and ribonucleolytic cleavage of transposon RNA (Kim et al., 2009;
Siomi et al., 2011)
Recruit chromatin modifiers and remodeling complexes, modulate transcription by recruitment
of protein cofactors to transcription starts sites and enhancers, function as molecular scaffolds
for nuclear RBPs (Batista and Chang, 2013; Ulitsky and Bartel, 2013); 7SK RNA regulates
transcription elongation (Peterlin et al., 2011)
Ribonucleolytic RNP complexes that carry out processing of precursor tRNAs, rRNAs,
snRNAs, and other noncoding RNAs; RNase P is an RNA-based enzyme, RNase MRP a
protein-based ribonuclease (Ellis and Brown, 2009; Esakova and Krasilnikov, 2010; Jarrous,
2002; Xiao et al., 2002)
Small noncoding RNAs that form an RNP complex with TROVE2 (Ro60) protein and act as
RNA-chaperones, have a role in DNA replication and immune response (Hall et al., 2013; Köhn
et al., 2013)
RNA of the signal recognition particle, which recognizes signal sequences of newly synthesized
peptides and targets them to the endoplasmatic reticulum (Akopian et al., 2013)

~260340

~80-140

Small noncoding RNAs, which are part of the vault RNP complex, thought to be involved in
drug resistance and to downregulate mRNA targets through posttranscriptional gene silencing
(Berger et al., 2008)
RNA component of the telomerase complex TERC, which acts as reverse transcriptase and
elongates telomer repeats. TERC is structurally related to box H/ACA snoRNAs (Egan and
Collins, 2012)
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RBPs execute PTGR, hence the characterization of the proteins transiently or stably
interacting with RNAs is a prerequisite for the dissection of RNA regulatory processes. In many
cases RBPs form a stable complex with an obligate RNA component, named ribonucleoprotein
complex (RNP), which is the basic regulatory unit (e.g. snRNPs, snoRNPs, RNase P, ribosome
subunits). However, many other types of RNAs, particularly mRNAs and tRNAs, only transiently
associate with RBPs, whose functions are necessary for their proper maturation, localization, and
turnover (Dreyfuss et al., 2002; Granneman and Baserga, 2004; Müller-McNicoll and
Neugebauer, 2013; Phizicky and Hopper, 2010). Most mRNA-binding proteins (mRBPs) regulate
thousands of targets, thus the proper assembly and function of RNA-protein complexes is critical
for the maintenance of cellular metabolism in all cells and organisms. For a large fraction of
RBPs, we are only starting to understand the complexity of their basic molecular roles, modes of
recognition and global targets.

1.2

Aim of this thesis

In the present thesis I focused first on the system-wide analysis of RNA metabolism and second,
resulting from this analysis, I characterized the function of the putative 3’-5’ RNA exonuclease
NEF-sp in Drosophila melanogaster. First, I set out to create a foundation for the system-wide
study of PTGR factors. I developed a comprehensive census of human RBPs that regulate all
coding and noncoding RNAs, and demonstrated its utility to gain insights into patterns in PTGR
and to discover novel regulatory roles of RBPs. I created this catalog of RBPs based on structural
domain annotations and experimental evidence and defined the number of proteins in different
RNA regulatory pathways. I investigated their evolutionary conservation, protein families, and
expression across adult tissues using published RNA-seq and microarray gene expression data. I
further analyzed the co-expression of RBPs, finding common and unique trends in regulatory
RNA pathways. Lastly, I used this categorization to summarize phenotypic commonalities
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encountered for diseases caused by mutations in RBPs involved in the same RNA regulatory
pathways. From the computational analyses of RBDs and RNA-binding low complexity repeats, I
discovered a novel RBP, FAM98A and characterized its binding sites by PAR-CLIP
(Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation).
Furthermore, from the curated RBP census I discovered a highly tissue-specific 3’-5’
RNA exonuclease NEF-sp (LOC81691). Using a combination of genetic, biochemical and RNAsequencing experiments, I characterized the function of the Drosophila melanogaster homolog
dNEF-sp (CG8368) and discovered its role in ribosomal RNA biogenesis in Drosophila
melanogaster. The findings give unprecedented insights into the 3’ end maturation of 28S rRNA
in higher eukaryotes.
Together, the presented work developed a foundation for the system-wide analysis of PTGR
factors in humans and its conserved homologs in other species, and elucidated mechanistic details
of the 3’ end maturation of 28S rRNA in higher eukaryotes.
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2 A census of human RNA binding proteins

2.1
2.1.1

Introduction
Experimental and bioinformatic approaches towards a census of RBPs

PTGR is essential to cellular metabolism, coordinating maturation, transport, stability and
degradation of all classes of RNAs. Mechanistically, each of these events is regulated by the
formation of different RNP complexes with RBPs at their core. Among the first ribonucleoprotein
complexes discovered was the ribosome in the 1950s (Darnell 2011; Steitz, 2008). Early
biochemical studies on heteronuclear RNPs (hnRNPs) found that specific structural domains
within proteins conferred direct and specific RNA-binding, which led to the definition of the first
conserved, canonical RNA-binding domain (RBD) in RBPs (Burd and Dreyfuss, 1994). Different
strategies were initially employed towards the identification of RBPs. Early approaches for the
isolation of RBPs used gel electrophoresis of UV-crosslinked nuclear extracts, RNA pulldown or
conventional chromatography to recover associated RBPs from cell lysates, followed by their
mass spectrometric identification or immunodetection (Ascano et al., 2013; Dreyfuss et al., 1984;
Pinol-Roma et al., 1988). To distinguish direct RNA-protein interactions from proteins
associating with assembled RNPs UV-crosslinking became a refined method to isolate RNAprotein complexes during harsher purification steps, allowing the reduction of protein-proteinmediated background binders (Ascano et al., 2013). Alternatively, in vitro assays of
recombinantly expressed candidate proteins were performed to interrogate RNA-binding
properties. These allowed the quantitative assessment of binding preferences to specific RNA
targets in vitro.
The definition of RBDs in proteins was facilitated by the growing amount of experimental and
structural data, as well as the completion of sequenced genomes from all kingdoms of life, which
allowed sequence alignments of multiple, related proteins and computational RBD predictions
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across organisms based on sequence information (Finn et al., 2010; Haft et al., 2001; Letunic et
al., 2009; Marchler-Bauer et al., 2013; Murzin et al., 1995; Tatusov et al., 2000; Wilson et al.,
2009). These algorithms used Hidden Markov probabilistic models (HMM) that determine the
likelihood of a specific amino acid sequence based on multiple sequence alignments. HMMs
enable the detection of structural domains in uncharacterized protein sequences across organisms
based on probability calculations of observed states of amino acid sequences, assuming an
unobserved (hidden) state of a defined archetype structural domain sequence. At least 600
structural domains have been defined in RNA-related processes on Pfam by now (Finn et al.,
2010). Early counts of RBPs used predictions selecting a small number of single-stranded-RNAbinding domains (ssRBDs, e.g. KH, RRM, PUF, S1, Table 5.1), often named canonical RBDs.
These arrived at ~500 RBPs in human and mouse (Cook et al., 2011; Galante et al., 2009; McKee
et al., 2005), ~300 in D. melanogaster (Gamberi et al., 2006; Lasko, 2000), and ~250-500 in C.
elegans (Lasko, 2000; Lee and Schedl, 2006; Tamburino et al., 2013). An estimated ~700 RBPs
in humans was reached when including additional RBDs involved in other aspects of RNA
metabolism (Anantharaman et al., 2002). These approaches suggested a complex regulatory
network controlled by RBPs and recognized that a census of RBPs was a prerequisite for the
interpretation of synergistic and competitive action of RBPs on their targets.
Other approaches to obtain an estimate of the proteins involved in PTGR are automated
functional annotations, including the Gene Ontology (GO) project (Ashburner et al., 2000) and
the Kyoto Encyclopedia of Genes and Genomes database (KEGG) (Kanehisa and Goto, 2000),
which integrate literature reports, database entries, and structural features. Using GO annotation,
we arrived at ~1,900 human RBPs. While these gene groups are useful for gene set pathway
analyses, they are not designed to establish a census of RBPs, as they include falsely assigned
proteins due to inferred participation in biological processes or exclude valid proteins due to
absence of annotation.
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High-throughout experimental methods to determine the number of RBPs in different
organisms, such as RBP-immunoprecipitation (RIP) coupled with cDNA array hybridization of
recovered RNA (Tenenbaum et al., 2000), or SELEX-based (Systematic Evolution of Ligands by
Exponential Enrichment) RNA ligand selections (Stoltenburg et al., 2007), enabled researchers to
gain more global insights into specific RNA targets and RBP/RNPs preferential binding, but they
were still limited to a few hundred targets. Protein microarrays allowed increased throughput for
probing RNA-binding capabilities of a fraction of the proteome in vitro, using RNA probes of
defined sequence (Scherrer et al., 2010; Siprashvili et al., 2012; Tsvetanova et al., 2010). The
recent development of large-scale quantitative methods, especially next-generation sequencing
and modern protein mass spectrometry (Ascano et al., 2012a; Gerstberger et al., 2013; Konig et
al., 2011; Mann, 2006; Wang et al., 2009), now facilitates genome-wide identification of RBPs,
their protein cofactors, and RNA targets at an unprecedented scale. In addition, deep sequencing
approaches utilizing immunoprecipitation of RBPs, with or without in vivo RNA-protein
crosslinking (CLIP- and RIP-seq, respectively) (Ascano et al., 2012a; Konig et al., 2011), as well
as in vitro evolution methods (Ray et al., 2013; Stoltenburg et al., 2007), revealed binding spectra
of RBPs and showed that a large proportion of RBPs binds to thousands of transcripts in cells at
defined binding sites.
In an effort to experimentally validate RBPs across proteomes, four recent studies
employed a combination of in vivo UV RNA-protein crosslinking followed by poly(A) RNA
pulldown and protein mass spectrometry. These characterized the mRNA-binding proteome in
HEK293 and HeLa human cell lines, mouse embryonic stem cells, and yeast (Ascano et al., 2013;
Baltz et al., 2012; Castello et al., 2012; Kwon et al., 2013; Mitchell et al., 2013). The approach
identified ~800 mRNA-binding proteins (mRBPs) in human HEK293 and HeLa cell lines,
respectively (Baltz et al., 2012; Castello et al., 2012), 555 in mouse embryonic stem cells
(mESCs) (Kwon et al., 2013), and 200 mRBPs in yeast (Mitchell et al., 2013). A total of ~1100
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putative mRBPs were identified in the human and mouse datasets, ~600 of them were found in all
three of them (Figure 2.1). A significant portion of these (64%) overlapped with known GOclassified RBPs (Figure 2.1).

Figure 2.1 Results from different cataloging efforts for defining RBPs. (A) Venn diagram
showing the overlap of proteins with RNA-related Gene Ontology (GO) categories (Ashburner et
al., 2000) (orange), the human RNA-binding proteome identified by RNA-crosslinking and mass
spectrometry studies (MS RBP proteome, green) (Baltz et al., 2012; Castello et al., 2012; Kwon
et al., 2013), and the RBPDB database of human RBPs with canonical RBDs (Cook et al., 2011)
(red). (B) Venn diagram showing the overlaps of GO RBPs (orange), MS RBP proteome (green),
and the curated RBP list presented here based on domain analysis of RBDs and experimental
evidence of RNA-binding found in the literature (violet). (C) Composition of RBPs in the curated
census: Canonical-RBD RBPs (containing canonical RBDs (Cook et al., 2011; Lunde et al.,
2007), red) (Table 5.1), ribosomal proteins (bright violet), other RBPs (dark violet).
Many of the residual mRBP candidates did not contain previously described RBDs and
require further experimental validation, while other known and expressed RBPs were missed due
to the sensitivity of the experiments. However, in comparison to earlier predictive counts of the
number of mRBPs using only canonical RBDs (Cook et al., 2011) (Figure 2.1, Table 5.1), this
approach expanded the mRBP proteome from an estimated 400 to ~1,100 putative,
experimentally derived candidates. With increasing sensitivity, approaches like these may
represent the most suitable method to experimentally identify novel RBPs in proteome-wide
experiments in different cell types. Comparative large-scale studies isolating the many ncRNAbinding proteins have not been undertaken yet, reflecting the predominant focus in PTGR
centering around mRBPs. However, PTGR is not limited to mRNA regulation and a predominant
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part comprises processes acting on ncRNAs. In this respect, it may not be surprising that among
the ~150 RBPs listed in the Online Mendelian Inheritance (OMIM) (Hamosh et al., 2005) linked
to human diseases, only a third are described as binding mRNAs, while others target diverse
ncRNAs.
In summary, bioinformatic and experimental methods advanced enough to allow the
investigation of RBPs at a systems-wide level, but perhaps due to the complexity of RNA
metabolism, PTGR research is often focused on selected pathways and ignored that the
fundamental RNA regulatory processes are tightly interconnected. As a consequence, at the onset
of this project we did not have a clear understanding of the identity and number of all genes
involved in PTGR. To address this need, I synthesized the available knowledge of PTGR factors
through computational analyses to arrive at a curated census of the 1,542 proteins involved in
RNA metabolism (Figure 2.1 B-C). The work presents an important step towards the
comprehensive characterization of PTGR and the results of the analysis are presented here.
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2.2
2.2.1

Computational methods
Selection of RNA-binding proteins and transcription factors

To define the total number of RBPs in humans, the complete set of protein sequences of the
human proteome (105,237 isoforms) in Ensembl database (release v75) was searched for the
presence of protein domains defined by Pfam A (Pfam HMM profiles, release v27) (Finn et al.,
2010) using the domain-search algorithm hmmer3.0 (Eddy, 1998). We decided to set a
confidence cut-off at e-value <0.01 for protein domain annotations. Next, I selected 799 Pfam
domains (see Table 5.2) that were described to be involved in RNA-related processes (either
directly RNA-binding/ processing or typically found in RNP complexes) and filtered out all
protein isoforms that contained the selected RNA-binding domains (RBDs) (Figure 2.2).

Figure 2.2 Diagram for generating a curated list of human RBPs. 80,000 protein-coding
mRNA isoforms as curated by Ensembl were searched with defined HMM models for 799 RNAbinding domains (Table 5.2). The candidates were merged and compared with mass-spectrometry
data from RNA-protein crosslinking experiments and Gene Ontology annotations. The resulting
candidate genes were manually curated to arrive at a final census of 1,542 RBPs. The RBPs were
further analyzed for their evolutionary conservation, families, tissue specificity, and expression
trends across developmental stages.
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For the final gene list I took one representative protein isoform per gene, selecting either
the isoform with the highest number of RBDs or, in cases of an equal number of RBDs per gene
in each isoforms, the longest isoform was selected. This procedure resulted in 2,103 putative
RBPs. In a second filtering step I removed zinc finger proteins of the KRAB-, SCAN, and BTB
domain classes, which are exclusively found in DNA-binding proteins. I manually inspected the
residual 1,962 proteins using information available on NCBI’s Entrez Gene and publication
records to further remove proteins, which were unlikely to be involved in RNA metabolism based
on their literature reports, homolog and paralog annotation, or presented pseudogenes and gene
duplications. Finally, I manually added RBPs based on literature reports of the proteins or their
orthologs, if they were missed by domain annotation, refined the selection of RBDs, and added
known RBPs, which lacked a Pfam-defined structural protein domain. This resulted in a final
census of 1,542 proteins (Figure 2.2, Table 5.3).
I compared structural conservation of RBPs with the other main gene regulatory group,
transcription factors (TFs). For this comparison, I downloaded the curated TF dataset from
Vaquerizas et al. (Vaquerizas et al., 2009) and matched the gene names and IDs to the current
Ensembl v75 release, removing non-protein-coding genes and archived gene IDs. Of the 1,987
listed genes we could trace 1,874 genes. Duplicated genes were only listed once and genes, which
were also present in our curated RBP list (such as e.g. ZFP36 protein family), were removed and
classified as TF misannotations and predominant RBPs. The final list of TFs contains 1,704
proteins (see Table 5.5).

2.2.2

Expression analysis across 16 tissues

I used RNA-seq data from the human body map generated by Illumina, which comprised single
and paired-end sequencing reads from poly(A)-selected RNA, isolated from 16 adult human
tissues (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513/). I aligned the raw reads
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with tophat2 and cufflinks2 against the human genome (hg19) using default parameters (Kim et
al., 2013a; Trapnell et al., 2010). With a minimum expression threshold of rpkm=1 log2(rpkm)
expression values were calculated for RBPs, TFs, and the remaining protein-coding genes across
the 16 tissues. For the cumulative abundance analysis of RBPs and TFs, I added rpkm values for
both groups in each tissue. For the subdivision of mRBPs and ribosomal proteins I used the
manually curated annotation categories (see next section). Downstream analysis was performed in
R using ggplot2.

2.2.3

Categorization of RNA targets for RBPs

I manually inspected the list of 1,542 RBPs and defined categories for RNA targets based on
literature reports as ribosomal proteins, diverse targets, mRNA-, tRNA-, rRNA-, snoRNA-,
snRNA-, and ncRNA-binding. Proteins with reported RNA-binding properties but unknown
natural targets, were grouped into an unknown targets category. All other noncoding RNAs were
grouped together in the ncRNA-binding category, including miRNAs, piRNAs, 7SK, lncRNAs,
MRP RNA and RNase P, 7SL, vtRNAs, Y RNAs, viral RNAs and telomerase RNA. RBPs
binding DNA/RNA hybrids were categorized into the diverse category, together with RNA
nucleases and RNA exosome components. Proteins that are part of RNP complexes, but may not
bind RNA directly, were assigned to their main RNA pathways, e.g. candidates involved in
splicing or translation processes were classified as mRBPs.

2.2.4

RBP family definition, targets, and conservation analysis

I used Ensembl Compara (Vilella et al., 2009) to retrieve paralog information for the current
Ensembl v75 proteome and grouped protein families based on an average of 20% sequence
identity of the query and target percentage identities. I hand-curated cases where family
relationships were not well defined and overlapped. I furthermore removed pseudogenes, read15

through transcripts, cDNA clones, and open reading frames (ORFs), which had no protein-coding
entry on NCBI’s Entrez Gene. Using this approach, I defined 1,111 RBP families and 554 TF
families. Target categories for RBP families were defined by manually inspecting the annotation
categories of the individual members in each family and then assigning the common target group
per family based on the most frequently found target group in the family.
For the conservation analysis of paralogous protein families, the number of homologs and
average homologies to human were queried through the Ensembl Compara database, which
defined sequence identities and evolutionary relationships of proteins across organisms. The
identity scores were retrieved for RBPs and TFs from 10 selected species (macaque, mouse, rat,
Xenopus, zebrafish, zebrafinch, chicken, fruitfly, C. elegans, and S. cerevisiae). The average
homology for protein families was determined based on sequence identities in three subsequent
steps. First, for each homolog the average identity between the target and query score was
calculated. Next, if one gene had more than one homolog in the queried species, the geometric
average of the identity scores was taken to arrive at a final average homolog conservation score
per gene. Third, per family I took the geometric averages of the average identity scores calculated
for each individual member to give an average homology score per protein family. I grouped
families into 4 different conservation categories with average identity scores of 0-20%, 20-30%,
40-60%, 60-75%, and 75-100%. The average conservation of each RNA target group was
determined for RBP families conserved in S. cerevisiae.

2.2.5

Tissue specificity analysis of RBPs and RBP families

To assess tissue specificity of RBPs and TFs across human tissues, I used a microarray tissue
atlas by Dezso et al. (Dezso et al., 2008) that profiled expression of 16,867 genes across 31
human tissues using the ABI Human Genome Survey Microarray platform version 2. I directly
used the processed data deposited on GEO for further analysis, selecting per gene, if more than
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one probe was present, the probe with the highest reported minimum intensity value. I defined a
tissue specificity score S that assesses the deviation from a uniform distribution as information
content. S measures, analogous to the definition of sequence logos in information theory, the
difference between the logarithm of the total number of tissues and the Shannon entropy of the
expression values for a gene.
𝑆 = 𝐻!"# − 𝐻!"# = 𝑙𝑜𝑔! 𝑁 − (−
where the relative frequency 𝑝! =

!!
!
!!! !!

!
!!!

[𝑝! ×𝑙𝑜𝑔! 𝑝! ])

;

𝑥! is the microarray expression level for gene in tissue i, 𝐻!"# = maximum possible entropy,
𝐻!"# = observed entropy, N is the number of tissues, in this case 31. The scale of the tissue
specificity score S depends on the number of tissues, in the current dataset the maximum S (Hmax)
is reached when 𝑆 = 𝑙𝑜𝑔! 31 = 4.95. The plots show the maximum expression value per gene
against its tissue specificity score S. Assessing tissue specificities of RBP families, I examined
scores of the profiled genes per family and defined four categories of expression profiles for RBP
families. In the first category I defined tissue-specific protein families, in which all members had
tissue specificity scores S≥1. This score was set based on the tissue specificity scores of known
tissue-specific RBPs, such as the PIWI proteins exclusively expressed in the germline. In the
second category, I defined families with tissue-specific members, in which not all, but at least one
member had a tissue specificity score S≥1. For the third category I binned gradient RBP families,
if all their members had tissue specificity scores between 0.3>S>1. In the final category of
ubiquitous families, I grouped all protein families with tissue specificity scores for all their
members S<0.3.
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2.2.6

Expression analysis of RBPs across developmental stages

For analyzing the variation of expression of RBPs during human fetal ovarian development, I
used a microarray study by Houmard et al. (Houmard et al., 2009), which profiled expression of
17,508 genes during different gestational weeks using the Affymetrix Human Genome U133 Plus
2.0 Array platform. The publically available processed data was used for further analysis,
selecting, if more than one probe per gene was present, the probe with the highest minimum
expression value across the profiled stages. The geometric average for biological replicates of
developmental stages was computed. Tissue specificity scores were calculated as described above
across the developmental stages. 1,461 of the 1,542 RBPs profiled in this dataset could be
extracted and selected the top 200 RBPs with highest scores S, i.e. which showed the highest
deviation from a uniform distribution across the developmental stages, were selected for the
representation of differentially expressed RBPs. In order to display dynamics of expression on a
comparable, scale I further normalized the microarray intensity values for each gene to fold
changes over the mean intensities across the profiled stages (Fold change =

!!
!
!!! !!

× 1 𝑁 , where xi

= microarray intensity for stage i, N = number of stages). Heat maps show unsupervised
clustering of the log2(fold change over mean) expression values.
For the analysis of RBP expression in brain, I downloaded the publically available,
processed RNA-sequencing data for human brain development from the brainspan atlas
(http://www.brainspan.org) and selected 12 stages of hippocampus development as model for
assessing RBP expression changes during neural development. Geometric average for biological
replicates of the developmental stages were computed. To calculate tissue-specificity scores, a
pseudo counts of 0.1 was added to each rpkm value and tissue specificity scores calculated as
described above. A minimum expression cut-off of the sum of rpkm values across the
developmental stages was set to

!
!!!(𝑥! )

≥ 12, where N = total number of profiled stages, and xi

= rpkm value in stage i. 1,402 RBPs were above this threshold. The top 200 RBPs with highest
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tissue specificity scores S were selected for the heat map analysis. Rpkm values were further
transformed to fold changes over the mean by dividing the rpkm values over the mean rpkm
across the developmental stages. This allowed comparison of expression changes of different
genes at a similar scale (𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =

!!
!
!!! !!

∗ 1/𝑁, where xi = rpkm for stages i, N = number

of stages). Unsupervised clustering of the log2(fold change over mean) was used for the heat map
representation. Pearson correlation and heat maps were generated using the gplots package in R.

2.2.7

Analysis of PAR-CLIP Libraries

FAM98A PAR-CLIP reads were adapter extracted, clipped with length of at least 20 nts and
mapped to the hg19 human genome with Bowtie 0.12.9 (Langmead et al., 2009) (Bowtie
parameters “-v 1 -m 10 --all --best –strata”), allowing for one mismatch in read alignments and up
to 10 multimatches in the genome. Processing and annotation of clusters to the ENCODE
GRCh38 genome annotation was performed using the PARalyzer software as described in
Corcoran

et

al.

(Corcoran

et

al.,

2011)(http://www.genome.duke.edu/labs/ohler/research/PARalyzer/). Downstream analysis was
performed in R. Shuffling of protein-coding ORFs was performed using the shuffling algorithm
in the HMMER-3.0 suite using dinucleotide shuffling to preserve the dinucleotide composition
(Eddy, 1998).

2.2.8

Analysis of FAM98A RNA-sequencing data

Illumina HiSeq 2000 100-base-pair (bp) single-end sequence reads were aligned to the reference
genome (GRCh38/ hg19) using TopHat version 2.0.5 (Kim et al., 2013a) in default settings. Gene
expression was estimated using the Ensembl GRCh38 gene model and the Cufflinks software
version 2.0.2 (Trapnell et al., 2012b). Downstream cumulative distribution and statistical analyses
were performed in R.
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2.3
2.3.1

Experimental methods
Cell lines and plasmids

pENTR4-FAM98A was generated by restriction enzyme digest with SalI and NotI according to
standard cloning procedures. The resulting pENTR4 vector was subsequently recombined into the
pFRT/TO/FLAG/HA-DEST destination vectors using Gateway LR recombinase according to
manufacturer’s protocol (Invitrogen). Primers for FAM98A cDNA amplification were designed
containing

the

BP

recognition

overhangs:

FAM98A-forward:

5’-

ACGCGTCGACATGGAGTGTGACCTCATGGAG; FAM98A-reverse: 5’- ATAGTTTAGCGGCCGCTCAACTAGTGTAATGTCTTCCCTG. Cell lines were established according to the
manufacturer’s protocol for generating stable cell lines using the FlpIn system (Invitrogen).
50,000 cells/ml HEK293T FlpIn cells were seeded in a 12-well plate in antibiotic-free DMEM
(Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Life Technologies) supplemented
with 10% heat inactivated fetal bovine serum (Thermo Scientific), 2 mM L-Glutamine, 100 U/ml
penicillin, 100 U/ml streptomycin). 0.1 µg pFRT/TO/FLAG/HA-FAM98A-DEST destination
vector was co-transfected with 0.9 µg pOG44 plasmid containing the Flp recombinase enzyme
and 2 µl Lipofectamine 2000 in 50 µl Opti-MEM according to the manufacturer’s instructions
(Invitrogen). After 24 hrs Flp-In T-REx HEK293 cells expressing doxycycline-inducible
FLAG/HA-tagged FAM98A were supplemented with a hygromycin and blasticidin selection
medium (Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Life Technologies)
supplemented with 10% heat inactivated fetal bovine serum (Thermo Scientific), 2 mM LGlutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 100 µg/ml hygromycin, 15 µg/ml
blasticidin). Colonies selected were after a few days, tested for inducible FLAG/HA-FAM98A
expression by Western blot analysis, and cell line stocks were flash frozen in liquid nitrogen with
50% DMSO and stored at -196°C in liquid nitrogen. Stable cell lines were generally maintained
in cell culture in DMEM supplemented with 10% heat inactivated fetal bovine serum (Thermo
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Scientific), 2 mM L-Glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 100 µg/ml
hygromycin, 15 µg/ml blasticidin. Parental HEK293FlpIn-TRex cells were maintained in DMEM
supplemented with 10% FBS, 2 mM L-Glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin, 15 mg/ml blasticidin, and 100 mg/ml zeocin.

2.3.2

RNA isolation and cDNA preparation

Total RNA was isolated with TRIzol following the manufacturer’s protocol. First strand cDNA
was synthesized from 5 µg total RNA using oligo(dT) priming and the Superscript III First Strand
synthesis kit following the manufacturer’s instructions (Invitrogen).

2.3.3

RNA phenol/chloroform isolation and ethanol precipitation

One volume of phenol/chloroform/isoamyl alcohol (25:24:1, phenol buffered at pH 4.3) was
added to one volume of an RNA solution and vortexed vigorously for 15 sec. The phases were
separated by centrifugation at 12,000 g at 4°C for 2 min. The upper aqueous layer was removed
to a new tube and re-extracted with an equal volume of ice-cold chloroform. The mixture was
vortexed for 15 sec and the phases were separated by centrifugation, 12,000 g at 4°C for 2 min.
The upper aqueous layer was removed and added to a new tube, and the salt concentration
adjusted to a final of 0.3 M NaCl. 3 volumes of 100% EtOH were added to the solution, mixed
thoroughly, and stored at -20°C for 10 min (long RNAs) or 1 hr/overnight (short RNAs). RNA
was precipitated by centrifugation at 12,000 g at 4°C for 30 min. The supernatant was removed
and the pellet dissolved in 10-50 µl water.

2.3.4
For

Radiolabeling of oligo size markers
5’

end

radiolabeling,

100

pmoles

of

RNA

size

markers

(19

nt:

5’

pCGUACGCGGGUUUAAACGA; 35 nt: 5’ pCUCAUCUUGGUCGUACGCGGAAUAGUUU
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AAACUGU) was incubated with 5 pmoles of γ-32P ATP and 10 units of T4 PNK (NEB) in 1 x T4
PNK buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl2, 5 mM DTT) in a 20 µl reaction for 15 min
at 37°C; followed by addition of 1,000 pmoles of non-radiolabelled ATP for another 5 min. The
reaction was stopped by 1 volume of stop buffer (8 M urea, 10 mM EDTA, bromophenol).
Labeled oligoribonucleotides were separated on an 18% polyacrylamide/ 8M urea gel at 28 W for
1 hr; the gel was exposed on a phosphorimaging screen, and gel pieces with the labeled oligomers
excised. The RNA was eluted from the excised gel pieces with 3x the gel volume of 0.3 M NaCl
solution overnight at 4°C, ethanol precipitated and the RNA pellet collected by centrifugation at
>12,000g for 30 min at 4°C as described above.

2.3.5

PAR-CLIP

PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation)
was performed as previously described in Hafner et al. (Hafner et al., 2010a; 2010b). Expression
of FLAG/HA-tagged FAM98A in stable FAM98A HEK293 cell lines was induced by addition of
doxycycline (1 µg/ml) 16 hrs prior to harvesting.
4-SU incorporation and in vivo crosslinking:
FAM98A expressing cells were incubated with 100 µM 4-thiouridine (4SU) nucleoside analog
for 16 hrs, the medium decanted and the cells irradiated on ice with a dose of 0.15 J/cm2 of at 365
nm UV light in a Spectrolinker XL-1500 (Spectronics Corporation) equipped with 365 nm light
bulbs or similar device. Cells were collected, frozen in liquid nitrogen, and stored at -80°C.
FAM98A cell pellets were lysed in 3x the volume of the cell pellet in NP-40 lysis buffer [50 mM
HEPES-KOH pH 7.2, 150 mM KCl, 0.5% (v/v) NP-40, 0.5 mM DTT, complete EDTA-free
protease inhibitor cocktail (Roche)]. The lysate was incubated 30 min on ice and cleared by
centrifugation at 12,000 g for 30 min at 4°C. The cleared supernatant was filtered through a 5 µm
membrane syringe filter (Pall).
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RNase T1 digest: In the first RNase T1 digest cell lysates were incubated with RNase T1
(Fermentas) at a final concentration of 1 U/µl at 22°C for 15 min and cooled on ice before
proceeding. 50 µl magnetic Dynabeads Protein G coupled (Invitrogen) were used per 5 ml cell
pellet. Magnetic beads were washed 3x in 1 ml PBS-Tween 20 0.1% (PBS-T) and incubated with
25 µl anti FLAG mouse monoclonal antibody (M2, 1 mg/ml, Sigma) in 200 µl PBS-T on a
rotating wheel for 1 hr at room temperature.
Immunoprecipitation: Antibody-conjugated beads were washed 2x with PBS-T, resuspended in
200 µl lysis buffer and added to the lysate. Beads were incubated in the cell lysates on a rotating
wheel for 1 hr at 4°C. After immunoprecipitation, magnetic beads were collected in a magnetic
particle collector and washed 3x in 1 ml IP wash buffer [50 mM HEPES-KOH pH 7.5, 300 mM
KCl, 0.05% (v/v) NP-40, 0.5 mM DTT, complete EDTA-free protease inhibitor cocktail
(Roche)].
2nd RNase T1 digest: In a second RNase T1 digest beads were resuspended in one bead volume
IP wash buffer and incubated with RNase T1 to a final concentration of 100 U/µl for 15 min at
22°C.
Dephosphorylation: Prior to dephosphorylation of protein-bound RNA fragments, the magnetic
beads were washed 3x in 1 ml high salt wash buffer [50 mM HEPES-KOH pH 7.5, 500 mM KCl,
0.05% (v/v) NP-40, 0.5 mM DTT, complete EDTA-free protease inhibitor cocktail (Roche)], and
resuspended in 1 bead volume dephosphorylation buffer (NEB buffer #3, 50 mM Tris-HCl pH
7.9, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT). Calf intestinal alkaline phosphatase (CIP) (10
U/µl, NEB) was added to a final concentration of 0.5 U/µl, and the suspension incubated for 10
min at 37ºC. Beads were washed 2x in 1 ml phosphatase wash buffer (50 mM Tris-HCl, pH 7.5,
20 mM EGTA, 0.5% (v/v) NP-40), and 2x in 1 ml T4 polynucleotide kinase (PNK) buffer
without DTT (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM MgCl2).
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Phosphorylation with radioactive γ -32P-ATP: For radiolabeling of protein-bound RNA
segments beads were resuspended in one bead volume of PNK buffer with DTT (50 mM TrisHCl, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 5 mM DTT). Radioactive γ-32P-ATP (0.01 mCi/µl)
was added to a final concentration of 0.5 µCi/µl (1.6 µM ATP) and the reaction incubated with
T4 PNK (10 U/µl) added to a final concentration of 1 U/µl. The suspension was incubated at
37°C for 30 min. Non-radioactive ATP was added to a final concentration of 100 µM and the
reaction incubated for another 5 min at 37ºC.
SDS-PAGE separation and electro-elution: Beads were washed 5x with 1 ml PNK buffer
without DTT, resuspended in 70 µl of 4x SDS-PAGE loading dye (10% glycerol (v/v), 50 mM
Tris-HCl pH 6.8, 2 mM EDTA, 2% SDS (w/v), 100 mM DTT, 0.1% bromophenol blue) and
incubated at 90°C for 5 min. The supernatant was separated by SDS-PAGE, loaded onto a Novex
Bis-Tris 4-12% polyacrylamide gel (Nupage, Invitrogen), and the gel run at 200 V for 45 min in
1x Nupage MOPS running buffer according to the manufacturer’s instructions (Invitrogen). The
gel was exposed for 1 hr on a phosphorimaging screen and a band excised at the correct protein
size. The excised gel pieces were transferred into a dialyzer tube (Novagen) and the residual
volume filled with 800 µl 1x SDS running buffer (25 mM Tris base pH 8.3, 0.192 M glycine,
0.01% SDS). The RNA-protein complex was electro-eluted from the gel in SDS running buffer at
100 V for 1 hr.
Proteinase K digest: The electro-eluted supernatant was transferred to a new tube and mixed with
2x Proteinase K buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 12.5 mM EDTA, 2% (w/v)
SDS), followed by addition of Proteinase K (Roche) to a final concentration of 1.2 mg/ml and the
reaction incubated for 30 min at 55°C. The reaction mix was phenol-chloroform extracted,
ethanol precipitated (to aid precipitation 1 µl glycogen was added), and the RNA redissolved in
10 µl water.
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3’adapter ligation: RNA was incubated with 2 µl of 10x RNA ligase buffer without ATP [0.5 M
Tris-HCl, pH 7.6, 0.1 M MgCl2, 0.1 M 2-mercaptoethanol, 1 mg/ml acetylated BSA (Sigma)], 6
µl 50%

DMSO

and 1 µl of 100 µM

adenylated

RNA

3’adapter 21.930 (5’-

AppTCGTATGCCGTCTTCTGCTTGT), heat denatured at 90°C for 1 min and placed on ice. As
ligation control 40 fmol of 1:100 dilution of 5'-32P-labeled RNA size markers were prepared in a
separate reaction. 1 µl of truncated T4 RNA ligase Rnl2 (1-249)K227Q ligase (1 µg/µl, plasmid
for recombinant expression available from addgene.org) was added per reaction and incubated on
ice at 4°C overnight. The reaction was stopped by addition of 20 µl 2x formamide stop mix
(98.8% deionized formamide, 1% (v/v) 0.5 M EDTA pH 8.0, 0.2% Bromophenol blue),
denatured at 90°C for 1 min, and loaded onto a 18% polyacrylamide/8M urea gel. The RNA was
separated by electrophoresis in 1x TBE buffer (0.045 M Tris base, 0.045 M boric acid, 0.001 M
Na2EDTA) at 28 W for 45 min. The gel was exposed on a phosphorimaging screen for 1 hr and
gel bands of the 3’ ligation product excised in the size range of the ligated size marker control.
The RNA was eluted from the gel with 400 µl 0.3 M NaCl at 4°C overnight, ethanol precipitated
with 3 volumes, the pellet collected by centrifugation at 12,000 g and resuspended in 9 µl water.
5’adapter

ligation:

1

µl

of

100

µM

RNA

5'

adapter

26.68

(5’-

GUUCAGAGUUCUACAGUCCGACGAUC), 2 µl of 10x RNA ligase buffer with ATP (0.5 M
Tris-HCl pH 7.6, 0.1 M MgCl2, 0.1 M 2-mercaptoethanol, 1 mg/ml acetylated BSA, 2 mM ATP)
and 6 µl 50% aqueous DMSO were added to the RNA and the mixture denatured at 90°C for 1
min. The reaction was immediately placed on ice for 2 min, followed by addition of 2 µl T4 RNA
ligase Rnl1 (Fermentas) and incubated at 37°C for 1 hr. The ligation reaction was stopped by
addition of 20 µl formamide stop mix, heat inactivated at 90°C for 1 min, and separated on a 15%
polyacrylamide/ 8M urea gel in 1x TBE running buffer at 28 W for 45 min. The gel was exposed
on a phosphorimage screen for 1 hr and gel bands excised at the correct size range of the 5’
ligated product (assessed by the control ligation of size marker). RNA was eluted from the gel
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with 400 µl 0.3 M NaCl solution overnight at 4°C. To facilitate the recovery of the ligation
product 1 µl of 100 µM 3' primer 21.929 (5’-CAAGCAGAAGACGGCATACGA) was added
during the elution as carrier. The mixture was ethanol precipitated and re-dissolved in 5.6 µl
water.
Reverse transcription: The RNA ligation product was denatured for 30 sec at 90°C and
transferred to 50°C. cDNA reaction mix was prepared as following: 1.5 µl 0.1 M DTT, 3 µl 5x
first-strand synthesis buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2), 4.2 µl 10x
dNTPs (2 mM dATP, 2 mM dCTP, 2 mM dGTP, 2 mM dTTP) and the mix added to the RNA.
The reaction was incubated for 3 min at 65°C before addition of 0.75 µl Superscript III reverse
transcriptase (Invitrogen) and the reaction was incubated for 2 hrs at 50°C. The cDNA product
was diluted with 85 µl water and stored at -20°C.
PCR amplification of cDNA library: The PCR reaction mix was prepared per sample as
following: 40 µl of the 10x PCR buffer (100 mM Tris-HCl pH 8.0, 500 mM KCl, 1% Triton-X100, 20 mM MgCl2, 10 mM 2-mercaptoethanol), 40 µl 10x dNTPs, 2 µl of 100 µM 5’ primer
44.32 (5’- AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA), 2 µl of
100 µM 3’ primer 21.929, 272 µl H2O. 89 µl of PCR reaction mix was used for a pilot PCR while
the remaining reaction mix was kept for 3 large scale PCRs. 10 µl cDNA product, 1 µl Taq
polymerase (5 U/µl) and 89 µl reaction mix were added to a final volume of 100 µl. PCR
amplification was carried out under following cycle conditions: 45 sec at 94°C denaturation, 85
sec at 50°C annealing, 60 sec at 72°C extension. Aliquots were taken every second cycle between
12-28 cycles, mixed with 5x DNA loading dye (0.2% bromophenol blue, 0.2% xylene cyanol FF,
50mM EDTA pH 8, 20% Ficoll type 400) and analyzed on a 2.5% agarose gel for 1.5-2 hrs at 180
V. An expected length of about 95-110 nts and a lower band at 65 nts corresponding to the direct
3'adapter-5'adapter ligation product were separated. The optimal cycle number was obtained by
choosing the cycle number 5 cycles away from the saturation level of the PCR amplification.
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Large scale PCRs at the optimal cycle were performed, the PCR product was directly ethanol
precipitated, the DNA pellet dissolved in 60 µl of 5x DNA loading dye, and separated on a 2.5%
agarose gel for 1.5-2 hrs at 180 V. The upper band corresponding to the cDNA library product
was excised from the gel and eluted using the QiaQuick gel extraction kit according to the
manufacturer’s instructions (Qiagen). The DNA was eluted in 30 µl water and 10 µl submitted for
HiSeq sequencing.

2.3.6

siRNA-mediated knockdown

siRNAs with oligo U overhangs were chemically synthesized in the laboratory by C. Bognanni.
The

siRNAs

were

designed

using

the

algorithms

from

Dharmacon

siDESIGN

(http://dharmacon.gelifesciences.com/design-center/) and the Whitehead siRNA design center
(http://sirna.wi.mit.edu/home.php) and were antisense to the ORF of FAM98A. Sequences of the
sense strands of the three different siRNAs were the following: FAM98A siRNA#1: 5’GCUAAGAGCCAGACAGAAAUU;

FAM98A

siRNA#2:

5’-GGAGAAAGCU-

GCUAAUAAAUU; FAM98A siRNA#3: 5’-GGGAAAAGAUAGAAGCAAUUU. dsRNA
duplexes were annealed in 10 mM Tris pH 7.5, 20 mM NaCl with a final siRNA concentration of
20 µM by heating them for 1 min at 95°C and letting them cool down overnight at room
temperature. For siRNA-mediated knockdown 2.5x10^5 Flp-In T-REx HEK293 cells/well were
seeded in 6-well plates in DMEM antibiotic-free medium (DMEM supplemented with 10% FBS,
2 mM L-Glutamine, 100 U/ml penicillin, 100 U/ml streptomycin) and transfected with a 3.3 nM
final concentration for each dsRNA duplex using Lipofectamine RNAiMAX following the
manufacturer’s instructions (Invitrogen). All siRNAs were pooled to a final dsRNA concentration
of 10 nM (3.3 nM per siRNA duplex) and transfected together to obtain efficient knockdown with
reduced off-target effects. Cells were harvested 72 hrs post-transfection and the knockdown
efficiency was evaluated on the protein level by Western blot analysis.
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2.3.7

RNA-sequencing

Total RNA from knockdown and overexpression experiments performed in biological duplicates
was used as input for poly(A) purification and cDNA library construction using the TruSeq
version 1.5 kit (Illumina). cDNA was barcoded using the Illumina Multiplexing Sample
Preparation Oligonucleotide kit and sequenced on an Illumina HiSeq 2000 sequencer in a 100base-pair (bp) single-end sequencing run.

2.3.8

Western blot analysis

Cells were lysed in NP-40 lysis buffer [50 mM HEPES-KOH pH 7.2, 150 mM KCl, 0.5% (v/v)
NP-40, 0.5 mM DTT, complete EDTA-free protease inhibitor cocktail (Roche)] and cleared by
centrifugation at 12,000 g for 15 min at 4°C. Total protein concentration of supernatants was
assessed by BCA assay (Pierce). 40 µg lysate was mixed in 4x SDS loading dye (10% glycerol
(v/v), 50 mM Tris-HCl, pH 6.8, 2 mM EDTA, 2% SDS (w/v), 100 mM DTT, 0.1% bromophenol
blue), incubated at 90°C for 2 min, and samples were separated by SDS-PAGE at 30 mA per gel
using standard Tris base glycine running buffer (25 mM Tris base pH 8.3, 0.192 M glycine,
0.01% SDS). After electrophoresis, proteins were blotted onto nitrocellulose membranes
(Hybond-ECL, GE Life Science), pre-wetted in transfer buffer (25 mM Tris base, 190 mM
Glycine, 20% MeOH, 0.05% SDS), and semi-dry transferred (Bio-Rad) at 250 mA for 1 hr.
Nitrocellulose membranes were taken through a standard immunoblot protocol, followed by
enhanced chemiluminescent detection (Crescendo ECL, Millipore) using a Lumimager (Fuji,
LAS-3000). Following primary antibodies were used: rabbit polyclonal anti-FAM98A (1:500,
abcam), mouse monoclonal anti-HA (HA-7, 1:1000, Sigma-Aldrich), mouse monoclonal anti-HA
(HA.11, 1:1,000, Covance). Horseradish-peroxidase-conjugated polyclonal goat secondary
antibodies raised against rabbit or mouse immunoglobulin (Dako, P0448 and P0447) were used at
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a titer of 1:5,000, in conjunction with the appropriate species primary antibody, for immunoblot
analyses.

2.3.9

Immunofluorescent stainings and microscopy

HEK293 cells expressing FLAG/HA-tagged FAM98A cells were grown on Lab-Tek II Chamber
slides and induced with 1 µg/mL doxycycline 24 hrs before fixation. Chamber slides were rinsed
with PBS and cells were fixed in 4% paraformaldehyde/PBS for 15 min at room temperature.
Cells were permeabilized in PBS supplemented with 0.1% Triton-X100 (PBS-T) for 5 min,
blocked with 5% normal goat serum in PBS-T for 30 min at room temperature and subsequently
incubated for 1 hr with anti-HA antibody solution (Sigma-Aldrich, HA-7, 1:1000 in 5% normal
goat serum in PBS-T). Chamber slides were washed 3x for 10 min in PBS-T, and incubated for 1
hr in PBS-T with Hoechst stain (1:1000), Alexa Fluor 488 anti-rabbit IgG (H + L) (1:500), and
Alexa-647 Phalloidin (1:300, in 5% normal goat serum in PBS-T). Chamber slides were washed
in PBS 3x for 10 at room temperature and disassembled according to the manufacturer’s
instructions. VectaShield mounting medium (Vector laboratories Inc.) was used for mounting.
Single-layer images were recorded on a Zeiss LSM-710 confocal microscope.
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2.4
2.4.1

Results
Defining the RBP repertoire: Generation of a curated list of RBPs

To annotate RBPs in the human genome, we defined proteins as RBPs if they contained domains
known to directly interact with RNA or which resided within well-characterized RNPs, even if
they were not directly contacting RNA, in some structurally characterized conformations.
Considering that most RNPs are dynamically assembled and disassembled, transient sequenceunspecific RNA contacts are still plausible, examples include components of the exosome
complex, the polyadenylation and cleavage complex, the spliceosome, and the ribosome. To
select RBPs with known defined structural RBDs, I extracted 799 Pfam-defined protein domains
(Table 5.2) known to be RNA-binding or exclusively found in RNA-related proteins and used
their protein domain Hidden Markov models to search the human genome (~20,500 proteincoding genes) for proteins containing these RBDs (Eddy, 1998; Finn et al., 2010). From these
candidates, I filtered out proteins with established RNA-unrelated functions, mostly DNAbinding zinc finger proteins, and manually added RBPs missed by domain searches but clearly
defined in the literature. This resulted in a final census of 1,542 RBPs (Table 5.3), or 7.5% of all
protein-coding genes in human, which constitutes the basis of subsequent analysis described in
this chapter. This catalog provides a fresh starting point for future curation efforts, yet is likely to
change as experimental studies continue to uncover novel RBPs or recognize that candidate RBPs
comprising established RBDs evolved to adopt new functionalities unrelated to RNA-binding.

2.4.2

Analysis of structural features of RBPs

RBPs are commonly classified based on their specific RBDs as their structure and function
provides some insight into their binding preferences and targets. Many excellent reviews have
covered the different RBD families and their modes of RNA-binding (Anantharaman et al., 2002;
Arcus, 2002; Auweter et al., 2006; Burd and Dreyfuss, 1994; Chang and Ramos, 2005; Curry et
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al., 2009; Draper and Reynaldo, 1999; Gerstberger et al., 2014b; Glisovic et al., 2008;
Jankowsky, 2011; Kim and Bowie, 2003; Kuchta et al., 2009; Linder and Jankowsky, 2011;
Lunde et al., 2007; Masliah et al., 2013; Meister, 2013; Mihailovich et al., 2010; Rajkowitsch et
al., 2007; Rocak and Linder, 2004; Singh and Valcarcel, 2005; Sommerville, 1999; Tanner and
Linder, 2001; Tharun, 2009; Valverde et al., 2008; Wang et al., 2002; Wilusz and Wilusz, 2005),
and the depth of their discussion is limited to the insights gained from this analysis. RBDs are
deeply conserved across bacteria, archaea, and eukaryotes. The 1,542 human RBPs contain a
repertoire of ~600 structurally distinct RBDs. Among the structural RBDs, only 20 have more
than 10 human gene members, while most of them have on average one or two members (Figure
2.3, Table 5.4). mRBPs predominantly comprise the large RBD classes, mirroring the rapid
expansion of mRNA metabolic processes in the evolution of higher eukaryotes (e.g. alternative
splicing and polyadenylation) (Chen and Manley, 2009; Keren et al., 2010). 405 of the estimated
692 mRBPs contain an RRM, KH, DEAD, dsrm, or zinc finger domain (Figure 2.3). In contrast,
the 169 ribosomal proteins have 119 distinct domains exclusively found in ribosomal proteins.
This diversity of RBDs complicates both the task of defining a census, as well as de novo
identification of RBPs, and explains why earlier approximations based on the few large structural
groups underestimated the number of proteins involved in PTGR.
Prototypical ssRNA-binding domains interact with their targets in a nucleobasesequence-specific manner, typically binding between 4-8 nucleotides (Glisovic et al., 2008;
Lunde et al., 2007; Singh and Valcarcel, 2005). Specificity is introduced mainly by hydrogen
bonding and Van-der-Waals interactions of the nucleobases with the protein side chains or the
carbonyl and amide groups of the main chain (Auweter et al., 2006), often leaving the RNA
phosphate backbone exposed to the solvent. Additional base stacking interactions with aromatic
amino acids or positively charged residues in cationic π-interactions serve to increase affinity.
dsRNA-binding proteins achieve specificity through recognition of shape of RNA secondary
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structure, such as stem loops (Masliah et al., 2013). Non-sequence-specific RBDs generally
interact with the negatively charged phosphate backbone, leaving the bases exposed to the
solvent. To achieve specificity, these RBPs can interact with cofactors recruiting them to specific
targets, as has been observed for many RNA helicases (Auweter et al., 2006; Rocak and Linder,
2004).
While many RBDs and DNA-binding domains derive from a few common superfamily
folds, such as the oligonucleotidyl transferase fold (Kuchta et al., 2009) and the oligosaccharidebinding fold (OB-fold) (Arcus, 2002), RBDs largely diversified throughout evolution.
Oligonucleotidyl transferase fold proteins include enzymatic RBPs such as TUTases, poly(A)
polymerases, RNA ligases, tRNA CCA-adding enzymes and immune-stimulatory 2’,5’oligoadenylate synthases (Kuchta et al., 2009). RBDs of OB-fold superfamily are the S1, PAZ,
and CSD domains (Arcus, 2002; Lunde et al., 2007; Murzin, 1993).
Analyzing the number and abundance of structural domain classes, it became evident that
most RBDs had only one member. Only 4% of all RBD classes found in human have more than 8
members. Further analysis of this newly curated census showed that members of the 26 most
abundant RBD classes constituted a third of the 1,542 RBPs - most of them were mRBPs. Most
of the prominently studied “canonical” RBDs (Lunde et al., 2007), such as the PUF (2 proteins),
S1, CSD, and PIWI domains (8 members each), did not represent highly abundant RBD classes in
humans and their overrepresentation in PTGR studies does not mirror their abundance in the
genome. One of the largest functional groups, ribosomal proteins and proteins involved in
ribosome maturation, possessed almost all unique domains for each protein and could not be
classified into large families of related structural organization (Korobeinikova et al., 2012). In
conclusion, mainly mRNA-related processes showed an expansion of protein families and are
frequently found in small families of paralogs.
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Figure 2.3 Overview of most abundant RNA-binding domains (RBDs) with selected
examples in humans. (A) Counts of proteins with Pfam-defined RBDs with 8 or more members
in humans. Domain names are listed according to Pfam nomenclature; additional information can
be found in Table 5.4. In addition, low complexity RG/RGG repeat regions in RBPs are shown,
defined as by at least three RG/RGG repeats spaced 10 amino acids or less apart. Counts are
further subdivided to indicate the number of genes containing (1) one RBD as the only structural
domain in the encoded protein (red), or (2) repeats of the same class RBD (orange), or (3) one or
more RBDs in combination with different class RBDs (yellow), or (4) combinations of the RBD
with one or more domains unrelated to RNA-metabolic function, e.g. protein kinase domains
(grey). (B) Domain structure organization of representative RBPs, scaled by amino acid length
and categorized into the domain combination classes listed in (A).
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A common feature of the large mRNA-binding domain classes is their frequent
occurrence in multiple repeats or in combination with other RBDs. The modular design also
allows for rapid evolutionary adaptation of proteins to new RNA targets (Lunde et al., 2007),
which in some cases poses interesting questions about the regulatory functions of RBPs and
evolution of targets. For example, while most KH-domain-containing RBPs have one or two KH
domains, the HDLBP gene expanded from 7 KH repeats in S. cerevisiae to 14 KH repeats in
humans (Figure 2.3).
Overall, this analysis highlighted the total number of structural RBD classes present in
humans and their members, and highlighted that many RBD classes are currently far from a
comprehensive characterization. Even among the established large RBD classes, the function of
many individual members, including RRM proteins, helicases (DEAD, HA2), zinc finger proteins
(zf-CCCH, zf-CCHC, jaz-like zf-CH2H2), RNA nucleases (RNase A, RNase T, RNase Zc3h12a),
and putative translation factors (GTP-EFTU) have not been characterized in their RNA-binding
capacity and physiological roles. For at least a third of all 1,542 RBPs their biological functions
are unknown or merely inferred from homologs.

2.4.3

Abundance of RBPs across tissues in comparison to other proteins

The importance of PTGR is revealed by analyzing RNA-seq expression levels of RBPs relative to
the

residual

proteome

across

16

human

tissues

of

the

Illumina

body

map

(http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513/). The majority of RBPs were
ubiquitously expressed and typically at higher levels than average cellular proteins (Figure 2.4
A), consistent with previous analyses (Kechavarzi and Janga, 2014; Vaquerizas et al., 2009).
While RBPs and TFs encoded a similar number of genes (1,542 and 1,704 genes, respectively),
the cumulative abundance of rpkm expression levels of RBPs contributed up to 20% of the
expressed, protein-coding transcriptome, whereas TFs constituted only up to 3% by transcript
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abundance (Figure 2.4 B). The equivalent of 10-12% of the expressed transcriptome originates
from the 169 ribosomal proteins but represents only about 0.8% of protein-coding genes in the
genome. In contrast, the transcripts encoded by the 692 mRBP genes, representing 3% of proteincoding genes, accounted for 4-5% of the transcriptome, while all remaining RBPs (tRNA-,
rRNA-, etc.) contributed the remaining 4-5%. The discrepancy between RBPs, TFs as the main
gene regulatory protein groups, and other cellular protein groups, such as cytoskeletal proteins
(CSK proteins), was also illustrated when one compares the number of total genes present in the
genome (Figure 2.4 C) to their relative expression in the transcriptome (Figure 2.4 D). Scaling
each by total mRNA abundance, the group of transcription factors displays the largest reduction
in percentage going from gene presence to expression (from 6.2% to 2.4%), while ribosomal
proteins show the largest percentage increase (1.1% to 10.3%). All other RBPs are relatively
unchanged in their contribution and CSK proteins increase by 50% in smooth muscle cells.
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Figure 2.4. Transcript abundance of RBPs and TFs across 16 different human tissues.
(A) Distribution of gene expression levels of protein-coding genes measured by RNA-seq with
rpkm expression values ≥ 1. Shown as subgroups are mRNA-binding proteins (mRBPs) (red),
ribosomal proteins (blue), the remaining RBPs (orange), TFs (magenta), and the residual proteincoding transcriptome (grey). For each group, the mean number of expressed proteins across the
tissues is shown in brackets. (B) Cumulative abundance of RBPs (blue, red, orange) and TFs
(magenta) as fraction of all RNA-seq reads. (C) Pie chart of the number of protein-coding genes
in the genome encoding for mRBPs (red), ribosomal proteins (orange), other RBPs (dark red),
transcription factors (yellow), cytoskeletal proteins (green), other proteins (grey). (D) Pie chart of
the rpkm cumulative expression in muscle cells of all genes in (C) expressed with rpkm ≥ 1.
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These relative mRNA abundances illustrated the central importance of translation-related
processes in the cell. Tumors and immortalized cell lines express mRBPs and ribosomal proteins
at even higher levels than normal tissues. The increased demand for continuous protein
production, changes in nucleolar size (the site of ribosome and rRNA biogenesis), and
translational activities have long been considered as hallmarks of cancer (Boisvert et al., 2012;
Montanaro et al., 2008; Ruggero and Pandolfi, 2003; Zhang et al., 2015a). More generally,
altered translational activity has been observed in a wide range of human pathologies and has also
recently been connected to neurodegenerative diseases, including Parkinson’s and Alzheimer’s
disease (Klein and Westenberger, 2012; Ma et al., 2013; Martin et al., 2014; Scheper et al.,
2007b). Given the central importance of protein translation and ribosome biogenesis for energy
metabolism and cellular growth, understanding disease-related changes in PGTR pathways is not
only of diagnostic and possibly prognostic value, but also enables therapeutic approaches.
Consequently, targeting of PTGR pathways has been explored in drug development of inhibitors
to block translation initiation or ribosome biogenesis, such as the anti-cancer drug silvestrol
inhibiting the translation initiation factors EIF4A1 and 2 (Grzmil and Hemmings, 2012; Hein et
al., 2013; Silvera et al., 2010; Skrtić et al., 2011).

2.4.4

Categorization of RBPs into target subclasses

A classification of RBPs by interacting RNA targets is useful as it isolates individual PTGR
pathways and can also explain similar phenotypes for RBP genes in human diseases. I grouped
the set of 1,542 human RBPs based on literature reports (Figure 2.5) into mRNA-, rRNA-, tRNA,
snRNA-, snoRNA-binding, and a residual ncRNA-binding category (Table 5.3). Further
categories were introduced to define protein components of the ribosome, diverse RBPs
interacting indiscriminately with many types of RNAs (such as the RNA exosome in general
RNA turnover) and unknown-target RBPs (proteins with known RBDs or some experimental data
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on RNA-binding, which lacked information on specific targets). RBPs with more than one target
class were also found and emerging transcriptome-wide binding studies reveal that it may be
common for certain RBPs to interact with and regulate multiple classes of RNAs, e.g. LIN28
proteins bind let-7 pre-miRNA, mRNAs, and snoRNAs, while DGCR8 binds dsRNA regions
within pre-miRNAs and mRNAs (Cho et al., 2012; Hafner et al., 2013; Macias et al., 2012;
Wilbert et al., 2012). For simplification we grouped RBPs, when known, by the predominantly
interacting RNA class based on literature reports, homolog conservation and structural domain
information.

Figure 2.5 Target RNA classification of RBPs and of RBP paralogous families. (A) RBPs
were grouped by their respective target RNAs: ribosomal proteins (dark blue), mRNA- (red),
tRNA- (dark green), rRNA- (orange), snRNA- (light green), snoRNA- (yellow), ncRNA-binding
(grey), diverse targets (light blue), unknown targets (blue). Percentage and counts (in brackets) of
RBPs in the category are shown. (B) Same as in (A) but paralogs are grouped into families
defined by 20% sequence identity according to Ensembl Compara.
Almost all categories of RBPs are directly or indirectly invested in the process of protein
synthesis: 692 proteins were mRNA-binding, 169 ribosomal proteins, and 130 proteins were
involved in biogenesis and delivery of charged tRNAs to the ribosome. Another 90 proteins were
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involved in biogenesis of snRNAs or the formation of snRNPs (snRNA-protein complexes) and
122 and 41 RBPs took part in rRNA- and snoRNA biogenesis, respectively, which may be an
underestimation given that rRNA biogenesis and some orphan snoRNAs or snoRNA-like
lncRNAs have yet to be fully characterized (Bratkovič and Rogelj, 2014; Henras et al., 2008;
Tafforeau et al., 2013; Yin et al., 2012). 122 RBPs were grouped together that interacted with the
remaining ncRNAs (including all remaining ncRNA categories, e.g. miRNAs, piRNAs, lncRNAs,
the RNA components of MRP and RNase P etc.. For the different categories see Table 1.1 and
5.3). These proteins associate with a range of ncRNAs, some of which are involved in gene
regulation, e.g. miRNAs, piRNAs, and lncRNAs, and control gene expression through
posttranscriptional RNA degradation, transcriptional silencing/activation of gene loci, and
translational repression/activation. Others act as structural and catalytic components of RNP
complexes (RNase MRP and P nucleases, telomerase RNP), or form RNP complexes of unknown
functions, e.g. vault RNAs and Y RNAs. 47 RBPs, mostly RNA nucleases involved in general
RNA turnover, were categorized into the diverse target RNA group.
The categorization of proteins into different pathways became highly useful for breaking
down the complexity of PTGR into basic units, and allows now detailed analyses of changes
taking place in different regulatory pathways in system-wide PTGR studies. Furthermore, it
facilitates exploration of areas in PTGR, which have been relatively overlooked. For example, our
curation highlights that the functions of many rRNA and tRNA biogenesis factors in humans are
largely inferred from distant homologs and domain relationships (Hopper et al., 2010; Kiss, 2004;
Phizicky and Hopper, 2010). As these processes are essential for cellular life and highly
conserved, core functions often remain the same. However, with increasing complexity of
organisms, protein factors and their family members, and/or the spectrum of target RNAs of
pathway components evolved, grew in size, and diverged. The recently discovered new roles of
tRNA methylases in mRNA and ncRNA metabolism may represent such an example (Hussain et
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al., 2013; Sibbritt et al., 2013). Future characterization of these proteins will be important to
delineate the specificities and targets of these factors in higher eukaryotes.

2.4.5

Conservation of RBP and TF families

Phylogenetic relationships of RBPs reveal the creation of gene families during evolution, a
process that in principle allows for diversification of RNA metabolic pathways. In most instances,
however, human paralogs are functionally overlapping, with similar or even identical binding
sites (Ascano et al., 2012a; Ray et al., 2013; Spencer et al., 2006; Todd et al., 2001), and the
evolution of paralogs represent an alternative to facilitating regulation across cell types.
Understanding family relationships and examining protein families together, instead of singular
members, is therefore a valuable approach.
To define redundant properties of RBPs, I compared the evolutionary characteristics of
RBPs to TFs, the regulatory group of proteins controlling gene expression at the transcriptional
level. I used the phylogenetic homology classification as already defined by the Ensembl
Compara database (Vilella et al., 2009) and further grouped together paralogs with even closer
homology. Most RBP paralogs shared 20-70% sequence identity and by this criteria known
functionally related RBPs grouped together, such as members of the CPEB1-4 cytoplasmic
polyadenylation family, which shared ~25% sequence identity. We refer to these grouped
paralogs as ‘paralogous RBP families’ throughout the text. We found a minimum of 20% to be
the best threshold to group functionally related or redundant proteins into families. Sequence
identity cut-offs below 20% included predominantly functionally unrelated, distant paralogs,
which were not in the same RNA regulatory pathways, while higher cut-offs often missed family
members of known functional similarity.
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Figure 2.6 Evolutionary conservation of RBP and TF families. (A, B) Number of human RBP
and TF families conserved across 10 species and their percentage identity score, (A) RBP (black)
and (B) TF families (magenta). The number of families with different degrees of conservation are
binned into 5 categories, color-coded in black-yellow and magenta-yellow shades: (i) ≥85%
homology, (ii) ≥60% and <85% homology, (iii) ≥40% and <60% homology, (iv) ≤20%
homology. (C,D,E) Number of paralogous families and their degree of sequence identity in
humans. (C) ribosomal proteins (blue), (B) mRBPs (red), and (D) tRNA-binding proteins (green).
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Consistent with their high structural diversity, the 1,542 RBPs formed 1,111 families, in
which individual members within RBP families generally have the same RNA target class (Figure
2.6). In contrast, the 1,704 human TFs, which diverged more recently than RBPs [census
generated by Vaquerizas et al. (Vaquerizas et al., 2009)], formed only 554 protein families by the
above stated homology criteria (Table 5.4). RNA- and DNA-binding domains often originated
from common superfamily folds, such as the OB-fold (oligonucleotide/oligosaccharide-binding
fold), nucleotidyltransferase, zinc finger, or DNA/RNA helicase domains (Arcus, 2002;
Jankowsky and Fairman-Williams, 2010; Krishna et al., 2003; Kuchta et al., 2009). However,
despite a shared evolutionary history, TFs expanded late in evolution into large families by
multiple gene duplications (Vaquerizas et al., 2009) and the current homology grouping resulted
in TF families with up to 50 members per family and 2.5 members on average, while RBPs
diversified early and paralogous families comprised 1.3 members on average, with the largest
RBP families including up to 10 members. Paralogous RBP families were well conserved across
eukaryotes and 50% of the human RBP families were also present in S. cerevisiae (Figure 2.6).
This finding is consistent with previous observations that at least 200 distinct RBPs were present
in the lowest common ancestor of animals (LCA), and 80 orthologous groups of RBPs were
traceable even to the lowest universal common ancestor (LUCA) (Anantharaman et al., 2002;
Kerner et al., 2011). In striking contrast, few TFs were conserved across evolution, and only 14%
of the human TF families were found in S. cerevisiae. Even the most rapidly expanding group,
mRBPs, had 178 of 422 (42%) mRBP families conserved in yeast. While the expansion of TFs
traced organismal complexity, possibly enabling the development of new functionalities
(Vaquerizas et al., 2009), evolutionary stability of RBPs went along with the early establishment
of core RNA metabolic processes in all cellular systems (Anantharaman et al., 2002).
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2.4.6

Conservation of RBP families interacting with different RNA classes

With the growing number of RBP families in higher eukaryotes the relative size of the various
RBP families committed to different RNA targets remained constant across phylogenies (38%
mRBPs, 12% tRNA-binding, 14% ribosomal proteins, Figure 2.6). However, RBP families in
different target groups displayed varying levels of evolutionary conservation. Most RBP classes,
including families in rRNA, tRNA, snRNA and snoRNA pathways, displayed average
homologies of 31% between human and yeast (e.g. tRNA-binding proteins in Figure 2.6).
Ribosomal proteins were among the most conserved, with an average homology of 51%, in
contrast to the factors involved in maturation and processing of rRNAs, which were conserved
only to 31%, reflecting the increasing divergence of rRNA biogenesis factors in higher
eukaryotes (Granneman and Baserga, 2004; Phipps et al., 2011). ncRNA- and mRNA-binding
protein families displayed the lowest conservation, with 20% and 27%, respectively, and only a
fifth of all ncRNA-binding families had homologous families in yeast.

2.4.7

Phylogenetic comparisons of small ribosomal and KH-domain proteins

Visualization of the evolutionary relationships of RBP families facilitates systems biology
approaches to dissect their regulatory roles by giving an intuitive graphic representation of the
conservation of proteins. They highlight closely related homologs and provide a glimpse into
function of uncharacterized RBPs when the homolog has been characterized. Phylogenetic
comparison of the predominantly mRNA-binding KH-domain-containing proteins and the
proteins of the small subunit of the cytosolic ribosome illustrate the differences in their
evolutionary trajectory and I used these extensively to judge family relationships and
conservation among RBP families (Figure 2.7).
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Figure 2.7 Phylogenetic trees of RBP families highlight their evolutionary history.
Phylogenetic trees of (A) KH-containing proteins and (B) ribosomal proteins of the small subunit.
Branch lengths are scaled to the sequence identity of the proteins. S. cerevisae proteins are
marked in red, human proteins in black, homologous families with conserved members in S.
cerevisae are highlighted in yellow.
KH proteins experienced multiple gene expansions, as noted earlier for mRBPs, and evolved new
RBP families at the later metazoan stages. Thereby they expanded and diversified, evolving new
factors involved in various regulatory pathways, such as mRNA splicing, translational regulation,
and transport. KH protein families contain between one to four members in human, and possess
generally one distantly related homolog in yeast (Figure 2.7). Multiple family members often
have redundant biological functions and RNA target spectra. For example, members of the FMR1
family (FMR1, FXR1, FXR2) or the IGF2BP1 family (IGF2BP1, 2, and 3) show >90% identical
RNA-binding specificities (Ascano et al., 2012b; Hafner et al., 2010a). In contrast, cytosolic
ribosomal proteins display an unusually high conservation, not too surprising, given that the
process of protein translation is conserved to such a high degree between prokaryotes and all
clades of eukaryotes that functional details of translation determined in bacteria are almost
identical to higher systems (Dever and Green, 2012; Melnikov et al., 2012; Wool et al., 1995).
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The ~90 ribosomal cytosolic proteins are highly similar in structure between yeast and human and
show late divergence in evolution, illustrated for the phylogenetic tree of small ribosomal subunit
proteins (Figure 2.7). With on average 55% protein identity, 96% of all human ribosomal proteins
have direct one-to-one, or due to a whole genome duplication in yeast, one-to-two or two-two
matching homologs (Anger et al., 2013; Wool, 1979; Wool et al., 1995). From the level sequence
identity and number of homologs we often also gain functional insights: high conservation of
RBPs with 1:1 conserved homologs (or in the case of S. cerevisiae gene duplication 1:2) often
points to either the RBP being part of a highly conserved RNP complex with a structural RNA
component at its core (e.g. ribosome, snRNPs, snoRNPs), or towards a conserved enzymatic
process with little mechanistic divergence (e.g. tRNA splicing). In contrast, RBPs involved in
mRNA-gene regulatory processes display much higher redundancy and less sequence
conservation. Thus, intuitively one can make a prediction about the likely process encountered
from the phylogenetic tree. The ~80 human mitochondrial ribosomal proteins form the exception
to the rule (Matthews et al., 1982). The majority (80%) have no homologs in yeast and the few
that do display low conservation of 22% sequence identity. The low conservation reflects their
evolutionary history. Mitochondrial ribosomes were acquired through eubacterial endosymbiosis
and rapidly evolved independently across species with major remodeling events happening later
during evolution (Cavdar Koc et al., 2001; O'Brien, 2003). In contrast, the nuclear encoded RBPs
show characteristic conservation patterns and protein family expansions for the different RNA
regulatory processes.

2.4.8

Tissue specificity of RBPs

Tissue-specific expression, phyletic age, and cellular functions of proteins often correlate. While
ancient and highly conserved genes are widely expressed and support basic cellular functions,
more recently evolved genes, such as TFs and secreted proteins, are expressed in a species- and
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tissue-specific manner (Freilich et al., 2005; Ramsköld et al., 2009; Winter et al., 2004). I
investigated mRNA expression of 1,441 RBPs and 1,463 TFs profiled in a microarray study
measuring transcript levels of 16,867 protein-coding genes across 31 human tissues (Dezso et al.,
2008). To analyze protein abundance, we assumed that transcript abundance approximated
protein abundance in the cell as previously shown by large-scale transcriptomic and proteomic
studies (Guo et al., 2010; Schwanhausser et al., 2011). Tissue-specific variation of RBP isoforms
due to alternative splicing and alternative cleavage and polyadenylation were not considered for
this analysis as they are not well understood. We favored microarray over RNA-seq studies
because the former profiled larger collections of different human tissues and organs. I calculated
a tissue specificity score S for every gene on the array across the profiled samples, which ranged
from 0 for ubiquitously expressed to 5 for highly tissue-specific proteins. Based on the score of
established tissue-specific RBPs, such as the germline-specific PIWI-family (S=1.7-2.3) or
neuronal members of the ELAVL family (S=3.2) (Li et al., 2007; Thomson and Lin, 2009), I set
an empirical cut-off score of 1 for referring to tissue-specific genes, at which 6% of RBPs and
13% of TFs showed some level of tissue-specific expression (Figure 2.8 A). As expected,
ribosomal proteins (Figure 2.8 A,B), as well as general components of the spliceosome, RNA
transport, and turnover machineries were ubiquitously expressed across tissues. Furthermore,
while tissue-specific variation has been reported for some tRNAs and snoRNAs (Castle et al.,
2010; Dittmar et al., 2006; Plotkin and Kudla, 2011), the biogenesis factors of tRNAs and
snoRNAs, as well as snRNA and rRNA maturation pathways, were generally uniformly
expressed across tissues (Figure 2.8 C). The majority of tissue-specific RBPs consisted of
mRNA- and ncRNA-binding proteins, as well as a range of RNA nucleases with diverse target
specificity (Figure 2.8D). Perhaps unexpectedly, some tissue-specific outliers were observed
among rRNA biogenesis factors and ribosomal proteins, including the uncharacterized, muscleenriched ribosomal multicopy gene RPL3L, a homolog of RPL3 (Figure 2.8B). These selectively
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expressed RBPs may reflect extra-ribosomal roles (Warner and McIntosh, 2009) or tissue-specific
adaptations in composition of ribosomes that regulate translation of subsets of proteins (Xue and
Barna, 2012).
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Figure 2.8 Tissue specificity of RBPs across 31 human tissues and organs. A tissue specificity
score S was calculated from mRNA expression levels of 1,441 RBPs and 1,463 TFs profiled in a
human microarray tissue atlas assessing expression across 31 tissues (Dezso et al., 2008). (A)
Densities of the log2 transformed tissue specificity scores are shown for RBPs (black), TFs
(magenta), ribosomal proteins (dark blue), mRNA- (red), tRNA- (dark green), rRNA-binding
(orange) proteins. The densities of RBPs and TFs are filled in shades of their original color to
highlight their shifts in distribution. (B) Log2 maximum expression intensity value of a gene
versus S for ribosomal proteins (dark blue), and rRNA-binding proteins (orange) compared to the
residual proteome (grey). Tissue-specific genes were defined as genes with scores S≥1 (dashed
line). Selected genes are highlighted. (C) Same as (B) for tRNA- (dark green), snRNA- (light
green), and snoRNA-binding proteins (yellow). (D) Same as (B) for mRBPs (red), ncRNAbinding (dark grey), and diverse target RBPs (blue). (E) Log2 maximum expression intensity
value of a gene is plotted against its tissue specificity score S. RBPs are highlighted in red, all
other proteins in grey. Tissue-specific RBPs with maximum expression in testis (orange) and
brain (green) are highlighted. (F) Same as in (E) highlighting tissue-specific RBPs expressed in
bone marrow (sky blue), liver/pancreas (dark green), muscle (blue), placenta (violet).
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The majority of profiled RBPs, including mRBPs, displayed no tissue specificity; 80% of
all RBPs (1,144 of 1,441 RBPs) had scores lower than 0.3. Among the paralogous RBP families,
808 (77%) of the 1,049 families, or 277 (68%) of 409 mRBP families, were ubiquitously
expressed with S<0.3, while only 20 families were tissue-specific with S≥1, and 53 had at least
one tissue-specific member (Figure 2.9).

Figure 2.9 RBP families with tissue-specific or ubiquitous expression. Expression of
paralogous families profiled in the tissue atlas: 1,049 RBP families, of which 409 are mRBP
families, are scaled to relative size. Families are binned into different categories of expression,
color-coded in shades of black-yellow and red-yellow. Representative paralogous families are
highlighted for mRBPs. 2% of RBP and 1% of mRBP families displayed tissue-specific
expression for all their members (yellow), 5% and 9% respectively had one or more members
with tissue specificity score S≥1, 16% and 22% of families had members with tissue-specificity
scores ranging between 0.3>S>1, classified here as gradient RBP families, and 77% of RBPs
(black) and 68% of mRBPs (red) display little variation in expression, with S<0.3, named here
ubiquitous RBP families.
Few tissues contained specialized RBPs and 90% of the 82 tissue-specific RBPs were
identified in germline, brain, muscle, bone marrow, placenta or liver (Figure 2.8 E-F). The
largest fraction, 47 proteins, were enriched in adult testis, where they contribute to gametogenesis
and fertility through regulation of transposon silencing, mitosis, meiosis, stem cell maintenance,
and differentiation (Kang and Han, 2011; Kotaja and Sassone-Corsi, 2007; Luteijn and Ketting,
2013; Seydoux and Braun, 2006; Siomi et al., 2011; Voronina et al., 2011) (Figure 2.8 E). These
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proteins were also expressed during fetal ovary development, at the stage of mitotic and meiotic
cell divisions and germ cell expansion (Houmard et al., 2009). 2% (20 families) of all RBP
families were exclusively tissue-specific and most of these families were expressed in the
germline, such as the DAZ1-4 and PIWI family, and other RBPs involved in the piRNA pathway
(Brook et al., 2009; Reynolds and Cooke, 2005; Siomi et al., 2011; Thomson and Lin, 2009)
(Figure 2.8 D-F).
Instead of RBP families where all paralogs are tissue-specifically expressed, the larger
proportion of tissue-specific RBPs belongs to sequence families with at least one ubiquitously
expressed member. 5% (52 families) of all RBP families were broadly expressed with one or
more highly tissue-specific member. Examples included a number of helicase families with
germline-specific paralogs, such as the tissue-specific DDX4 protein, comprising ubiquitously
expressed family members DDX3X and DDX3Y, the MOV10L1 helicase and its ubiquitously
present paralog MOV10, or the tissue-specific helicase DDX25 with the ubiquitous paralogs
DDX19A and DDX19B (Dufau and Tsai-Morris, 2007; Frost et al., 2010; Lasko, 2013; Zheng et
al., 2010). Also, most members of the secreted, vertebrate-specific RNase A family displayed
high tissue-specificity and were expressed in bone marrow cells and liver, where they have a role
in immune response and angiogenesis (ANG, RNASE2, and RNASE3) (Rosenberg, 2011)
(Figure 2.8D). Other families in this group were the mRNA splicing and regulatory families
ELAVL1-4 and IGF2BP1-3, which had ubiquitously expressed paralogs (ELAVL1, IGF2BP2)
and highly tissue-specific members (ELAVL3-4, IGF2BP1, IGF2BP3) in the brain, germline, and
liver (Li et al., 2007; Simone and Keene, 2013; Yisraeli, 2005) (Figure 2.8D). For 16% of RBP
families, here named gradient RBP families, individual members were ubiquitously expressed
with tissue-specificity scores below 1, but displayed, while not classified as tissue-specific, some
degree of differential expression across tissues (Figure 2.9). Loss-of-function of proteins in these
families often affects the tissue of highest expression most strongly. A prominent example for
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RBPs with this expression pattern is the FMR1 family comprising three ubiquitously expressed
members, FMR1, FXR1, and FXR2, with redundant target specificities (Ascano et al., 2012b). Of
these proteins, FMR1 has the highest expression levels in brain, thyroid, and gonads, and FXR1
and FXR2 are most abundant in skeletal muscle and testis. Thus, even though activity of this
protein family is necessary in every tissue, loss-of-function of FMR1 mainly affects the brain and
gonads and causes mental retardation and premature ovarian insufficiency in Fragile X syndrome
(FXS) or Fragile X-associated ataxia syndrome (FXTAS) (Wang et al., 2012), while mouse
knockout models for FXR1 are embryonic lethal due to skeletal muscle defects (Mientjes et al.,
2004). For families with some tissue-specific variation, the closely related paralogs often bind the
same sites on target RNAs with similar affinities, such as the members of the FMR1 and ELAVL
families, which have identical binding sites in cell culture models (Ascano et al., 2012a; 2012b;
Simone and Keene, 2013). The redundant functions of the ubiquitous paralogs can therefore
complicate the dissection of the role of the tissue-specific proteins and may require technically
challenging experimental designs, such as generation of animals with tissue-specific knock-in/out
of family members.
In conclusion, 98% of paralogous RBP families were ubiquitously expressed and their
deep evolutionary conservations supports their predominant basic cellular function. Of these a
fifth are families with tissue-specific and ubiquitous paralogs or ubiquitous members that are
enriched in some tissues. Only 2% of families are tissue-specific for all paralogs, suggesting for
these, similar to the evolution of TFs, a strictly cell-type specific contribution to PTGR pathways.
Cell-type specific expression levels of an RBP and its paralogs must be considered when
choosing a system to study regulatory networks and targets.
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2.4.9
2.4.9.1

Co-regulated expression of RBPs in common pathways
Dynamic complexes of RBPs

RBPs assemble into dynamic RNP complexes that mature, process, regulate, or transport RNAs.
Remodeling RNA structure to keep RNAs accessible to other RBPs and enzymatic RNA
processing complexes, RBPs and RNPs also act as RNA chaperones, prevent aggregation,
misfolding, and incomplete processing, and facilitate movement of RNA targets to required
locations in the cell across cellular compartments. As a consequence, abundance of RBPs and
their constituents differentially affects RNA regulation (Dreyfuss et al., 2002; Glisovic et al.,
2008; Keene, 2007; Mitchell and Parker, 2014; Müller-McNicoll and Neugebauer, 2013). For
example, the abundance of various splicing factors can influence mRNA splicing patterns (Chen
and Manley, 2009; Kalsotra and Cooper, 2011; Kornblihtt et al., 2013; Smith and Valcarcel,
2000; Wahl et al., 2009), while U1 snRNP levels control alternative polyadenylation sites (Berg
et al., 2012; Kaida et al., 2010). The competition among RBPs with similar or overlapping target
specificity can also define regulatory modes. For example, ELAVL1 protein antagonizes miRNA
regulation on a number of mRNA targets (Mukherjee et al., 2011), LIN28 protein competes with
the miRNA-processing machinery to suppress pre-let-7 miRNA processing (Cho et al., 2012;
Hafner et al., 2013; Wilbert et al., 2012), and PUM proteins synergize with miR-221/222 to
destabilize the CDKN1B mRNA (Kedde et al., 2010). Similarly, multiple RBPs are involved in
localization and transport of RNA to distinct RNP granules, which contain highly concentrated
subsets of RNAs and RBPs and act in the storage and/or degradation of mRNAs (Anderson and
Kedersha, 2009; Kedersha and Anderson, 2007). The central position of PTGR regulatory
networks in cellular processes shows in genetic knockouts of RBPs that are often lethal or affect
all tissues, consistent with their high conservation, number of targets, and low tissue-specificity.
Selective expression of a single RBP typically does not result in differentiation or
dedifferentiation into distinct cell types, in contrast to TFs (Hanna et al., 2010). Instead, the
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interactions of many RBPs in regulatory complexes determine specificity of PTGR processes.
Hence, groups of RBPs in common PTGR pathways are often co-expressed and can drive
coordinate expression of targets in cells, tissues, and across developmental processes (Cirillo et
al., 2014; McKee et al., 2005; Mittal et al., 2009). Specific expression of RBPs can be used to
deduce their putative roles and to identify novel components of regulatory pathways. In the next
two sections I investigated co-regulated RBP expression and used available gene expression data
across several developmental stages in human ovary, testis, and brain to identify correlated
expression of groups of RBPs that potentially act in the same developmental pathways.

2.4.9.2

Co-expression of RBPs required for ovarian development

The germline presents a unique system for functional studies of process-specific RBPs, as it has a
highly specialized RNA metabolism. At least 50 tissue-specific RBPs contribute to differentiation
and maintenance of germ cells (Seydoux and Braun, 2006) and many are involved in germlinespecific piRNA-induced transposon silencing, alternative polyadenylation and translational
regulation affecting hundreds of mRNA targets (Di Giammartino et al., 2011; Lianoglou et al.,
2013; MacDonald and McMahon, 2010; Norbury, 2013; Seydoux and Braun, 2006; Siomi et al.,
2011). Between 8 to 20 weeks of gestation, oogonia proliferate and their numbers increase from
0.6 to 6 million cells (Oktem and Urman, 2010). By 20 weeks of gestation, primordial oocytes
enter meiosis and arrest in the diplotene stage of meiosis I prophase I until oogenesis resumes in
puberty. I examined RBP expression in a microarray study of 9-18 week human fetal ovary
(Houmard et al., 2009). Expression of germline-specific RBPs peaked at 14, 16.4, 16.9, and 18
weeks (Figure 2.10), and displayed highly correlated expression dynamics, reaching Pearson
coefficients close to 1 (Figure 2.10).

55

Figure 2.10 Expression of RBPs across 9 gestational stages of fetal human ovarian
development. The top 200 most differentially expressed RBPs from a microarray study profiling
human fetal gonad development are shown (Houmard et al., 2009). For each gene microarray,
intensity values were normalized to relative fold changes by dividing the expression value by the
mean expression value across developmental stages. (A) Heat map of the log2 transformed
relative fold changes of the RBPs shown sorted by unsupervised clustering. Some gonad-specific
RBPs are indicated. (B) Pearson correlation map indicates correlated expression changes of the
200 selected RBPs. Functionally related RBPs in gonad development cluster into a distinct
expression group. (C) Plot showing the normalized expression changes of selected genes relevant
in gonad development.
While some of the expression changes may be attributed to changing percentages of
tissue composition of germline and somatic cells, the increase in expression for known germlinespecific RBPs was evident and also correlated with their high tissue-specific expression in adult
testis, confirming a role in germline development for both sexes. The expression dynamics were
clearly distinct from differentially expressed, somatic RBPs with functions unrelated to germline
development. For instance, the IGF2BP1-3 proteins, required during embryogenesis and organ
development, were highly expressed at week 9 before expression levels rapidly decreased (Bell et
al., 2013; Yisraeli, 2005). All constituents of the piRNA pathway (Siomi et al., 2011) were
upregulated in the course of germline development, including piRNA biogenesis factors such as
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the RNA endonucleases MAEL and PLD6, the RNA helicases DDX4, DDX39A (UAP56
homolog), and MOV10L1, and most members of the Tudor protein family (TDRD1-9, RNF17)
(Siomi et al., 2011) (Figure 2.10). In addition to the piRNA pathway, we observed coordinated
expression of the established germline-specific translational regulators DAZ1-4, DAZL, and
BOLL, which are also essential regulators of gametogenesis (Brook et al., 2009; Kee et al., 2009).
The expression dynamics of groups of RBPs during ovarian development and expression patterns
mirrors their role in germline development derived from genetic experiments. In conclusion, the
clustering of expression profiles of RBPs across developmental stages allowed us to investigate
novel regulatory roles of RBPs not previously studied in germline development, including
RBM46, PIH1D2, ADAD1, and PNLDC1 (Figure 2.10). Resulting from this clustering analysis I
discovered one novel factor, LOC81691 (NEF-sp), which displayed differential expression across
development identical to gonad-specific RBPs and characterized this factor in detail in Chapter 3.

2.4.9.3

Co-expression of RBPs in brain development

Neurons demonstrate unique alternative splicing and polyadenylation of mRNAs (Chen and
Manley, 2009; Di Giammartino et al., 2011; Li et al., 2007; Lianoglou et al., 2013; Norbury,
2013). Furthermore, the considerable length of neuronal projections makes mRNA transport and
local translation at neuronal dendrites indispensable for development, synaptic plasticity, and
long-term memory (Bramham and Wells, 2007). Not surprisingly, many RBPs regulating
splicing, RNA transport, storage, and translation are critical for neuroplasticity (Jung et al., 2014;
Kandel et al., 2014; Sutton and Schuman, 2006). In order to capture brain-specific PTGR
networks, I examined the expression dynamics of RBPs at different fetal and postnatal stages in
human hippocampus development using RNA-seq data from the BrainSpan database
(http://www.brainspan.org). While more than 75% of all protein-coding genes were reported to
be expressed in brain (Hawrylycz et al., 2012), the expression of thousands was found to be either
57

restricted to a particular cell-type or to be temporally regulated (Hawrylycz et al., 2012; Miller et
al., 2014). We found in our analysis that RBPs were generally expressed ubiquitously, but we
detected distinct groups of RBPs that were upregulated at different developmental stages,
consistent with previous studies (McKee et al., 2005; Mody et al., 2001).

Figure 2.11 Expression of RBPs across fetal human hippocampus development. The top 200
most differentially expressed RBPs across 12 stages of human hippocampus development ranging
from post-conception week (PCW) 9 up to 12 months after birth profiled by RNA-seq (Houmard
et al., 2009). For each gene, rpkm values were normalized to relative fold changes by dividing the
expression value by the mean expression value across developmental stages. (A) Heat map of the
log2 transformed relative fold changes of the RBPs sorted by unsupervised clustering. (B)
Pearson correlation map indicates correlated expression changes of the 200 selected RBPs. (C)
Characteristic expression fold changes across developmental stages for genes in the three
different groups. Group I: Genes with high expression levels at early PCW, which rapidly
decrease at later stages. Group II: Genes with low expression at early PCW and rapidly increasing
levels at late PCW and postnatal stages. Group III: Genes with a single, high expression peak at
37 PCW.
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The largest cluster of differentially expressed RBPs in hippocampus contained ~100
RBPs, which were highly expressed during early development, but then were rapidly downregulated at later stages (Figure 2.11, group I). This cluster included proteins required for the
regulation of developmentally relevant pathways, such as the IGF2BP1-3 family (Bell et al.,
2013; Yisraeli, 2005) and LIN28 (Thornton and Gregory, 2012), as well as general factors
involved in translation, mRNA splicing, transport, and rRNA biogenesis.
Opposite in trend, a group of ~20 proteins displayed low expression in the first fetal postconception weeks (PCW), which rapidly increased during the period coinciding with
hippocampal development. This group comprised multiple splicing regulators required for
neuronal function, such as the RBFOX family, which contributes to the characteristic splicing
pattern of many neuronal transcripts (Gehman et al., 2011; Lovci et al., 2013) (Figure 2.11, group
II). Another distinct group of ~20 RBPs, enriched in RNA nucleases and mRNA-regulatory
proteins involved in inflammatory and innate immune responses, was highly expressed at 37
PCW (Figure 2.11, group III), coinciding with a maturation wave of pyramidal neurons and
synaptogenesis at 34-36 PCW (Arnold and Trojanowski, 1996). Consistent with a neuronal
function, mutations in the RNA nucleases ANG and RNASET2 are found in patients with the
neurological diseases ALS and cystic leukoencephalopathy, respectively (Greenway et al., 2006;
Henneke et al., 2009; Skorupa et al., 2012; Thiyagarajan et al., 2012). Strikingly, the mRNAregulatory protein ZFP36 (tristetraprolin, TTP) was the most specifically upregulated RBP in the
hippocampus by more than 200-fold. ZFP36 is known to destabilize mRNAs coding for cytokines
and other inflammatory immune genes by recruiting the CCR4-NOT1 complex to AU-rich
elements in the 3’UTR of targets, leading to deadenylation and subsequent degradation of
mRNAs (Brooks and Blackshear, 2013; Fabian et al., 2011; 2009; Mukherjee et al., 2014; ReyesTurcu and Grewal, 2012). Recently, it was found that cytokines and other immune regulatory
proteins are expressed in the developing and adult nervous system, where they are required for
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normal brain development and synaptic plasticity (Boulanger, 2009; Deverman and Patterson,
2009). Indeed, coinciding with ZFP36, immune regulatory genes such as the members of the
major histocompatibility complex class I (e.g. HLA-A/B/C/E/F) were also selectively expressed
at 37 PCW (Figure 2.11, group III) (Zhang et al., 2013). Whether or not the molecular function of
ZFP36 remains the same in neurons is unknown, but the coordinated expression of these
regulatory RBPs may imply a biological role during neural development and synaptic plasticity.

2.4.10 RBPs in human diseases
Disease phenotypes of RBPs may correlate with tissue-specific expression, e.g. loss-of-function
of germline-specific proteins causes infertility (Reynolds and Cooke, 2005) and loss of the mRBP
Fragile X mental retardation (FMR1) protein causes severe phenotypes in the tissues where it is
most enriched (Wang et al., 2012). However, highly tissue-specific pathologies are often
observed for loss-of-function of RBPs with no specificity in expression at all. These tissuespecific phenotypes may be explained by either (1) tissue-specific expression of critical RNA
targets and cofactors of the RBP, or (2) a greater sensitivity to expression changes of PTGR
components in general for the affected tissue.
Within the previously categorized RBP regulatory groups we found as general trend that RBPs,
which interacted with the same RNA classes (e.g. mRNA-, tRNA-binding, etc.), displayed similar
pathologies. Understanding diseases involving RBPs in the context of their RNA pathway was
therefore the most important factor for predicting and interpreting their disease phenotypes. For
example, ribosomopathies, such as Diamond-Blackfan anemia and Shwachman-Diamond
syndrome, are caused by defects in ribosomal proteins and rRNA biogenesis factors, severely
affecting the bone marrow and skin (Narla and Ebert, 2010), while mutations in mRBPs are found
in multiple neurodegenerative and neuromuscular diseases, affecting mRNA metabolism in
neurons and, in particular, motor neurons (Cooper et al., 2009; Lukong et al., 2008; Scheper et al.,
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2007b). Here, mutations in mRBPs or their RNA targets cause impaired RNA transport and
translation, often leading to protein/RNA aggregation and inefficient clearance of neuronal
RNA/protein granules, which cause a range of neuropathological diseases (Buchan et al., 2013;
Cooper et al., 2009; Kim et al., 2013b; Lagier-Tourenne et al., 2010; Liu-Yesucevitz et al., 2011;
Lukong et al., 2008; Ramaswami et al., 2013; Scheper et al., 2007b). Examples include
amyotrophic lateral sclerosis (ALS), caused by mutations in the mRBPs TDP43, FUS, and
HNRNPA2B1/A1 (Kim et al., 2013b; Lagier-Tourenne et al., 2010), leading to prion-like
accumulation of proteins in RNA granules in motor neurons, and spinocerebellar ataxia, caused
by polyglutamine expansions in ATXN proteins leading to protein aggregations (Banfi et al.,
1994; Orr et al., 1993). Defect in RNA transport and protein translation, such as loss-of-function
of FMR1, and defects in mRNA splicing, caused by loss-of-function of e.g. the splicing
RBFOX1, both manifest in neurological phenotypes as mental retardation and autism (Voineagu
et al., 2011; Wang et al., 2012). mRNA repeat expansions typically lead to sequestration of RBPs,
often splicing factors and have been linked to muscular diseases caused by dysregulated splicing,
such as myotonic dystrophies, mental retardation, and ataxia (Echeverria and Cooper, 2012).
Loss-of-function of the snRNP assembly factor SMN1 directly affects the spliceosome and causes
spinal muscular atrophy (SMA), a motor neuron disease (Cooper et al., 2009). Loss-of-function
mutations in tRNA splicing components and aminoacyl tRNA synthetases typically cause
encephalopathies and the neurological Charcot-Marie tooth disease (Budde et al., 2008; Scheper
et al., 2007b; Yao and Fox, 2013). A number of RNA/DNA nucleases critical for nucleic acid
clearance have been implicated in the autoimmune disease Aicardi-Goutieres syndrome (Crow et
al., 2006b; Rice et al., 2009).
In summary, our target categorization of RBPs allowed to detect and interpret patterns in
RNA metabolic diseases. From this analysis it became clear that, instead of RBP expression, the
interacting RNA targets are often a better predictor for the disease pathologies observed and it is
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more useful to separate RBPs by their targets in order to interpret disease phenotypes and affected
organs. Furthermore, for novel RBPs with unknown targets involved in human diseases, the
disease phenotypes can point towards the likely dysregulated RNA pathways. In Table 2.1 I
generated a human disease table of RBPs listed by OMIM and separated the RBPs by their
dominant RNA targets. This analysis gives an overview of recurring patterns and phenotypes
encountered in the different target groups. In the sections below, I briefly summarized the main
characteristic phenotypes of diseases typically encountered in each RNA category.

2.4.10.1 Diseases of mRBPs
Most of the ~150 RBPs currently listed in the OMIM database (Hamosh et al., 2005) are mRBPs.
Mutations in mRBPs typically display neurological and neuromuscular dysfunctions due to
dysregulation of splicing, translation, localization or protein aggregation (Cooper et al., 2009;
Hanson et al., 2011; Kapeli and Yeo, 2012; Lukong et al., 2008; Ule, 2008). Family members
tend to have overlapping phenotypes, reflecting their functional redundancies. For instance, the
paralogs RBM20 and MATR3 are both involved in myopathies due to dysregulated splicing of
their targets (Guo et al., 2012; Senderek et al., 2009).
RNA gain-of-function diseases do not necessarily occur within an mRNA coding for an
RBP, but they commonly lead to altered mRBP binding patterns, thereby they directly affect
PTGR (Cooper et al., 2009; Echeverria and Cooper, 2012; Nelson et al., 2013). In these disorders,
repeat expansions in introns or UTRs of mRNAs lead to sequestration of mRBPs in the nucleus,
thereby causing dysregulation of their respective targets. The myotonic dystrophies DM1 and
DM2 are caused by repeat expansions in the 3’UTR of DMPK and the intron of CNBP (ZNF9),
which sequester the mRBPs CELF1 and MBNL1 and their paralogs (Echeverria and Cooper,
2012). FXTAS (Fragile X-associated tremor/ataxia syndrome), caused by trinucleotide repeat
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expansions in the 5’UTR of the FMR1 mRNA, directly leads to loss-of-function of FMR1
(Hagerman, 2013).
Another common disease mechanism encountered for RBPs are mutations that lead to
prion-like aggregation of cytoplasmic or shuttling mRBPs into RNA granules. Defective
clearance and dysregulation in assembly and disassembly of cytoplasmic RNP granules have been
found to be the underlying cause in a range of neurodegenerative disorders. For example,
cytoplasmic inclusion of TARDBP/TDP43 and FUS have been found in amyotrophic lateral
sclerosis, a motor neuron disease leading to muscle atrophy (Anthony and Gallo, 2010; LagierTourenne et al., 2010; Lee et al., 2012; Ling et al., 2013). Accumulation and inefficient removal
of these RNA-protein granules leads to cellular stress predominantly affecting neuronal cells
(Buchan et al., 2013; Li et al., 2013; Liu-Yesucevitz et al., 2011; Ramaswami et al., 2013).

2.4.10.2 Mitochondrial RBPs in disease
Generally, mitochondrial RBPs, such as translation elongation factors GFM1 and TSFM, cause
deficiencies in oxidative phosphorylation, that manifest themselves on a physiological level as
neurological and muscular myopathies (Smeitink et al., 2006; Smits et al., 2010; Yao and Fox,
2013).

2.4.10.3 Diseases involving snRNA-binding proteins
Mutation or loss-of-function of snRNA-binding and assembly factors are known to lead to defects
in assembly of spliceosomal U snRNPs and thus ultimately cause mRNA splicing defects.
Overall, only a few snRNA-binding proteins have been linked to human disease so far. Loss-offunction of the snRNP assembly factor SMN causes spinal muscular atrophy (SMA). SMN
proteins form a multimeric complex with Gemin proteins, which carries out assembly of snRNPs
and other RNP complexes in the cytoplasm (Battle et al., 2006; Paushkin et al., 2002). Autosomal
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recessive loss-of-function of the SMN1 gene is the molecular cause for SMA, affecting one in
6000 births (Gubitz et al., 2004). In the autosomal recessive disorder, the SMN1 locus is deleted
and SMN2 becomes the main transcription locus. Due to a point mutation in SMN2 very low
amounts of full-length SMN protein are produced, which leads to highly skewed ratios of snRNPs
and results in global aberrant splicing patterns (Cooper et al., 2009; Zhang et al., 2008). While
snRNP assembly defects are detected in all tissues upon SMN1 deletion, the physiological
phenotype manifests itself mainly in motor neurons (Cooper et al., 2009; Glisovic et al., 2008;
Liu-Yesucevitz et al., 2011), similar in phenotypes to defects in mRBP splicing factors.
Interestingly, loss-of-function of RBPs in the U2, U12 and U4/U6-U5 snRNP complexes
specifically cause myelodysplastic syndromes (Lindsley and Ebert, 2013) and retinitis
pigmentosa, a retinal degeneration leading to blindness caused by incorrect splicing of mRNAs
encoding for photoreceptors (Daiger et al., 2013). Why mutations in components of the general
splicing machinery display highly tissue-specific phenotypes in the eye remains unclear (Singh
and Cooper, 2012; Wang and Cooper, 2007).

2.4.10.4 Diseases of tRNA-binding proteins
Disease-causing mutations in tRNA-binding proteins are found in the tRNA maturation and
aminoacylation pathways and show predominantly neurological phenotypes (Scheper et al.,
2007b) (Table 2.1). Mutations in a number of cytoplasmic tRNA synthetases cause CharcotMarie-Tooth disease, affect the peripheral nervous system and lead to muscular atrophy
(Antonellis and Green, 2008; Yao and Fox, 2013). Loss-of-function of components of the TSEN
tRNA-splicing

endonuclease

lead

to

pontocerebellar

hypoplasia,

a

sometimes

fatal

underdevelopment of the cerebellum that causes intellectual disability and impairs muscle control
and motor skills (Budde et al., 2008). Mutations in cytoplasmic tRNA aminoacyl synthetases lead
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to inefficient translation (Scheper et al., 2007b). The disease phenotypes for cytoplasmic tRNA
aminoacyl synthetases overlap with mRBP diseases.

2.4.10.5 Diseases of rRNA-biogenesis and ribosomal proteins
Loss-of-function of rRNA biogenesis factors and ribosomal proteins are generally embryonically
lethal and only few diseases, classified as ribosomopathies, are known for these RBPs (Narla and
Ebert, 2010; Ruggero and Pandolfi, 2003). Ribosomopathies commonly show growth retardation,
organ malformation and frequently bone marrow failure (Liu, 2006). Examples of
ribosomopathies include mutations in the SBDS involved in rRNA biogenesis that causes
Shwachman-Bodian syndrome, patients also show exocrine pancreatic dysfunction; mutation in
SBDS leads to a deficit in neutrophils (Boocock et al., 2003). A number of mutations in
ribosomal proteins cause Diamond-Blackfan anemia, a disease which impairs red blood cell
formation (Narla and Ebert, 2010). A number of other ribosomopathies are caused by mutations
in RNA Pol I components or rRNA-specific transcription factors, such as in Treacher-Collins
syndrome (Dauwerse et al., 2011; Edwards et al., 1997) [reviewed in (McCann and Baserga,
2013)].

2.4.10.6 Diseases of snoRNA-binding proteins
snoRNA-binding proteins are required for the maturation of rRNAs, snRNAs, and the H/ACAsnRNA-like telomerase RNA. snoRNPs introduce nucleotide modifications in their targets, which
are essential for viability (Watkins and Bohnsack, 2012). Thus loss-of-function of snoRNPs leads
to deficient nucleotide modifications in rRNAs, snRNAs and telomerase RNA (Bachellerie et al.,
2002; Filipowicz and Pogacić, 2002). As a consequence, snoRNP disease phenotypes overlap
with ribosomopathies, as well as genetic diseases of components involved in telomerase
assembly, such as TERT and WRAP53 of the telomerase complex. Defects in snoRNA
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biogenesis manifest themselves in the severe developmental disorder dyskeratosis congenita, lead
to bone marrow failure, growth retardation, neurological defects and premature aging (Filipowicz
and Pogacić, 2002; Ruggero et al., 2003; Smogorzewska and de Lange, 2004).

2.4.10.7 Diseases of microRNA pathway components
Mutations in miRNA-binding proteins are found in different cancers and developmental disorders
(Kaneko et al., 2011; Merritt et al., 2008; Perron and Provost, 2009). Mutations, loss-of-function,
or reduced levels of DICER1, TARBP2, and XPO5 have been found in pleuropulmonary
blastomas, ovarian and other cancers (Hill et al., 2009; Melo et al., 2010; 2009; Zhang et al.,
2006).

2.4.10.8 Autoimmune diseases caused by RBPs
In recent years it has become evident that nucleic acids play a central role in autoimmune and
cellular-stress-related diseases. A number of nucleases and RBPs specific for DNA/RNA hybrids,
or which have overlapping DNA/RNA specificity, display autoimmune disease phenotypes.
Mutations or loss-of-function in three RNA/DNA nucleases, SAMHD1, the RNase H2 complex,
and TREX1, lead to development of the autoimmune disease Aicardi-Goutieres syndrome (AGS),
a neurodevelopmental disorder causing white matter abnormalities and cerebral atrophy.
Symptomatically, AGS overlaps with the autoimmune disorder systemic lupus erythematosus
(SLE) (Crow et al., 2006b). In both cases, a failure to remove accumulating nucleic acids is
central to disease development and activates the innate immune system by type I interferon
signaling (Atianand and Fitzgerald, 2013; Rabe, 2013). The triphosphatase SAMHD1 possesses
3’-to-5’ exonuclease activity for ssRNA, ssDNA, and DNA/RNA hybrids. Its antiviral and
autoimmune-suppressive function has been attributed to its role in the removal of nucleotides and
nucleic acids in the cell (Beloglazova et al., 2013). The heterotrimeric RNase H2 complex
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endonucleolytically cleaves DNA/RNA hybrids and is thought to be required for the removal of
Okazaki fragments during DNA replication (Cerritelli and Crouch, 2009; Rabe, 2013). Mutations
in all three subunits of the RNase H2 complex (RNASEH2A, RNASEH2B, RNASEH2C) have
been found to cause AGS (Crow et al., 2006b; Rabe, 2013). The 3’-to-5’ ssDNA and ssRNA
exonuclease TREX1 is involved in the degradation of ssDNA fragments during replication and
antiviral defense (Rabe, 2013; Yuan et al., 2015). Mutations in TREX1 are found in AGS patients
(Crow et al., 2006a) and TREX1 knockout mice accumulate endogenous retroelements. The
accumulating nucleic acids are thought to trigger a subsequent interferon response (Stetson et al.,
2008). Loss-of-function of the dsRNA-editing ADAR enzyme has also been shown to cause AGS
by an as yet unknown mechanism (Rice et al., 2012).
Notably, while not directly related to loss-of-function mutations in RBPs, many
autoantibodies against other RBPs and even RNA have been detected in autoimmune diseases,
pointing to a central importance of a dysregulation of nucleic acid/RNA metabolism in the
mechanism of autoimmune diseases (DeHoratius et al., 1975; Gelpi et al., 1992; Gold et al., 1988;
Hendrick et al., 1981; Pettersson et al., 1984). It is thought that dysregulation of RNA clearance
mechanisms triggers innate immune responses and leads to apoptosis and release of RBP-RNA
complexes into circulation. There these granules mobilize the immune system to develop
autoantibodies against self-RNA-protein complexes (Gaipl et al., 2005; Muñoz et al., 2010). The
Ro60 complex, consisting of the TROVE2 (Ro60) protein and Y RNAs, was among the first
identified targets of autoimmune antibodies in SLE patients was the Ro-RNP particle (Hendrick
et al., 1981; Lerner et al., 1981). The Ro60 complex plays a regulatory role in DNA replication
and stress response, removing misfolded RNAs, and mice lacking Ro60 develop lupus-like
syndromes (Chen and Wolin, 2004; Hall et al., 2013; Sim and Wolin, 2011). Cleavage of tRNAs
and Y RNAs accompanies cellular stress response and apoptosis (Hall et al., 2013; Köhn et al.,
2013; Nawrot et al., 2011; Phizicky and Hopper, 2010) and these stress-induced small RNA
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fragments may also act as immune-stimulatory RNAs. Autoantibodies against RBPs associating
with these RNAs have been found in serum of SLE patients, stressing the importance of efficient
clearance of circulating RNP granules in autoimmune diseases.
Dysfunctional nucleic acid clearance has not only been associated with autoimmune
diseases, but also with neurological defects of the peripheral nervous system, as seen in loss-offunction of the RNA exosome component EXOSC3 and RNASET2 (Henneke et al., 2009; Monti
et al., 2008; Wan et al., 2012). Loss of these general RNA turnover factors more closely
resembles loss of mRBPs or tRNA-binding proteins.
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Table 2.1 Overview of RBPs involved in human genetic diseases. Overview of RBPs with
identified genetic disease-causing mutations collected in the OMIM database (Hamosh et al.,
2005), categorized into their main RNA target groups. Mitochondrially localized proteins are
indicated with (mt). Proteins within the same RBP family are written in one line, family members
also involved in the same disease are highlighted in bold, family members involved in other
diseases are highlighted in brown and listed elsewhere again in a separate category.
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RBP
class
mRNAbinding

Disease
category
cancer

muscular/
cardiac
disease

neurological
disease

RBP family

Disease

Genetic mutation

Reference

EWSR1, FUS,
TAF15

Ewing sarcoma, soft
tissue tumors

gene fusion

TPR

gastric, thyroid
carcinoma, sarcoma

gene fusion

CNBP,
ZCCHC13

myotonic dystrophy

MBNL1,
MBNL2,
MBNL3
CELF1,
CELF2-6
MATR3,
RBM20
PABPN1,
PABN1L

myotonic dystrophy

RNA repeat
expansion sequesters
RBPs
sequestered RBP in
repeat expansion

(Gill et al., 1995; Ichikawa
et al., 1994; May et al.,
1993; Panagopoulos et al.,
1994; 1999)
(Dean et al., 1987;
Gonzatti-Haces et al.,
1988)
(Liquori et al., 2001)

muscular dystrophy

polyalanine
expansion leading to
protein aggregation

AFF1, AFF2,
AFF3, AFF4

mental retardation

(Knight et al., 1993;
Stettner et al., 2011)

ATXN1,
ATXN1L

spinocerebellar ataxia

ATXN2,
ATXN2L

spinocerebellar ataxia,
susceptibility to lateonset Parkinson disease,
susceptibility to
amyotrophic lateral
sclerosis (ALS)

deletion, loss-offunction through
repeat expansion in
mRNA
polyglutamine
expansion leading to
protein aggregation
polyglutamine
expansion leading to
protein aggregation

DYNC1H1,DN
AH1-11,
DNAH17,
DYNC2H1

Charcot-Marie-Tooth
disease, mental
retardation, spinal
muscular atrophy
(SMA)
leukoencephalopathy
with vanishing white
matter

missense mutation

(Harms et al., 2012;
Vissers et al., 2010;
Weedon et al., 2011)

missense mutation

(van der Knaap et al.,
2002)

leukoencephalopathy
with vanishing white
matter
leukoencephalopathy
with vanishing white
matter
leukoencephalopathy
with vanishing white
matter
leukoencephalopathy
with vanishing white
matter
Parkinson disease

missense, nonsense
mutation

(Leegwater et al., 2001)

missense mutation

(van der Knaap et al.,
2002)

missense mutation

(van der Knaap et al.,
2002)

missense mutation

(Fogli et al., 2002;
Leegwater et al., 2001; van
der Knaap et al., 2002)
(Chartier-Harlin et al.,
2011)

fragile X mental
retardation syndrome
(FXS), fragile X
tremor/ataxia syndrome
(FXTAS), premature
ovarian failure

deletion, repeat
expansion leading to
protein loss-offunction (FXS) or
RNA-gain-offunction (FXTAS)

EIF2B1

EIF2B2
EIF2B3
EIF2B4
EIF2B5
EIF4G1,
EIF4G2,
EIF4G3
FMR1, FXR1,
FXR2

myotonic dystrophy
cardio-/distal myopathy
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sequestered RBP in
repeat expansion
missense mutation

missense mutation

(Fardaei, 2002; Mankodi
et al., 2001; Miller, 2000)
(Roberts et al., 1997;
Timchenko et al., 1996)
(Brauch et al., 2009;
Senderek et al., 2009)
(Brais et al., 1998)

(Banfi et al., 1994; Orr et
al., 1993; Servadio et al.,
1995)
(Cancel et al., 1997; Elden
et al., 2010; Gwinn-Hardy
et al., 2000; Pulst et al.,
1996)

(Devys et al., 1992;
Gedeon et al., 1992;
Hagerman et al., 2001;
Kremer et al., 1991;
Murray et al., 1998;
Wöhrle et al., 1992)

EWSR1, FUS,
TAF15

amyotrophic lateral
sclerosis (ALS)

DAZAP1,
HNRNPA2B1,
HNRNPA0,
HNRNPAB,
HNRNPA1L2,
HNRNPA1,
HNRNPA3,
HNRNPD,
HNRNPDL
TARDBP

amyotrophic lateral
sclerosis (ALS)

IGHMBP2

distal spinal muscular
atrophy (DSMA1)
Leigh syndrome
Rett syndrome, Xlinked mental
retardation

LRPPRC
MECP2

MTPAP,
PAPD4, TUT1,
ZCCHC6,
ZCCHC11
PARK7
PQBP1
PRKRA,
TARBP2
RANBP2,
RGPD1-6,
RGPD8
NOVA1,
NOVA2
ELAVL1,
ELAVL2,
ELAVL3,
ELAVL4
UPF3A,
UPF3B
TIA1, TIAL1

neurological/
developmental
disease
developmental
disease

RBFOX1,
RBFOX2,
RBFOX3
GLE1
BICC1
EEF2,
EFTUD2
EIF2AK1,
EIF2AK2,
EIF2AK3
FTO
NR0B1,
NR0B2
RBM5, RBM6,
RBM10
RBM11,
SF3B4

amyotrophic lateral
sclerosis (ALS)

sequesters RBPs
missense mutation
leading to prion-like
protein aggregation
missense mutation
leading to prion-like
protein aggregation

(Kwiatkowski et al., 2009;
Vance et al., 2009)
(Kim et al., 2013b)

missense mutation
leading to protein
aggregation
missense mutation

(Sreedharan et al., 2008)

missense mutation
missense, nonsense
mutation, frameshift,
deletion

(Grohmann et al., 2001)

spastic ataxia

missense mutation

(Mootha et al., 2003)
(Amir et al., 1999;
Cheadle et al., 2000;
Huppke et al., 2000; Wan
et al., 1999)
(Crosby et al., 2010)

Parkinson disease
Renpenning syndrome 1
dystonia

missense mutation
frameshift
frameshift, missense
mutation
missense mutation

(Bonifati et al., 2003)
(Kalscheuer et al., 2003)
(Camargos et al., 2008;
Seibler et al., 2008)
(Neilson et al., 2009)

autoantibodies

(Buckanovich et al., 1996)

autoantibodies

(Sakai et al., 1994)

frameshift, missense,
nonsense mutation
missense mutation

(Tarpey et al., 2007)

deletion, breakpoint

(Bhalla et al., 2004; Martin
et al., 2007)

lethal congenital
contracture syndrome

splice site mutation,
missense mutation

(Nousiainen et al., 2008)

susceptibility to renal
dysplasia
mandibulofacial
dysostosis with
microcephaly
Wolcott-Rallison
syndrome, multiple
epiphyseal dysplasia
growth retardation,
developmental delay
congenital adrenal
hypoplasia
TARP syndrome

missense, nonsense
mutation
splice site mutation,
nonsense, missense
mutation, frameshift
missense, nonsense
mutation, splice site
mutation
missense mutation

(Kraus et al., 2012)

deletion, missense
mutation
frameshift, missense
mutation
missense, nonsense
mutation, frameshift

(Muscatelli et al., 1994;
Yanase et al., 1996)
(Johnston et al., 2010)

acute, infection-induced
susceptibility to
encephalopathy
paraneoplastic
opsoclonus-myoclonus
ataxia (POMA)
paraneoplastic
neurological disorders,
encephalomyelitis,
neuropathy
mental retardation
Welander distal
myopathy
mental retardation,
epilepsy

acrofacial dysostosis
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(Hackman et al., 2012)

(Bernier et al., 2012;
Gordon et al., 2012; Lines
et al., 2012)
(Brickwood et al., 2003;
Delépine et al., 2000;
Durocher et al., 2006)
(Boissel et al., 2009)

(Bernier et al., 2012;
Czeschik et al., 2013)

SKIV2L
infertility
metabolic
disease

BOLL, DAZ14, DAZL
AUH, ECH1,
ECHS1,
ECHDC2,
ECHDC3
C12ORF65
(mt)
GFM1 (mt)
TSFM (mt)
EEFSEC,
TUFM (mt)

hematologic
disease

Immunologica
l/ skin disease

tRNAbinding

cancer/
metabolic
disease
muscular/
metabolic/
hematologic
disease

SECISBP2,
SECISBP2L
FIP1L1
U2AF1,
U2AF1L4
ZRSR1, ZRSR2
ADAD1,
ADAD2,
ADAT, ADAR,
ADARB1,
ADARB2
ELAC1,
ELAC2
PUS1

YARS2 (mt)
neurological
disease

AARS, AARS2
(mt)
AIMP1, YARS

CLP1
KARS
GARS
ANG,
RNASE1-4,
RNASE6-8
DARS2 (mt)

trichohepatonenteric
syndrome 2
azoospermia

missense, nonsense
mutation
deletion

(Fabre et al., 2012)

3-methylglutaconic
aciduria

nonsense mutation,
frameshift, splice site
mutation

(IJlst et al., 2002; Ly et al.,
2003)

combined oxidative
phosphorylation
deficiency, spastic
paraplegia-55 (SPG55)
combined oxidative
phosphorylation
deficiency
combined oxidative
phosphorylation
deficiency
combined oxidative
phosphorylation
deficiency
abnormal thyroid
metabolism
spontaneous
hypereosinophilic
syndrome
myelodysplastic
syndrome

frameshift, missense,
nonsense mutation

(Antonicka et al., 2010;
Shimazaki et al., 2012)

missense, nonsense
mutation

(Coenen et al., 2004;
Valente et al., 2007)

missense mutation

(Smeitink et al., 2006)

missense mutation

(Valente et al., 2007)

missense mutation

(Dumitrescu et al., 2005)

deletion leading to
gene fusion

(Cools et al., 2003; Griffin
et al., 2003)

missense mutation

(Graubert et al., 2012)

Aicardi-Goutieres
syndrome (AGS),
dyschromatosis
symmetrica hereditaria
1 (DSH1)
prostate cancer,
combined oxidative
phosphorylation
deficiency
myopathy, lactic
acidosis and
sideroblastic anemia 1

missense, nonsense
mutation

(Miyamura et al., 2003;
Rice et al., 2012)

missense, nonsense
mutation, frameshift

(Haack et al., 2013;
Tavtigian et al., 2001)

missense, nonsense
mutation

(Bykhovskaya et al., 2004;
Fernandez-Vizarra et al.,
2007)

myopathy, lactic
acidosis and
sideroblastic anemia 2
Charcot-Marie Tooth
disease
hypomyelinating
leukodystrophy,
Charcot-Marie Tooth
disease
Pontocerebellar
hypoplasia
Charcot-Marie Tooth
disease, deafness
Charcot-Marie Tooth
disease
amyotrophic lateral
sclerosis (ALS)

missense mutation

(Riley et al., 2010)

missense mutation
frameshift, missense
mutation, deletion

(Latour et al., 2010; Lin et
al., 2011)
(Feinstein et al., 2010;
Jordanova et al., 2006)

missense mutation

(Karaca et al., 2014)

missense mutation,
frameshift
missense mutation

(McLaughlin et al., 2010;
Santos-Cortez et al., 2013)
(Antonellis et al., 2003)

missense mutation

(Greenway et al., 2006)

leukoencephalopathy

frameshift, missense,
nonsense mutation,
splice site mutation
nonsense, missense
mutation, splice site
mutation
frameshift, splice site

(Scheper et al., 2007a)

NSUN2

mental retardation

FTSJ1

mental retardation
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(Reijo et al., 1995)

(Abbasi-Moheb et al.,
2012; Khan et al., 2012)
(Freude et al., 2004;

mutation
splice site mutation,
missense mutation

Ramser et al., 2004)
(Edvardson et al., 2007;
Rankin et al., 2010)

pontocerebellar
hypoplasia
pontocerebellar
hypoplasia
pontocerebellar
hypoplasia
pontocerebellar
hypoplasia
spinocerebellar ataxia

missense mutation

(Agamy et al., 2010)

missense mutation

(Budde et al., 2008)

missense mutation

(Budde et al., 2008)

missense, nonsense
mutation, deletion
missense mutation

(Budde et al., 2008;
Cassandrini et al., 2010)
(Hekman et al., 2012)

combined oxidative
phosphorylation
deficiency

missense mutation

(Götz et al., 2011)

MTO1 (mt)

combined oxidative
phosphorylation
deficiency

frameshift, missense
mutation

(Ghezzi et al., 2012)

EARS2 (mt)

missense mutation,
insertion

(Steenweg et al., 2012;
Talim et al., 2013)

missense mutation

(Elo et al., 2012;
Shamseldin et al., 2012)

missense mutation

(Belostotsky et al., 2011)

TRMU (mt)

combined oxidative
phosphorylation
deficiency
combined oxidative
phosphorylation
deficiency
hyperuricemia,
pulmonary
hypertension, renal
failure, and alkalosis
liver failure, deafness

missense mutation

HARS,
HARS2 (mt)

Usher syndrome,
Perrault syndrome

missense mutation

(Guan et al., 2006; Zeharia
et al., 2009)
(Pierce et al., 2011;
Puffenberger et al., 2012)

EMG1

Bowen-Conradi
syndrome
lipodystrophy, muscular
dystrophy

missense mutation

(Armistead et al., 2009)

frameshift

(Hayashi et al., 2009;
Shastry et al., 2010)

Shwachman-Diamond
syndrome

frameshift, missense,
nonsense mutation

(Boocock et al., 2003;
Nakashima et al., 2004)

WDR36

open angle glaucoma

missense mutation

(Monemi et al., 2005)

SMN1, SMN2

spinal muscular atrophy
(SMA)

missense, nonsense
mutation, frameshift,
deletion

RBM28

alopecia, neurologic
defects, endocrinopathy
syndrome
porokeratosis
retinitis pigmentosa

missense mutation

(Cobben et al., 1995;
Gambardella et al., 1998;
Hahnen et al., 1997;
Lefebvre et al., 1995;
Parsons et al., 1996; Sossi
et al., 2001)
(Nousbeck et al., 2008)

missense mutation
missense mutation

(Zhang et al., 2005)
(Zhao et al., 2009)

retinitis pigmentosa
retinitis pigmentosa

missense mutation
splice site
mutation/deletion,
missense mutation
missense mutation
missense mutation
missense mutation

(Chakarova et al., 2002)
(Vithana et al., 2001)

RARS, RARS2
(mt)

pontocerebellar
hypoplasia

SEPSECS
TSEN2
TSEN34
TSEN54
metabolic
disease

EEF2,
EFTUD2
AARS, AARS2
(mt)

FARS2 (mt)
SARS2 (mt)

rRNAbinding

snRNAbinding

opthalmologic
disease/
hearing loss
developmental
disease

developmental
/ hematologic
disease
opthalmologic
disease
neurological
disease

skin disease
opthalmologic
disease

MURC, PTRF,
PRKCDBP,
SDPR
SBDS

SART3
SNRNP200,
ASCC3
PRPF3
PRPF31
PRPF6
PRPF8
RP9

retinitis pigmentosa
retinitis pigmentosa
retinitis pigmentosa
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(Tanackovic et al., 2011)
(McKie et al., 2001)
(Keen et al., 2002)

snoRNA
-binding

neurological
disease

NOP56

spinocerebellar ataxia

hematologic/
neurodevelop
mental/
developmental
disorder

DKC1

dyskeratosis congenita

RNA repeat
expansion sequesters
RBPs
missense mutation,
deletion, intron
insertion, splice site
mutation

NHP2
NOP10

dyskeratosis congenita
dyskeratosis congenita

missense mutation
missense mutation

(Kobayashi et al., 2011)
(Heiss et al., 1998;
Kanegane et al., 2005;
Knight et al., 1999; 2001;
Pearson et al., 2008;
Vulliamy et al., 1999)
(Vulliamy et al., 2008)
(Walne et al., 2007)

Cytosolic
ribosomal
proteins

skin disease

USB1

neurological
disease
hematologic
disease

RPL10,
RPL10L
RPL11
RPL35A
RPL5
RPS10
RPS17,
RPS17L
RPS19
RPS24
RPS26
RPS7

Mitochondr.
(mt)
ribosomal
proteins

metabolic
disease

MRPL3
MRPS16
MRPS22

lncRNAbinding

miRNAbinding

poikiloderma with
neutropenia
autism

deletion, splice site
mutation, frameshift
missense mutation

(Tanaka et al., 2010; Volpi
et al., 2010)
(Klauck et al., 2006)

Diamond-Blackfan
anemia

frameshift, deletion,
splice site mutation,
nonsense mutation
missense, nonsense
mutation, deletion
missense, nonsense
mutation, frameshift,
splice site mutation
missense, nonsense
mutation, frameshift
missense, frameshift

(Gazda et al., 2008)

Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
Diamond-Blackfan
anemia
combined oxidative
phosphorylation
deficiency
combined oxidative
phosphorylation
deficiency
combined oxidative
phosphorylation
deficiency
breast, ovarian,
pancreatic cancer

cancer

BRCA1

developmental
disorder
cancer

EZH1, EZH2

Weaver syndrome 2

DICER1

pleuropulmonary
blastoma, goiter with
testicular tumors,
embryonal
habdomyosarcoma
colorectal cancer
colorectal cancer,
Loeys-Dietz syndrome,
juvenile polyposis,
pancreatic cancer

cancer/
developmental
disorder

XPO5
SMAD1,
SMAD2,
SMAD3,
SMAD4,
SMAD5,
SMAD6,
SMAD7,
SMAD9
PRKRA,

colorectal cancer
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missense, nonsense
mutation, frameshift
nonsense mutation,
frameshift
missense mutation,
splice site mutation,
frameshift
splice site mutation

(Farrar et al., 2008)
(Gazda et al., 2008)
(Doherty et al., 2010)
(Cmejla et al., 2007;
Gazda et al., 2008)
(Draptchinskaia et al.,
1999; Matsson et al.,
1999)
(Gazda et al., 2006)
(Doherty et al., 2010)
(Gazda et al., 2008)

missense mutation

(Galmiche et al., 2011)

nonsense mutation

(Miller et al., 2004)

missense mutation

(Saada et al., 2007)

missense, nonsense
mutation, deletion,
frameshift
missense mutation,
frameshift
missense, nonsense
mutation, frameshift

(Al-Sukhni et al., 2008;
Castilla et al., 1994;
Simard et al., 1994)
(Gibson et al., 2012)

frameshift, insertion
missense, nonsense
mutation, frameshift

(Melo et al., 2010)
(Broderick et al., 2007;
Howe et al., 1998;
Regalado et al., 2011;
Schutte et al., 1996; van de
Laar et al., 2011)

frameshift

(Melo et al., 2010)

(Foulkes et al., 2011; Hill
et al., 2009; Rio Frio et al.,
2011)

developmental
disorder

telRNAbinding

7SLRNAbinding
immunestimulatory
RNAbinding
RNA/
DNAhybridbinding

TARPBP2
DIS3, DIS3L,
DIS3L2

deletion, splice site
mutation, missense
mutation
missense mutation

(Astuti et al., 2012)

missense, nonsense
mutation

(Drake et al., 2011; Nasim
et al., 2011; Tan et al.,
2012)

coronary artery disease,
dyskeratosis congenita,
aplastic anemia

missense mutation,
frameshift

(Armanios et al., 2007;
Marrone et al., 2007;
Tsakiri et al., 2007;
Yamaguchi et al., 2005)

WRAP53

dyskeratosis congenita

missense mutation

(Zhong et al., 2011)

SRP72

bone marrow failure

missense mutation

(Kirwan et al., 2012)

metabolic
disease
cancer

OAS1, OAS2,
OAS3, OASL
RNASEL

susceptibility to diabetes
mellitus
prostate cancer

missense mutation

(Tessier et al., 2006)

nonsense, missense
mutation

(Carpten et al., 2002;
Casey et al., 2002)

autoimmune/
neurological
disease

RNASEH2A

Aicardi-Goutieres
syndrome (AGS)
Aicardi-Goutieres
syndrome (AGS)
Aicardi-Goutieres
syndrome (AGS)
Aicardi-Goutieres
syndrome (AGS),
Chilbain lupus 2
pontocerebellar
hypoplasia, spinal motor
neuron degeneration
leukoencephalopathy,
cancer

missense mutation
missense mutation

(Crow et al., 2006b; Rice
et al., 2013)
(Crow et al., 2006b)

missense mutation

(Crow et al., 2006b)

missense mutation

(Ravenscroft et al., 2011;
Rice et al., 2009)

missense mutation,
deletion

(Wan et al., 2012)
(Henneke et al., 2009)

(Koss-Harnes et al., 2002;
McLean et al., 1996;
Pulkkinen et al., 1996;
Selcen et al., 2011; Smith
et al., 1996)
(Orloff et al., 2011)

neurological
disease

SNIP1

pulmonary
disease

SMAD1,
SMAD2,
SMAD3,
SMAD4,
SMAD5,
SMAD6,
SMAD7,
SMAD9
TERT

developmental
/ cardiovascular/
pulmonary
disease
developmental
disorder
hematologic
disease

RNASEH2B
RNASEH2C
SAMHD1

diverse
targets

neurological
disease

EXOSC3
RNASET2

unknown
targets

psychomotor
retardation, epilepsy,
craniofacial
dymorphism
pulmonary
hypertension, aortic
valve disease (AOVD2)

CALR3,
CALR, CANX,
CLGN
PLEC, DSP,
EPPK1

cardiomyopathy

missense mutation,
deletion, splice site
mutation
missense mutation

epidermolysis bullosa
simplex with muscular
dystrophy

insertion, deletion,
missense, nonsense
mutation

developmental
disorder
neurological
disease

ASCC1

barrett esophagus

missense mutation

APTX, PNKP

ataxia

pulmonary
disease
ophthalmol.
disease

DNAAF2

ciliary dyskinesia

TDRD7

cataract

deletion, splice site
mutation, missense
mutation
insertion, nonsense
mutation
frameshift

cardiac
disease
connective
tissue/ skin/
muscular
disease

RBPinteracting
proteins

Perlman syndrome
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(Puffenberger et al., 2012)

(Chiu et al., 2007)

(Amouri et al., 2004;
Criscuolo et al., 2005)
(Omran et al., 2008)
(Lachke et al., 2011)

2.4.11 FAM98A is a novel RG/RGG-rich RBP
Several decades ago, arginine/glycine-rich structural repeats were identified to be often present in
heteronuclear RBPs (hnRNPs) [reviewed in (Thandapani et al., 2013)]. Consecutive repeats of
RG/RGG amino acid motif, separated by few amino acids in between, created a functional unit
defined as an RG/RGG box and were enriched in RBPs and some extracellular proteins such as
collagens. These RG/RGG boxes were subsequently shown to influence RBP transport through
posttranslational modifications of the RG residues and also to directly bind to RNA (Kiledjian
and Dreyfuss, 1992; Shen et al., 1998). The prion-like, undefined structural properties of
RG/RGG rich RBPs causes them to easily aggregate in RNA-protein granules, and a number of
them have been implicated in diseases with prion-like aggregation into stress granules (Kim et al.,
2013b; Li et al., 2013; Ramaswami et al., 2013). The location of RG/RGG boxes is often
conserved within these RBPs, suggesting functional conservation (Thandapani et al., 2013).
However, because of their loose structural definition, these low-complexity regions are not
defined as structural domains by public protein domain databases such as Pfam, SMART, or
InterPro, and currently missed by protein domain annotations (Apweiler et al., 2001; Finn et al.,
2010; Letunic et al., 2009).
We noticed the density of RG/RGG boxes in a number of RNA transport proteins such as
FUS, EWSR1, HNRNPU, and hypothesized that if RG-rich repeats were RNA-binding or
characteristic of RBPs, their presence may be a sufficient predictor for RBPs. To identify de novo
RBPs based on RG/RGG-rich regions, I conducted a genome-wide search of RG/RGG repeats in
human proteins. I scanned all human protein isoforms for the presence of at least three RG/RGG
motifs and examined the distribution of RG/RGG motifs across known RBPs, comparing them to
the residual proteome (Figure 2.12 A). On average distances of <20 amino acids were found
between RG/RGG motifs in RBPs (Figure 2.12 A). Based on the distribution of RG repeats in
RBPs, I defined a conservative approach to identify and classify RG/RGG boxes in proteins, if a
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minimum of at least three RG/RGG amino acid motifs were found within a distance of ≤10 amino
acids between each RG/RGG amino acid sequence. This gave a local density measure of
RG/RGG boxes independent the total number of RG/RGG motifs and the length of the protein.
From this definition I ranked the number of genes with one or more RG/RGG box. Further
excluding collagen genes, 369 proteins had at least one or more RG/RGG repeat. The highest
enriched Gene Ontology pathway was mRNA-binding and indeed 80 of those proteins were
known characterized RBPs in our RBP census. In fact, RG repeats are a commonly encountered
structural feature in RBPs and the second most abundant structural motif in our curated census,
after the RRM domain (Figure 2.3 A). The top five RG/RGG rich proteins in humans were all
RBPs: ZC3H4, TAF15, EWSR1, CHTOP, SYNCRIP with 21, 20, 20, 19 and 16 RG-boxes
respectively. Of the 98 proteins with at least three RG/RGG boxes, 50 were known RBPs; the
uncharacterized FAM98A and B protein were among the 48 putative RBP candidates.
The FAM98 protein family is absent in S. cerevisae, but highly conserved across higher
eukaryotes, from C. elegans, fruitfly, to vertebrates. FAM98 proteins contain one conserved
protein domain of unknown function (DUF2465) (Finn et al., 2010) (Figure 2.12 B). FAM98A
has two paralogs in humans, FAM98B and C. FAM98C remains uncharacterized, but FAM98B
was recently identified in a complex with the HSPC117 (RtcB) tRNA splicing ligase (Popow et
al., 2011). FAM98A contains six RG/RGG boxes, FAM98B contains three, and FAM98C has
none. While the number of RG/RGG boxes varies across organisms, the location of the RG/RGG
repeats is generally conserved in FAM98A: one RG/RGG box lies within the conserved
DUF2465 domain and two other boxes lie in the C-terminal region (Figure 2.12 C). To test
whether the FAM98 family may be an RBP family, I chose FAM98A as candidate, since it had
the highest count of RG/RGG boxes and their density most likely suggested a role in RNAbinding. To assess the closest structurally homologous relationship of the unknown domain of
FAM98A, I ran a Phyre2 domain folding prediction of the conserved DUF2465 domain of
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FAM98A, which most strongly resembled the kinetochore Hec1/human NDC80 protein (Kelley
et al., 2015) (Figure 2.12 B). Hec1 is required for spindle checkpoint signaling, which assures
correct chromosome segregation during cell division (Martin-Lluesma et al., 2002). A previous
computational study also noted the structural similarities of FAM98 proteins with Hec1
kinetochore and other microtubule associated proteins (Schou et al., 2014).
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Figure 2.12 FAM98A is a conserved RG-rich mRBP. (A) Density plot of the geometric mean
distances of RG/RGG repeats of proteins with at least three RG/RGG repeats. RBPs are shown in
red, other proteins in grey. The highest density of RG/RGG amino acid repeats is 17 for RBPs
and 43 for non-RBPs. (B) Phyre2 predicted domain folding of the conserved DUF2465 domain of
FAM98A shows similarities to the Hec1 kinetochore protein. (C) FAM98A is a conserved protein
across vertebrates and invertebrates. Domain distribution of the DUF2465 (green) and RG repeats
(dark blue) and conservation of FAM98A proteins are shown across human, mouse, Xenopus and
Drosophila. (D) Schematic overview of PAR-CLIP: First photoactivatable thioribonucleosides
are incorporated into nascent transcripts, RNA-protein complexes are crosslinked in vivo at UV
365 nm. After cell lysis and limited RNase T1 treatment, RNA–RBP complexes are
immunoprecipitated. The crosslinked RNA segments are recovered, converted into cDNA
libraries and deep sequenced. (E) PAR-CLIP 4-SU crosslink and Western blot of
immunoprecipitated FLAG/HA-tagged FAM98A protein in HEK293 cells. (F) Length
distribution of FAM98A PAR-CLIP reads mapping to mRNA genes. Reads mapping to the
human mRNA reference annotation are split into T>C crosslinked reads (red), reads mapping
with distance 0 to the reference annotation (white), reads mapping with distance 1, but which
contain transitions other than T>C (grey), and reads mapping with distance 2 (black). The x-axis
shows read length, the y-axis shows read number. (G) Pie chart of the distribution of PARalyzer
clusters with ≥20 reads for all annotation categories. (H) Pie chart of the distribution of clusters
with ≥20 reads in mRNA genes alone, given are also the number of total mRNA targets. (I)
Immunostaining of FLAG/HA-FAM98A shows cytoplasmic localization in HEK293 cells.
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To test whether FAM98A had direct RNA-binding activity, I generated stable HEK293
cell lines with doxycycline inducibly expressing FLAG/HA-FAM98A protein and performed
PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation).
In the PAR-CLIP protocol 4-thiouridine (4-SU) metabolically-labeled RNA is crosslinked at 365
nm to interacting protein components in vivo (Hafner et al., 2010a). The photochemical reactivity
of the thio group at the 4-position of the uridine analogue shows increased efficiency of photoinduced

crosslinking

compared

to

the

natural

nucleoside

(Sontheimer,

1994).

Immunoprecipitation of the crosslinked RBP-RNA complex with an RBP-specific antibody,
followed by cDNA library preparation of the RNA for HiSeq sequencing, allows us to identify
transcriptome-wide targets of RBPs (Figure 2.12 D). During crosslinking of the photoreactive 4thiouridine with aromatic amino acids the chemical structure of the uridine analogue changes
such that the reverse transcription step of the library preparation results in a significant
enrichment of T to C (T>C) transitions on the DNA level. Hence, PAR-CLIP sequences
intrinsically contain the information of specific crosslinking events. This is important as during
the RT-PCR step the reverse transcriptase is in many cases blocked as soon as protein-RNA
crosslinks are encountered. As a consequence, about 70-90% of background RNA sequences copurified during immunoprecipitation will be amplified more frequently and make peak detection
of real crosslinking events of RNA to protein very difficult. Consequently, T>C transitions
created by crosslinking of 4-SU to protein targets become an essential parameter for the
identification of specific crosslink events and distinguish specific RNA-protein interactions from
background RNA. For a successful experiment we expect the largest fraction of distance 1
mismatches against the genome to be T>C transitions.
Using PAR-CLIP I established that the previously unknown FAM98A protein was an
RBP and showed that FAM98A crosslinked with high efficiency to the mRNA-transcriptome.
The results are described in the next few sections.
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2.4.11.1 FAM98A is a cytoplasmic mRBP
The FAM98A showed good crosslinking capacity as assessed by phosphorimaging and the
resulting PAR-CLIP library had an unusually high T>C crosslinking efficiency, with thousands of
targets, detecting significant enrichment of T>C transitions over background nucleotide
transitions in sequence reads (Figure 2.12 E, F). To extract the binding regions, sequence reads
were grouped by PARalyzer, which identifies regions with locally enriched T>C conversions in
PAR-CLIP reads over background mismatch errors (Corcoran et al., 2011). Defining a cut-off of
≥20 reads per cluster, 62,980 clusters (or binding regions) were identified by PARalyzer, 54,731
(87%) of those were located in the coding regions, introns, 5’UTR or 3’UTRs of mRNAs (Figure
2.12 G,H). These corresponded to 10,422 total genes; 8,155 of these were protein-coding (Figure
2.12 H). By immunofluorescent analysis FAM98A was predominantly localized in the cytoplasm,
which was in agreement with the PAR-CLIP results of FAM98A predominantly binding to
mature mRNAs (Figure 2.12 I).

2.4.12 FAM98A binds to G-rich regions in mRNA targets
Further inspection of the extracted PAR-CLIP binding regions revealed that FAM98A bound
broadly along the entire transcript, in coverage similar to RNA-seq data, and preferentially bound
to G-rich regions (Figure 2.13 A). To quantify enrichment of sequence motifs in the binding sites,
I used kmer cluster analysis to calculate the enrichment of 4mers along a 20-nt sliding window
within clusters of coding regions, normalizing them over 4mer counts within a 20-nt sliding
window of shuffled coding regions of the complete human transcriptome. By this analysis the
most frequently enriched motifs contained variations of GG, GGG, GNGG, GNNG (Figure 2.13
B). I confirmed this G enrichment using the motif finding algorithm cERMIT, which ranks
clusters based on T>C conversion specificity to give an evidence based estimate of preferred
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binding sites (Georgiev et al., 2010). The top cERMIT motifs of FAM98A clusters were G-rich
motifs (Figure 2.13 C).
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Figure 2.13 PAR-CLIP target clusters, motif enrichment, and RNAi knockdown of
FAM98A. (A) (i) PAR-CLIP cluster along the FAM98A gene. (ii) Representative PAR-CLIP
cluster of FAM98A within the FAM98A gene. Shown is the signal T base enrichment (red),
background intrinsic sequence T enrichment (blue), and read coverage (grey). G-rich regions are
highlighted in yellow in sequence alignments of reads. Number of reads is given behind each
read, T>C transitions are highlighted in red. T>C frequency transitions are shown in a heat map
from blue to yellow below the cluster. (B) Enrichment of 4mers in FAM98A PAR-Clip clusters
normalized over shuffled coding regions. (C) cERMIT motif enrichments resulting from
FAM98A PAR-CLIP clusters. (D) Western blot of knockdowns (three different siRNA duplexes
and all three pooled together) and overexpression of FAM98A, compared to control parental
HEK293 FlpIn T-Rex cells. (E) Log2 fold down- (orange) and up-regulation (blue) of FAM98A
mRNA and control RBP gene (IGF2BP1) assessed by RNA-seq. (F) Cumulative distribution plot
for mRNA abundance of FAM98A targets (red) and background mRNAs (black) in knockdown
versus overexpression experiments.
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2.4.13 FAM98A knockdown does not affect target mRNA stability
To study putative regulatory effects of FAM98A on mRNA stability, I recorded mRNA
expression profiles of siRNA-mediated knockdown of endogenous FAM98A or overexpression
of FLAG/HA-FAM98A in HEK293 cells. Successful knockdown of all three siRNAs was
assessed by Western blot analysis and the pooled knockdown submitted for RNA-sequencing.
siRNA-mediated knockdowns reduced protein levels of FAM98A >10-fold, while doxycycline
induced overexpression of FAM98A slightly reduced expression of endogenous FAM98A, but
increased overall FAM98A levels approximately 2-fold (Figure 2.13 D). FAM98A mRNA levels
were reduced 1.7-fold, while FAM98A overexpression resulted in >4-fold increase in mRNA
levels. To assess the affect of FAM98A knockdown on mRNA stability of its targets, I analyzed
the fold change differences in targets and nontargets mRNA levels in knockdown and
overexpression experiments. The cumulative distribution of FAM98A PARalyzer-defined PARCLIP targets and non-targets showed no significant changes on mRNA stability of its targets
(Figure 2.13 F). At an expression cut-off of rpkm ≥ 0.1 most expressed mRNAs (74%) were
bound by FAM98A. Adding PARalyzer-defined PAR-CLIP binding sites with less than 20 reads
resulted in an even larger fraction of the expressed transcriptome being bound to FAM98A. We
concluded that FAM98A broadly bound most expressed mRNAs in HEK293 cells. Furthermore,
at the protein level, targets displayed no measurable changes in abundance upon FAM98A
knockdown or overexpression by Western blot analysis. Both assays, measuring mRNA and
protein abundance, showed no indication that FAM98A had a role in regulating mRNA or protein
stability, or translation. We reasoned that either FAM98A had an independent role in other RNA
metabolic pathways (such as RNA transport) or that the family members of FAM98A could exert
some redundancy upon RNAi knockdown of FAM98A and that knockdown of one member, but
not the entire family was not sufficient to see regulatory effects. However, in our experience most
studied RBPs with a role in mRNA or protein stability show measurable regulatory effects upon
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knockdown or overexpression even if the expression of their paralogs are unaltered in the cell.
Given the results we decided that the experimental conditions and design had to be significantly
changed to elucidate the function of FAM98A in vivo. With a lacking phenotype upon loss-offunction and an unidentified process to pursue, I decided to not further investigate the effects of
FAM98A expression levels on protein levels using methods such as quantitative mass
spectrometry methods with stable isotope labeling (SILAC) (Mann, 2006). Our analysis of the
PAR-CLIP experiment together with the RNA-seq data showed that generally abundant proteincoding mRNAs were bound by FAM98A and and that all unbound mRNAs were expressed at on
average lower levels than bound targets. Thus, a regulatory role of FAM98A for specific subsets
of mRNAs seemed unlikely and FAM98A may have a general role in RNA translation or
transport.

2.4.14 Summary and discussion on the physiological role of FAM98A
I identified, using low-complexity domain definitions, the novel RBP FAM98A and confirmed its
RNA-binding ability by PAR-CLIP. A number of proteins of unknown function with high
numbers of RG/RGG boxes still remain uncharacterized and it will be interesting to characterize
their role in RNA-binding in the future. Interestingly, also a number of chromatin regulatory
proteins such as MBD2 (methyl-CpG binding protein 2), BRWD3 (bromodomain and WD repeat
domain containing protein 3), KMT2B (Histone-lysine N-methyltransferase 2B) are also highly
RG/RGG rich (12,11,11). For MBD2 (Tan and Nakielny, 2006) RNA-binding capability has been
demonstrated, but physiological RNA targets have not been characterized and a putative role in
RNA-binding of other chromatin regulatory proteins with RG-rich regions would be interesting to
investigate further.
In conclusion, we found that FAM98A bound to most expressed mRNAs with some
enrichment in G-rich regions. FAM98A is a cytoplasmic protein that binds broadly along the
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entire mature mRNA transcript, predominantly in the coding region. Overexpression or
knockdown of FAM98A did not alter mRNA or protein abundance of its targets.

The

predominant localization of PAR-CLIP clusters in coding regions could support a putative role in
protein translation, where it perhaps is required to assist unwinding of extended secondary
structures and thereby to facilitate protein translation. To measure translation changes, a more
global assay such as ribosome profiling may present a better approach to investigate a putative
role of FAM98A during translation (Ingolia, 2014).
Independent of my own studies, two proteome-wide pulldown studies of RBPs also
isolated FAM98A (Baltz et al., 2012; Castello et al., 2012) and one study verified its binding
activity in vitro (Strein et al., 2014). However, their findings disagree with our results in
localization, which was reported to be predominantly nuclear, and RNA-binding capability,
detecting low RNA affinity of FAM98A in GFP-multiTrap essays. In contrast, a proteomic study
of proteins involved in 5’terminal oligopyrimidine (TOP) motif RNAs found FAM98A associated
with the translation regulatory factor LARP and the mTOR complex and supports our finding that
FAM98A is localized to the cytoplasm (Tcherkezian et al., 2014).
FAM98 is highly conserved in metazoan with 33% sequence conservation of the human
FAM98A protein to the Drosophila melanogaster FAM98 homolog CG5913. I tested the
viability of a loss-of-function genetic mutant of CG5913. CG5913 was not an essential gene and
homozygous mutants did not show any physiological abnormalities (data not shown). Together,
given our data, as well as the domain similarities to kinetochore proteins such as Hec1, and
previous studies on RG-rich proteins, it seems likely that FAM98A is a nonessential, cytoplasmic
(or nuclear/cytoplasmic) shuttling/transport RBP or could have a general function in protein
translation. Recent findings for the paralog FAM98B support the idea of a shuttling protein and
find that FAM98B is a component of a shuttling RNA-transporting complex with
HSPC117/DDX1/C14orf166 (Pérez-González et al., 2014).
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2.5

Chapter 2 Discussion

A census of human RBPs is critical to organize our current molecular and genetic understanding
of PTGR. This catalog provides researchers with a newly curated resource to guide their
investigations of PTGR processes and to systematically study RBPs. An analogous catalog that
assesses the abundance and classifies all expressed RNAs, i.e. the RBP targets, across tissues and
cell types is still missing and would represent a useful addition to this census. Among the 20,500
protein-coding genes in humans, our curated census estimates that 7.5% (1,542 genes) are directly
involved in RNA metabolism by binding and/or processing RNA or comprising essential
components of RNPs. RBPs are structurally diverse and include many distinct classes of RBDs.
In contrast, the three most abundant DNA-binding domains account for 80% of the 1,704 TFs in
humans (Vaquerizas et al., 2009). The three most abundant RBDs only accounted for 20% of all
RBPs in our census.
Based on our target RNA categorization, nearly 50% of RBPs acted in mRNA metabolic
pathways and 11% constituted ribosomal proteins, while the rest were involved in the diverse
number of ncRNA metabolic processes. From the categorization of RBPs into RNA pathways, we
can deduce the percentage of RBPs committed to different pathways and interpret expression
changes of RBPs by regulatory process. The target-based categorization of RBPs also assists the
interpretation of disease phenotypes and mutations emerging from rapidly increasing patient
genome sequencing and may guide future functional studies.
Analyzing expression data across multiple tissues in humans and also other organisms I
found that the majority of RBPs were ubiquitously expressed at higher levels than the residual
protein-coding transcriptome, and represented up to a fifth of the total expressed protein-coding
transcripts encoded for RBPs. We conclude that RNA metabolism not only constitutes one of the
most conserved processes in the cell, but is also one of the cellular processes with the highest
protein copy number demand.
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Lastly, I demonstrated how structural data mining could be used to discover novel RBPs.
Through a simple count of RG/RGG repeats across the human proteome I discovered the novel
RBP FAM98A, a metazoan-conserved protein, and characterized its RNA-binding affinity by
PAR-CLIP. FAM98A predominantly bound mature mRNAs in G-rich regions. Based on domain
homologies, the domain of unknown function (DUF2465) in FAM98A may point towards a
regulatory role in kinetochore/RNA-transport related processes, while its predominant
localization to coding regions may also point to a putative role in protein translation. Further
studies are needed to determine its physiological need in the cell.
Many details of PTGR remain to be revealed, including the dissection of newly
discovered RNA regulatory processes, such as nuclear noncoding RNAs transcriptionally
regulating gene expression and chromatin conformation or the dynamic regulation of
posttranscriptional modifications of mRNAs (Cech and Steitz, 2014; Meyer and Jaffrey, 2014;
Ulitsky and Bartel, 2013). However, even at the basic biochemical level we still have an
incomplete understanding of how binding specificity is achieved, and how the regulatory function
of an individual RBP is influenced by synergy and competition with other RBPs. How is PTGR
executed in the cell with such high precision? A balanced approach of detailed biochemical and
functional studies paired with complex, systems biology methods will ultimately lead to an
understanding of the principles underlying PTGR networks. The more recent development of next
generation sequencing-based methods aids the investigation of PTGR networks, such as RIP and
CLIP-based methods (Ascano et al., 2012a; Konig et al., 2011; McHugh et al., 2014), ribosome
profiling (Ingolia, 2014), in vivo RNA-secondary structure profiling (Ding et al., 2014; Rouskin
et al., 2014; Wan et al., 2014), small and long RNA-sequencing (Jan et al., 2011; Ozsolak and
Milos, 2011; Wang et al., 2009), or 3’-end sequencing methods profiling of alternative
polyadenylation sites and poly(A) tail lengths (Chang et al., 2014; Jan et al., 2011; Lianoglou et
al., 2013; Subtelny et al., 2014). These studies reveal an unanticipated complexity in RBP binding
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and targeting and highlight the need to experimentally dissect PTGR networks in various cellular
systems. Much of our current efforts are still focused on developing the tools and collecting largescale datasets to understand the breadth of regulatory mechanisms of RBPs and their targets. With
this census I hope to have created a foundation for the system-wide study of PTGR factors, which
facilitates our understanding and interpretation of their gene regulatory patterns.
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3 The DEDDh RNA exonuclease NEF-sp is involved in the
3’ETS removal of 28S rRNA

3.1
3.1.1

Introduction
Ribosomes

Ribosomes are highly conserved RNA-protein complexes central to protein synthesis. They
decode information of mRNAs and translate it into proteins, catalyzing peptide bond formation.
Ribosomes are composed of two subunits, the small (40S in eukaryotes) and large (60S in
eukaryotes) ribosomal subunit. The large subunit catalyzes the peptide bond formation, also
referred to as peptidyl transferase activity, while the small subunit has the decoding function of
the ribosome [reviewed in (Lafontaine and Tollervey, 2001)]. The large ribosomal subunit
contains three ribosomal RNAs, 5S, 5.8S, and 28S rRNA, while 18S rRNA forms the RNA
component of the small ribosomal subunit. Eukaryotic ribosomes have 80 core ribosomal proteins
(Anger et al., 2013), the large ribosomal subunit contains 47 proteins, while the small subunit
possesses 33 proteins; together the human ribosome forms a 4.3 MDa complex (Anger et al.,
2013; Khatter et al., 2015). The majority of cellular metabolism is committed to ribosome
synthesis and about 90% of all cellular transcribed RNA is rRNA (Warner, 1999). The number
and production of ribosomes determine protein synthesis and growth rates of cells. In highly
growth-stimulated cells, such as cancerous cells, ribosomal proteins and rRNA biogenesis factors
are often expressed at higher levels. Nucleolar size (the site of rRNA production) and rRNA
transcription are increased and lead to a higher number of ribosomes and protein synthesis in the
cell (Boisvert et al., 2012; Montanaro et al., 2008; Ruggero and Pandolfi, 2003; Zhang et al.,
2015a). Several oncogenes, such as p53 and Myc, directly regulate ribosome biogenesis (Ruggero
and Pandolfi, 2003). Mutations that lead to dysfunctional ribosome assembly are generally lethal
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early on during development. However, some defects in ribosomal proteins or rRNA biogenesis
have been found to occur in several genetic diseases, commonly referred to as ribosomopathies
[reviewed in (Hannan et al., 2013; Sondalle and Baserga, 2014)]. These show predominantly
pathologies in bone marrow malfunction and growth defects. Several mutations in ribosomal
proteins of the small (RPS7, 10, 17, 17L, 19, 24, 26) and large (RPL5, 10, 11, 35A) subunit cause
Diamond-Blackfan anemia, a disorder that affects the production of red blood cells, while
mutations in the ribosome biogenesis factors SBDS and EMG1 cause Shwachman-Diamond
syndrome and Bowen-Conradi syndrome, which affect the production of white blood cells
(neutrophils) and cause growth defects (Gerstberger et al., 2014b; Narla and Ebert, 2010;
Sondalle and Baserga, 2014) (also see Table 2.1). Mutations in RNA polymerase I components,
as well as rDNA transcription factors, such as TCOF1, have also been found in a number of
genetic diseases causing growth and developmental defects, mental retardation, craniofacial and
limb abnormalities (Hannan et al., 2013).
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Figure 3.1 Overview of rRNA biogenesis in eukaryotes. Electron microscopy image of
transcribed rRNA transcription units of amphibian oocytes and schematic overview of rRNA
biogenesis steps in eukaryotes [adapted from (Lafontaine, 2015), image by (Miller and Beatty,
1969)]. Three out of four rRNAs are transcribed in the nucleolus by Pol I as a long 47S precursor
(47S pre-rRNA). The precursor is further processed, cleaved and modified to give the mature
18S, 5.8S and 28S rRNAs, which are assembled into the pre-40S (green) and pre-60S (orange)
ribosomal subunits. 5S rRNA (pink) is transcribed by Pol III in the nucleus and incorporated into
maturing 60S subunits. 80 ribosomal proteins, >200 auxiliary factors and 200 snoRNAs are
required for assembly. Pre-60S subunits require more nuclear maturation steps than pre-40S
subunits and are exported after the 40S export to the cytoplasm. Final structural modifications
take place in the cytoplasm (Panse and Johnson, 2010), such as formation of the beak on the
small subunit and the stalk on the large subunit (Nerurkar et al., 2015).
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3.1.2

rRNA transcription, processing, assembly and export

Eukaryotic ribosome biogenesis is a highly orchestrated process and involves >200 assembly
factors in S. cerevisiae and >400 in humans (Lafontaine, 2015; Tafforeau et al., 2013). By
complexity and number of proteins involved, ribosome biogenesis is perhaps the most complex
RNA metabolic pathway in the cell. rRNA processing is highly conserved among species, but
additional protein factors, and processing pathways have evolved in higher eukaryotes
concomitant with increasing organismal complexity. Due to its relative organismal simplicity,
most of our knowledge on rRNA biogenesis results from the functional studies in S. cerevisae.
The main site of rRNA biogenesis is the nucleolus. Here, three of the four ribosomal
RNAs, 18S, 5.8S and 28S, are transcribed by RNA polymerase I as a long 47S (35S in S.
cerevisiae) precursor transcript, posttranscriptionally cleaved, nucleotide modified and assembled
into early ribosomal complexes. ~200 proteins have been found in S. cerevisiae nucleoli
(Woolford and Baserga, 2013) and up to ~4500 proteins have been detected in human nucleoli
(Ahmad et al., 2009). Most of these are likely to be involved directly or indirectly in rRNA
biogenesis and assembly (Mullineux and Lafontaine, 2012). 5S rRNA is transcribed separately
by RNA polymerase III in the nucleus and assembled into pre-60S ribosomal complexes
(Ciganda and Williams, 2011; Lafontaine, 2015). rDNA gene loci are organized in tandemly
repeated arrays, with copy numbers varying between 400-100,000 copies in eukaryotic cells
(Prokopowich et al., 2003). 400-600 copies are found in S. cerevisiae and humans, which are
distributed between the nucleolar organization regions (NORs) (Carmo-Fonseca et al., 2000;
Stults et al., 2009). About 50% of all rDNA loci are actively transcribed, while the others are
nonfunctional or transcriptionally inactive repeats (Boulon et al., 2010). When visualized by
electron microscopy, nascent precursor transcripts branch off from actively transcribed rRNA
genes and form characteristic Christmas tree structures, at which ends RNP protein complexes,
also termed terminal knobs, carry out rRNA processing (Kass and Sollner-Webb, 1990; Miller
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and Beatty, 1969; Mougey et al., 1993) (Figure 3.1). In yeast, these have been identified as the
small subunit (SSU) processome complexes [(Dragon et al., 2002), reviewed in (Granneman and
Baserga, 2004; Henras et al., 2014; Woolford and Baserga, 2013)]. The long rRNA precursor is
co- and post-transcriptionally processed, with endo- and exonucleolytic cleavage reactions taking
place that remove the internal and external transcribed spacer regions (5’ETS, 3’ETS, ITS1,
ITS2). Site-specific RNA modifications, such as methylation or pseudouridylation, are introduced
by enzymes or snoRNPs guided by sequence specific basepairing of the snoRNAs to their target
site. Instead of nucleotide modifications, some snoRNAs, such as U3 snoRNA, guide cleavage of
rRNA precursors at specific sites [reviewed in (Henras et al., 2008)]. Concomitantly with
posttranscriptional processing, rRNAs and ribosomal proteins are assembled into the ribosomal
precursor complexes of the small and large subunit, assisted by a plethora of transport, folding
and assembly complexes in the nucleolus, nucleus and cytoplasm. 18S rRNA assembles into the
small subunit, while 5S rRNA, 28S, and 5.8S rRNA are incorporated into the large ribosomal
subunit.

3.1.3

RNA exo- and endonucleases involved in rRNA processing

rRNA cleavage sites within the long precursor have been mapped in detail in yeast and the main
pre-rRNA processing intermediates have also been characterized in higher eukaryotes [reviewed
in (Mullineux and Lafontaine, 2012)] (Figure 3.2). The characterization, however, of the enzymes
catalyzing the cleavage reactions has been challenging in all organisms. For some sites we do not
know the identity of the cleavage factors, and for others understanding the overlapping substrate
specificity has resulted in some uncertainty about how substrates are recognized and how
processing is regulated (Mullineux and Lafontaine, 2012). Table 3.1 summarizes the current
knowledge of RNA endo- and exonucleases involved in pre-rRNA processing.
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Table 3.1 Overview of RNA exo- and endonucleases in rRNA processing. RNA exo- and
endonucleases characterized in rRNA biogenesis in S. cerevisae and higher eukaryotes, their
cleavage sites and nuclease domains are listed [based on (Henras et al., 2014; Zuo and Deutscher,
2001)].
S. cerevisiae
RNA nuclease

S. cerevisiae
cleavage site

Nuclease domain (endo/exo)

Mammalian
homolog
(human)
NOB1
RNase MRP
(POP1,
POP4, POP5,
POP7,
RPP14,
RPP21,
RPP25,
RPP25L,
RPP30,
RPP38,
RPP40)
RCL1

Mammalian
cleavage site

NOB1
RNase MRP
(MRP RNA in
complex with
POP1, POP5,
RPP20, RPP25,
RPP30, RPP38
and RPP40)

D
A3

PIN (endo)
Catalytic RNA (endo)

RCL1 (SSU
component)
Utp24
(Fcf1p)/cofactor
Utp23 (Faf1p)
(SSU
component)
RNT1
Rrp6 (RNA
exosome)
Rrp44 (Dis3)
(RNA exosome)
Rat1p/cofactor
Rai1p

A0 , A1 , A2

RNA 3’terminal phosphate
cyclase-like domain (endo)
PINc (endo)

E

Rtc1

FCF1

SSU exosome
component,
putative A’,
A0, 1

Bka

DROSHA
EXOSC10

-

Drosha
Rrp6

7S>5.8S+30

Ribonuclease III (endo)
DNA_pol_A_exo1/DEDD/
RNase D (3’-5’ exo)
PIN/RNR (endo, 3’-5’ exo)

DIS3

7S>5.8S+40

Dis3

C2>C1, A3>B1S

Xrn1/ 5PX (5’-3’ exo)

2>5.8S rRNA,
4>28S rRNA,

Rrp17p

A3>B1S

Nop25 domain (5’-3’ exo)

XRN2/
cofactor
DXO
NOL12

Rat1/ putative
cofactors
CG912/ cuff
viriato

Ngl2p

6S>5.8S rRNA

-

Rexp1

28S rRNA, 5S
rRNA, 5.8S rRNA(?)
(Piper et al., 1983;
1987; van Hoof et al.,
2000)

Exo_endo_phos/ DEDD/ Ccr4p
(3’-5’ exo)
DEDDh RNase T (3’-5’ exo)

REXO1,
NEF-sp

unknown

Rex2p

DEDDh RNase T (3’-5’ exo)

REXO2

-

DEDDh RNase T (3’-5’ exo)

-

-

-

DEDDh RNase T (3’-5’ exo)

REXO4

DEDDh RNase T (3’-5’ exo)

ISG20L2

-

-

DEDDh RNase T (3’-5’ exo)

Eri1

(ITS1
regulation)
5.8S+40>6S
rRNA
6S>5.8S
rRNA

CG6833

-

5.8S rRNA(?) (van
Hoof et al., 2000)
5.8S rRNA(?) (van
Hoof et al., 2000)
ITS1 processing
(Faber et al., 2004)
-

CG42666
(dREXO1),
CG12877
(dREXO1),
CG8368
(dNEF-sp)
CG10214

Rex3p
Rex4p

A0 , A1 , A2

B0
5.8S+30>6S

100

3
-

Putative
2>5.8S rRNA
-

Drosophila
melanogaster
homolog
CG2972
RNase MRP
(l(1)G0045,
CG8038,
CG14057,
Rpp20,
CG9422,
Rpp30)

-

Figure 3.2 pre-rRNA processing in S. cerevisiae, humans, and Drosophila. rRNA size
nomenclature is shown in dark blue, U3 and U8 snoRNAs are highlighted in light blue, RNA
nucleases characterized in 28S rRNA 3’ end processing are highlighted in orange,
endonucleolytic cleavage sites are shown with orange triangles, exonucleolytic cleavages are
shown in direction of the cleavage sites. (A) rRNA processing in S. cerevisiae: The majority of
nascent transcripts is already co-transcriptionally cleaved at sites A0, A1, A2 dependent on U3
snoRNP, yielding 20S and 27S-A2 precursors. Alternatively, the full-length 35S pre-rRNA
precursor is released by cleavage by the dsRNA endonuclease Rnt1p and processed
posttranscriptionally. Cleavage A2 involved Rcl1p, while RNase MRP is involved in cleavage at
A3. Nuclear export (NE) of the 20S precursor precedes final maturation of 20S to 18S rRNA by
the RNA endonuclease Nob1 in the cytoplasm. The 5’-3’ exonucleases Rrp17p and Rat1p trim
the 5’ ends of 27S-A3, 26S, 25S’, while the 3’-5’ exonucleases of the nuclear exosome trim 7S/L
and 6S/L rRNA precursors in the nucleus, and the yeast-specific cytoplasmic RNA exonuclease
Ngl2p matures the 3’ ends of 5.8S rRNA. The 3’-5’ exonuclease Rex1p (RNH70) trims off the
3’ETS overhangs from 28S rRNA. (B) rRNA processing in humans/mammalian cells [processing
steps are adapted from (Henras et al., 2014)]: The rRNA precursor is fully transcribed before it is
posttranscriptionally processed. The precursor is initially cleaved at sites 01 and 02. The 45S
precursor can be processed in two different pathways, either first in the 5’ETS (at site A0 and 1)
or first in the ITS1 (site 2). Cleavage at site 2 depends on Rcl1p, endonucleolytic cleavage of
Nob1 of the 18S-E precursor generates the mature 18S rRNA. The 5’-3’ exonuclease XRN2 trims
5’ overhangs of 32S and 28S precursors after cleavage 2 and 4. Isg20l2 and the nuclear exosome
trim different 5.8S rRNA precursors, namely the 12S, 7S, and 5.8S+40, while the final 5.8S
exonucleolytic maturation of 5.8S takes place in the cytoplasm processed by Eri1. (C) rRNA
processing in D. melanogaster: Few studies have investigated rRNA processing in D.
melanogaster, but the main rRNA processing intermediates have been characterized (Long and
Dawid, 1980). Similar to mammalian and Xenopus laevis pre-rRNA processing, Drosophila also
contains U8 snoRNA (Peculis, 1997). Drosha is not involved in rRNA processing (Smibert et al.,
2011). MRP RNase is involved in cleavage at site 3 (Schneider et al., 2010). Conceptionally, the
two alternative processing pathways are conserved among mammalian and Drosophila rRNA
processing.
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3.1.4

pre-rRNA processing in S. cerevisiae

In S. cerevisiae transcription terminates 210 nts downstream of the mature 28S rRNA site. The
precursor transcript is co-transcriptionally cleaved by the dsRNA-binding endonuclease Rnt1p,
which results in the 35S precursor with a 3’ETS of 10-20 nts in length (Kressler et al., 1999)
(Figure 3.2 A). The resulting primary 35S rRNA precursor is cleaved in the 5’ETS at site A0, A1,
and A2, a process that requires the small subunit processome (SSU) in complex with U3 snoRNA
(Woolford and Baserga, 2013). At present the enzyme carrying out endonucleolytic cleavage
remains unknown, but both the endonucleases Rcl1 and Utp24 have been implicated as putative
catalytic factors at A1 and A2, most recent studies favor Rcl1 as the catalytic factor based on its
mammalian homolog that is also involved in ITS1 cleavage (Henras et al., 2014; Mullineux and
Lafontaine, 2012; Woolford and Baserga, 2013). After A2, 20S intermediates are exported to the
cytoplasm, where Nob1 endonuclease cleaves the remaining 3’ end of ITS1 from the precursor to
generate the mature 18S rRNA (Henras et al., 2014). Following 5’ETS cleavage, precursors are
cleaved either at A3 by RNase MRP or cleaved at B1L by an unknown RNA endonuclease. Some
uncertainty about the required enzymatic factors also exists at A3, since cleavage at A3 is not
strictly dependent on RNase MRP and cleavage by MRP seems to be not conserved in higher
eukaryotes (Henras et al., 2014; Kressler et al., 1999). After cleavage at A3 or B1L, the resulting
27S intermediate is 3’ end processed by RNH70 (also known as Rex1p), which
exonucleolytically trims the 3’ETS overhangs of the 27S precursor (Kempers-Veenstra et al.,
1986; Mullineux and Lafontaine, 2012; Piper et al., 1984; Skowronek et al., 2014; van Hoof et
al., 2000) (highlighted in Figure 3.2 A). 27S intermediates cleaved at A3 possess 5’ extensions of
ITS1, which are 5’-3’ exonucleolytically removed by Rat1p/Rai1 or Rrp17p to generate the
mature end of 5.8S rRNA (Hage et al., 2008; Henras et al., 2014; Oeffinger et al., 2009). After A3
or B1L cleavage, the resulting 27S-BS/L intermediates undergo endonucleolytic cleavage at C2,
releasing the 7S precursor and the mature 25S rRNA. The mature 25S rRNA is transported to the
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cytoplasm, while the 7S precursor is trimmed by the RNA exosome, assisted by unwinding of
secondary structures by the RNA helicase Mtr4p. The nuclear exosome component Rrp6 further
trims 7S to generate the 6S precursor, which is then exported to the cytoplasm. The yeast specific
RNA exonuclease Ngl2p exonucleolytically 3’-5’ trims the final extensions, generating the
mature 5.8S rRNA.

3.1.5

pre-rRNA processing in higher eukaryotes

In Xenopus laevis RNA Pol I transcribes the entire ribosomal gene repeat unit far into the 3’
external spacer and terminates ~200 nts upstream of the rDNA promoter of the next rDNA unit
(Labhart and Reeder, 1986). A processing event at a site ~250 nt downstream of the mature 28S
rRNA (T2) forms the 7,800 kb precursor (Labhart and Reeder, 1987). Similarly, near-promoter
termination sites -200 nts upstream of the initiation site have also been found in mouse rDNA
repeats, but rRNA transcription is thought to terminate ~560 nts downstream of the 28S 3’end
(Grummt et al., 1986; Henderson and Sollner-Webb, 1986). In humans, precursor transcripts
extend to ~350 nts downstream of 28S rRNA (Bartsch et al., 1987; Gurney, 1985; Kuhn and
Grummt, 1989). In Drosophila melanogaster transcription termination can extend throughout the
entire 3’ETS and spacer region without a fixed termination point, however the long 47S precursor
transcript has a defined length of ~8 kb (Long and Dawid, 1980; Mandal and Dawid, 1981; Tautz
and Dover, 1986).
In mammals, the 47S precursor is first cleaved at site 01, ~600 nts downstream of the
transcription start site, followed by cleavage at 02 (also known as site 6) (Figure 3.2 B). This
generates the 45S precursor, which already contains the mature 3’ end of 28S rRNA. Two
alternative pathways for maturation can take place then. In pathway 1 the precursor undergoes
cleavage at site A0 and 1, generating the 41S precursor. The 41S precursor has already the mature
5’ and 3’ ends of 18S and 28S rRNA defined (Figure 3.2 B). Internal cleavage 2 in the ITS1
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generates 21S, the 3’ extended 18S precursor, and 32S, the 5.8-28S precursor. Cleavage at site 2
depends on the PES1/BOP1/NOL12 complex (Henras et al., 2014). Alternatively, in pathway 2,
cleavage at 2 precedes cleavage at A0 and 1, generating first the 32S precursor of 28S and a 30S
precursor of 18S, which is then rapidly cleaved by A0 and 1 to generate the 21S precursor.
Cleavage at A’, A0 and 1 depend on the U3 SSU processome (Henras et al., 2014). Ultimately,
both pathways arrive at the 21S and 32S precursors. The 21S rRNA precursor undergoes cleavage
at site E, which is dependent on RCL1, followed by a series of exonucleolytic trimming reactions
before it is exported to the cytoplasm, where Nob1 endonucleolytically cleaves off the 3’
extension to generate mature 18S rRNA. The 5.8S-28S containing 32S precursor undergoes
endonucleolytic cleavage at site 4, generating the 12S precursor of 5.8S rRNA and a 5’ extended
28S rRNA. 28S rRNA is 3’-5’ exonucleolytically trimmed by Xrn2. The 12S rRNA precursor
undergoes a series of 3’-5’ exonucleolytic trimming reactions, first to by the RNA exosome and
Isg20L2, which generate the 7S precursor in the nucleus. The nuclear RNA exosome component
Rrp6 further trims the 7S to generate the 6S precursor. The 6S precursor is transported to the
cytoplasm, where Eri1 3’-5’ exonucleolytically trims the final ends to form mature 5.8S rRNA
(Ansel et al., 2008).
Pre-rRNA processing in Drosophila has been characterized in less detail, and only the
main rRNA precursor intermediates have been described (Long and Dawid, 1980), however the
basic outline, as well as conserved protein factors closely mirror mammalian pre-rRNA
processing steps (Figure 3.2 C). Additionally, Drosophila 5.8S rRNA is split into two pieces, a
shortened 5.8S rRNA and an additional 2S rRNA downstream, presenting essentially the 3’ end
of 5.8S rRNA (Pavlakis et al., 1979). 2S rRNA basepairs with 5.8S and 28S rRNA and is also
incorporated into the large ribosomal subunit. Furthermore, insect 28S rRNAs contains a natural
hydrolytic internal cleavage site, which cleaves 28S rRNA into two fragments 28Sa and 28Sb
(Long and Dawid, 1980).
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3.1.6

28S rRNA maturation in S. cerevisiae

The 3’ ends of the primary precursor transcript are processed co-transcriptionally in yeast by the
dsRNA-specific RNA endonuclease Rnt1p. The resulting precursor transcripts terminate 10-20 nt
downstream of the mature 28S 3’ end (Henras et al., 2014; Kressler et al., 1999) (Figure 3.2 A).
The 3’-5’ DEDDh RNA exonuclease RNH70 (Rex1p) exonucleolytically trims the 3’ overhangs
of 28S during late ribosome biogenesis (Mullineux and Lafontaine, 2012). RNH70 has also been
shown to trim the 3’ trailer of 5S rRNAs in yeast (Kempers-Veenstra et al., 1986; Piper et al.,
1983; 1984; Skowronek et al., 2014; van Hoof et al., 2000). While Rnt1p is essential for rRNA
biogenesis in yeast, RNH70 is a nonessential enzyme and deletion strains are viable without any
growth defects (Henras et al., 2008; Kufel et al., 1999; van Hoof et al., 2000). The 28S rRNA is
released from the precursor after cleavage at site C2 by an unknown RNA endonuclease. Rat1p
does a final trimming by exonucleolytically removing 5’-3’ overhangs on 28S rRNA to generate
the mature 5’ end (Wang and Pestov, 2011).

3.1.7

28S rRNA maturation factors in higher eukaryotes

In metazoans, under steady state conditions the majority of the precursor is already processed at
the mature 3’ end of 28S rRNA (site 02), by an unknown nuclease (Labhart and Reeder, 1986).
Removal of the 3’ETS is thought to take place as precise endonucleolytic cleavage reaction at the
mature 28S rRNA end and depends on the presence of U8 snoRNA. Drosha, the homolog of
Rnt1p, is functionally not conserved in 3’ETS cleavage and processes microRNA precursors in
the nucleus (Johanson et al., 2013; Lee et al., 2003). Knockdown of Drosha with antisense
oligonucleotides in HeLa cells had no effect on 47S precursor levels, but a small increase
observed for the 12S and 32S intermediates suggested a minor role of Drosha in ITS2 cleavage
(Wu et al., 2000). However, an in vivo knockout of Drosha in mice or in Drosophila had no
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effects on precursors or mature rRNA species, leading to the conclusion that Drosha has no role
in pre-rRNA processing (Chong et al., 2008; Smibert et al., 2011).
Absent in yeast, U8 snoRNA is conserved across verte- and invertebrates and displays
base complementarity to the 28S 3’end and the 5.8-28S ITS2 junction. U8 is thought to assist
long range pre-rRNA folding and correct positioning of the RNAs for 3’ETS and ITS2 cleavage
(Peculis, 1997; Peculis and Steitz, 1993). U8 snoRNA depleted Xenopus laevis oocytes show
depleted cytoplasmic 28S rRNA pools and cleavages at the 28S-3’ETS border, ITS1 and ITS2
sites are inhibited. Cleavage at T1 (site 02 in mammals) is completely blocked and rRNA
precursors are extended by ~800 nts to the termination site T2 in U8 depleted oocytes. The
inhibition leads to accumulation of aberrant 32S and 36S intermediates with extended nucleotides
at both 3’ and 5’ ends (Peculis and Steitz, 1993). Currently, apart from the U8 snoRNP, only two
other protein factors are implicated in the 3’ end maturation of 28S rRNA in mammalians: the
DEAD box helicase Ddx51 with its interaction partner Nog1, while an additional helicase,
Ddx27, is required for correct 3’ETS end definition (Kellner et al., 2015; Srivastava et al., 2010).
The nuclease that removes the 3’ETS remains unknown in metazoans. To generate the 5’ end of
28S rRNA cleavage takes place at site 4 in the ITS2 of the 32S precursor by an unknown RNA
endonuclease, thereby releasing the 28S precursor. The resulting 28.5S rRNA precursor is 5’-3’
exonucleolytically trimmed by Xrn2 to generate the mature 5’ end (Wang and Pestov, 2011).

3.1.8

Role of snoRNPs in rRNA modification and processing

rRNAs undergo extensive co- and posttranscriptional RNA modifications. These modifications
are essential in eukaryotes, required for cell growth, and strengthen RNA stability, specific
secondary structural folds, and influence ribosome activity (Granneman and Baserga, 2004;
Henras et al., 2008; Sharma and Lafontaine, 2015; Watkins and Bohnsack, 2012). snoRNPs
catalyze site-specific 2’-O-methylations and pseudouridylations in rRNAs, other snoRNAs,
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telomerase RNA and snRNAs. Alternatively, some snoRNPs are required for rRNA processing
by guiding cleavage and assisting folding of rRNA precursors. snoRNPs are ribonucleoprotein
complexes composed of small nucleolar RNAs (snoRNAs) of ~150 nts (range from 50-450 nts)
bound to their obligate protein partners. Based on their conserved sequence motifs and secondary
structure, snoRNAs can be grouped into two classes, box C/D and box H/ACA snoRNAs
(Filipowicz and Pogacić, 2002) (Figure 3.3).

Figure 3.3 Structure of box C/D and H/ACA snoRNPs. Box C/D snoRNPs 2’-O-methylate
their targets, while box H/ACA snoRNPs isomerize uridines to pseudouridines. (A) Schematic
structure of the box C/D family snoRNAs bound to their protein binding partners. In eukaryotes
box C/D snoRNPs form heterodimers with the complex partners Nop58 or Nop56, Fbl, Snu13.
Guiding 2′-O-methylation involves base-pairing of the 10-21 nt-long sequence positioned
upstream of box D (or D′) to the target RNA, the nucleotide positioned 5 bp upstream of the D/D′
box is selected for methylation. (B) Box H/ACA snoRNAs form a double loop. Within the
pseudouridylation pocket 3-10 nucleotides are complementary to the nucleotides in the target
RNA flanking the isomerization site. Figure adapted from [(Fatica and Tollervey, 2003;
Filipowicz and Pogacić, 2002; Watkins and Bohnsack, 2012)].
Each class associates with a distinct set of four evolutionary conserved core proteins
(human orthologs official gene name given in parentheses): box C/D snoRNAs bind to Snu13
(SNU13), Nop56 (NOP56), Nop58 (NOP58), and the 2’-O-methylase Nop1 (Fibrillarin, FBL);
box H/ACA snoRNAs protein complex partners are Nhp2 (NHP2), Nop10 (NOP10), Gar1
(GAR1), and the pseudouridine synthase catalytic subunit Cbf5 (DKC1). snoRNAs are
transcribed by RNA Pol II, and are predominantly located in introns of mRNA genes in higher
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eukaryotes (Dieci et al., 2009). Through complementary base pairing, the RNA component of
snoRNPs guides the complex site-specifically to the target rRNAs to introduce nucleotide
modifications. Most snoRNAs are involved in RNA modification, but a subset assists RNA
folding or cleavage during rRNA processing (Watkins and Bohnsack, 2012). U3 snoRNP is a
component of the SSU processome and is essential for cleavage in the 5’ETS at A0, A1 and A2
(in yeast) (Phipps et al., 2011). In higher eukaryotes (not present in S. cerevisiae) U8 snoRNA is
required for 28S rRNA maturation and cleavage of the 3’ETS. Few other snoRNAs have been
characterized in the context of 90S pre-ribosomal complex processing, where they assist folding
and interact with the 35S rRNA precursor (C/D: U14, U22; H/ACA: snR30/U17, snR10) (Henras
et al., 2008).

3.1.9

Tissue-specificity of rRNAs, ribosomal proteins and rRNA processing factors

Ribosomal proteins and rRNA biogenesis factors are among the highest expressed proteins in the
cell. Based on the analysis in Chapter 2, we find that they are generally expressed ubiquitously
across human tissues with very little tissue-specific variation in mRNA levels (Gerstberger et al.,
2014a) (Figure 2.8). However, tissue-specific differences in pre-rRNA intermediates, the
processing pathways, rRNA species (e.g. ratio of 5.8SS/L rRNA), as well as heterogeneous
compositions of ribosomes have been described (Lafontaine, 2015; Mullineux and Lafontaine,
2012). Heterogeneous ribosomes arise from tissue-specific ribosomal protein composition
through incorporation of different ribosomal protein isoforms or variations in the rRNA
sequences, resulting from stage-specific transcription of different rDNA gene loci (Lafontaine,
2015; Xue and Barna, 2012). Furthermore, rRNA modifications and posttranslational
modifications of ribosomal proteins introduce additional levels of heterogeneity (Mauro and
Edelman, 2002; Ramagopal, 1992). Incorporation of specific ribosomal protein paralogs affects
the production and function of yeast ribosomes (Parenteau et al., 2011). Tissue-specific and
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stress-response tailoring of ribosomes by tissue-specific incorporation of ribosomal proteins has
been shown to enhance translation of specific mRNA targets (Kondrashov et al., 2011; Vesper et
al., 2011; Xue and Barna, 2012; Zhang et al., 2015b). Other extraribosomal roles for ribosomal
proteins have also been reported (Warner and McIntosh, 2009). Most of these cases are incidental
and a systematic survey of ribosome composition in different cell types and tissues, their
expressed rRNA and ribosomal protein isoforms, as well as the level of protein and rRNA
modifications has been challenging (Lafontaine, 2015; Xue and Barna, 2012). Profiling protein
and rRNA isoforms, as well as their posttranslational modifications, across cell types,
developmental stages and tissues remains an important goal for elucidating the underlying
principles of ribosome composition in adaptation to different developmental and tissue-specific
needs.
Furthermore, while tissue-specific regulation of ribosomal proteins has been reported so
far, much less is understood about the processes of posttranscriptional regulation during rRNA
biogenesis. We know very little about the regulation and redundancy of rRNA processing and the
involved enzymes, their stoichiometry, and activity. Given the functional redundancies of some
exonucleases, as well as the regulation of rRNA biogenesis factors by growth stimulatory factors
(e.g. mTOR, p53, myc) (Buszczak et al., 2014), the question arises how rRNA biogenesis is
regulated by signaling pathways and maintains adaptation and homeostasis in the cell. A detailed
understanding of ribosome composition and the different rRNA processing pathways will be
important in order to explain the observed heterogeneity of rRNAs and the resulting functional
consequences for protein translation.
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3.1.10 NEF-sp is a conserved, tissue-specific RNA exonuclease uncharacterized in higher
eukaryotes
In the previous genome-wide gene expression analysis of RBPs across human 31 tissues (Chapter
2), I noticed the uncharacterized protein LOC81691, human NEF-sp RNA exonuclease (hNEFsp), among the most tissue-specific RBPs (top 3 in our ranking of tissue-specific RBPs in Chapter
2) with a tissue specificity score ~4 (Gerstberger et al., 2014a) (Figure 2.8 B). hNEF-sp, a
member of the DEDDh RNase T exonuclease family, displayed unique expression in comparison
to all other members of the RNase T class and had exceptional tissue specificity in adult human
testis and human fetal ovaries, where it was found among the top 100 expressed genes (Figure 3.4
A-C).
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Figure 3.4 NEF-sp is highly expressed in gonads in humans, mouse and Drosophila. (A)
Microarray expression profiles for human DEDDh RNA exonucleases across 31 human tissues.
NEF-sp is the only DEDDh RNA exonuclease with such high and selective tissue-specific
expression. (B) Plot showing the normalized expression changes of selected RBPs relevant in
female ovarian gonad development and NEF-sp in comparison [analysis is the same as in Figure
2.10 C, (Houmard et al., 2009)]. (C) Microarray intensity levels for germline-specific RBPs
DDX4, MAEL, TDRD5, MOV10L1, in comparison to NEF-sp and the ubiquitous RBP ELAC2
as control across gestational stages in human ovary and testis development. (D) Microarray
intensities of NEF-sp mRNA levels across 31 human adult tissues, 32 mouse adult tissues and 30
Drosophila embryonic, larval and adult tissues.
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Its expression clustered with gonad-specific RBPs, such as the PIWI proteins, DDX4, or
BOLL proteins (Gerstberger et al., 2014a) and suggested to us a putative role of NEF-sp during
gonad development (Figure 3.4 B). Supporting a conserved role during gonad development, the
observed tissue-specific of NEF-sp in testis was found across organisms, in mouse
(2610020H08Rik, mNEF-sp) and Drosophila melanogaster (CG8368, dNEF-sp).

3.1.11 DEDDh RNase T class exonucleases
The RNase-T class of single-stranded 3’-5’ RNA exonucleases is highly conserved across
prokaryotes and eukaryotes and belongs to the DEDD 3’-5’ exonuclease superfamily, also known
as DnaQ-like or RNase D superfamily (Aravind and Koonin, 2001a; Hsiao et al., 2011; Zuo and
Deutscher, 2001) (Figure 3.5 A).
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Figure 3.5 Active site of DEDD RNA exonucleases. (A) ClustalX multiple sequence alignments
for bacterial, viral and eukaryotic DEDD RNA exonucleases. Two main classes of DEDD RNA
exonucleases exist, DEDDy and DEDDh, where four acidic catalytic residues coordinate a
divalent cation (e.g. Mg2+, Mn2+), and one general base residue, tyrosine (y) or histidine (h)
deprotonates the coordinated water molecule in the active site. Figure adapted from (Zuo and
Deutscher, 2001). The three conserved DEDD regions are indicated on the top (green arrow), the
conserved residues are highlighted in red. Residues that are only highly conserved in subfamilies
are highlighted in yellow. (B) Schematic representation of the active site residues coordinating
two Mg2+ residues and one water molecule for nucleophilic attack at the 5’ phosphate of the
target RNA. Figure adapted from bacterial RNase T active site (Hsiao et al., 2011).
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Members of the DEDD family contain four acidic catalytic residues that chelate two
Mg2+ ions and coordinate a water molecule for nucleophilic attack on the phosphate bond of
nucleic acids (Beese and Steitz, 1991a; 1991b; Zuo et al., 2007). RNase T exonucleases contain a
DEDDh catalytic domain with a conserved histidine residue that acts as a general base and
deprotonates the chelated water molecule for nucleophilic attack (Figure 3.5 B). The bacterial
RNase T protein forms a homodimer and is involved in the maturation of tRNAs, 5S and 23S
rRNA, and other noncoding RNAs (Li and Deutscher, 1995; Li et al., 1998; 1999). In S.
cerevisiae the RNase T class has five members, Rex1p (RNH70), Rex2p, Rex3p, Rex4p and
Pan2p (Figure 3.6). The Rex1-Rex4 proteins have been described in rRNA, tRNA and small
nuclear noncoding RNA metabolism. Rex1p was demonstrated to trim the 3’ ends of tRNAs, 5S,
23S (Copela et al., 2008; Ozanick et al., 2009; Piper and Stråby, 1989; Piper et al., 1983; 1987).
In addition, Van Hoof et al. reported that deletion of Rex1p affected 5.8S rRNA, U5L snRNA and
RNase P maturation (van Hoof et al., 2000). In the same study Rex2 was shown to also affect
processing of 5.8S rRNA, RNase P, U4 and U5S/L snRNA; and Rex3 trimmed RNase MRP, P,
U5L snRNA and 5.8S rRNA (van Hoof et al., 2000). Rex4p has been reported in ITS1 processing
(Faber et al., 2004). In higher eukaryotes additional RNase T families evolved, namely the Eri1
family (ERI1-3), the ISG20 family (ISG20, ISG20L2, AEN), and the ssDNA/ssRNA-specific
TREX1 family involved in ssDNA 3’ end repair (TREX1-2) (Stetson et al., 2008; Yuan et al.,
2015).
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Figure 3.6 Phylogenetic tree of DEDDh RNA exonucleases. Phylogenetic tree generated from
multiple sequence alignments of DEDDh RNA exonucleases across human (black), mouse (blue),
Xen. laevis (green), D. melanogaster (red), S. cerevisae (brown). The NEF-sp and its paralog
REXO1 family are highlighted in red. Branch lengths are scaled according to sequence identity.
Very few RNase T class members have been characterized in higher eukaryotes. PAN2 is
cytoplasmic, nonessential for viability, and regulated mRNA stability through deadenylating the
long (~200 nts) poly(A) tail of mRNAs; however, it does not efficiently remove the last 20-25
nts, a process which is catalyzed by the Ccr4-Not complex (Wolf and Passmore, 2014). Eri1 was
originally discovered to have a negative regulatory effect on siRNAs in C. elegans (Kennedy et
al., 2004). In S. pombe Eri1 was shown to negatively regulate the RNA-induced silencing (RITS)
complex (Buhler et al., 2006; Iida et al., 2006). In mouse and C. elegans Eri1 trims 5.8S rRNA as
the final maturation step in the cytoplasm (Ansel et al., 2008; Gabel and Ruvkun, 2008).
Metazoan Eri1 also trims the polyuridine tails of histone mRNAs (Dominski et al., 2003; Hoefig
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et al., 2013). Furthermore, Eri1 affects miRNA homeostasis and Eri1-/- knockout mice show a
twofold increase in total miRNA abundance (Thomas et al., 2012; 2014). The other two Eri
family members, Eri2 and Eri3, remain uncharacterized. Interferon stimulated exonuclease gene
20 kDa (ISG20) was initially identified as interferon- or double-stranded RNA induced
exonuclease (Espert et al., 2004; Gongora et al., 1997). ISG20 was found to specifically degrade
single-stranded viral RNA (Espert et al., 2003) and was shown to associate with snRNAs and
snoRNAs in the nucleolus and Cajal body, suggesting a role of ISG20 in snRNA/snoRNA and
rRNA maturation (Espert et al., 2006). The nucleolar exonuclease ISG20L2 has been shown to
trim 7S rRNA precursor transcripts (Coute et al., 2007; Henras et al., 2014). The third member of
the ISG20 family, ISG20L1 was renamed to nuclear apoptosis enhanced nuclease (AEN) as it
was initially characterized as p53 induced RNA exonuclease, which degrades both double and
single-stranded RNA and DNA in the nucleus (Kawase et al., 2008).
The REX1-4 family remains largely uncharacterized in higher eukaryotes. Only REXO2
has been described as oligoribonuclease in mitochondrial RNA and DNA turnover, where it
shows exonuclease activity for small (≤ 5 nts) oligomers and appears to have similar in function
to its bacterial homolog, the ORN nuclease (Bruni et al., 2013; Nguyen et al., 2000).

3.1.12 Drosophila testis and ovarian development
To characterize the role of NEF-sp in gonad development we used Drosophila melanogaster as a
model system. Figure 3.7 illustrates the developmental stages of germ cell development in the
context of the anatomical structures of female and male gonads of Drosophila.
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Figure 3.7 Drosophila melanogaster testis and ovary development. (A) Drosophila testis
development: Adult testes form a coiled tube with the seminal vesicle at the basal end and the
apical tip forming the hub with the germline stem cell (GSC) niche. Spermatogenesis occurs
throughout larval and adult life, and all stages of differentiation are represented in a single adult
testis. GSCs divide asymmetrically to self-renew themselves and produce a spermatogonium. The
gonialblast undergoes four rounds of mitosis with incomplete cytokinesis and is encapsulated by
two somatic cyst cells. The resulting 16-cell cyst enters two meiotic divisions with incomplete
cytokinesis yielding 64 interconnected haploid round spermatids. During terminal spermatid
differentiation, major morphological changes take place: spermatids elongate, nuclei condense
and migrate to the posterior end; and actin-based cones form an individualization complex that
drives expulsion of the cytoplasmic contents into cystic bulges, which grow in size as they
increasingly collect more material during their travel away from the nuclei towards the spermatid
tail. The thereby formed waste bag is subsequently degraded (Steller, 2008; White-Cooper, 2010).
Confocal image shows actin staining (Phalloidin, red), DNA (Hoechst, blue), proteoasome (b5GFP, green). Figure courtesy Sigi Benjamin. (B) Drosophila ovary development: Egg-chamber
development begins in the germarium. At the anterior tip, specialized somatic follicle cells create
a niche that supports 2-3 GSCs. The GSCs divide asymmetrically to produce two daughter cells, a
cystoblast and a daughter stem cell that remains in the niche. The cystoblast goes through four
rounds of mitosis that give rise to 16 germline cells; these remain connected as a result of
incomplete cytokinesis. Of the 16 cystoblast cells, one differentiates into the oocyte and enters
meiosis, while the other 15 become polyploid nurse cells. Follicle cells then surround the 16-cell
cyst and the oocyte moves into the most posterior position. At this point, the nascent egg chamber
buds off the germarium to form stage 1. In stages 2–7 nurse cells undergo polyploidization,
follicle cells go through mitotic division and the size of the egg chamber increases. As the egg
chamber continues to grow, it is pushed further posterior within the ovary as successive egg
chambers bud off from the germarium. Egg chambers remain connected to each other by chains
of stalk cells. Polar cells, specialized follicle cells, start to differentiate at each end of the egg
chamber. They stop dividing soon after they become specified, while all other follicle cells
continue to divide until stage 6. The oocyte begins to accumulate yolk at stage 8. By stage 10, the
oocyte occupies half the total volume of the egg chamber. The nurse cells nourish the oocyte by
transferring cytoplasm. In the final few hours of oogenesis, the nurse cells undergo apoptosis and
the follicle cells produce the eggshell. Figure adapted from (Montell, 2003).
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Drosophila melanogaster testis is a long tube that coils at the basal end around a seminal
vesicle. The stem cell niche is located at the apical tip of the testis, also called the hub (Figure 3.7
A). At the hub, germ stem cells (GSCs) divide asymmetrically to generate one cell that remains
the hub and a daughter gonialblast that is displaced from the niche and differentiates. Each
gonialblast is surrounded by two somatic cyst cells, which arise through asymmetric division
from cyst stem cells. A gonialblast undergoes four rounds of mitotic divisions to produce a cluster
of 16 spermatogonial cells. The mitotic divisions are synchronized and cytokinesis incomplete,
resulting in 16 cells interconnected through cytoplasmic bridges (ring canals). A cytoplasmic,
germline-specific membranous structure, the fusome, branches throughout the connected mitotic
cells and regulates mitotic divisions (stained by 1B1, probing for the adducing-like protein hts)
(Lin et al., 1994). These 16 spermatogonial cells progress through premeiotic S phase and then
undergo a prolonged G2 phase in which the cells grow substantially. Genes that are needed for
the development of spermatocytes and spermatids are transcribed at this time (de Cuevas and
Matunis, 2011). Two meiotic divisions finally lead to 64 round spermatids in incomplete
cytokinesis, which enter terminal differentiation. During spermatid elongation, histones become
replaced with protamines, the nuclei condense and transform into needle-shaped structures and
migrate towards the seminal vesicle, where they form the spermatid head. Spermatid terminal
differentiation begins as actin cones form around the nuclei. The actin cones move along the cyst
from the nuclei along the length of the cyst removing excess cytoplasm and organelles into a
cystic bulge. At the end of the individualization process, excess cellular material is deposited in a
waste bag and each mature spermatid is enclosed by its own membrane (Fuller, 1998) (Figure 3.7
A). Male gonad development starts during embryogenesis. Mitotic divisions are completed at the
end of 2nd instar larval development and wild type testes have undergone all four mitotic divisions
forming the 16-cell cyst (Sheng et al., 2009). Importantly, transcription stops at the end of
meiosis and posttranscriptional regulation, including RNA processing, nuclear RNA export,
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translation and RNA decay become critical for controlling protein levels during subsequent stages
of sperm development both in mice and Drosophila (Bettegowda and Wilkinson, 2010).
Each Drosophila ovary is composed of 12 to 16 ovarioles. In each ovariole, stem cells are
located in the germarium, which forms the most apical structure, followed by the developing egg
chambers, which are arranged in a linear fashion with the most mature egg chamber at the most
distal end (Eliazer and Buszczak, 2011; Kirilly and Xie, 2007) (Figure 3.7 B). The germarium
contains three types of stem cells, germline stem cells (GSCs), somatic stem cells (SSCs) and
escort stem cells (ESCs). GSCs undergo asymmetric self-renewing divisions; the daughter is
displaced away from the niche and differentiates. The newly formed cystoblast undergoes four
mitotic divisions with incomplete cytokinesis to form an interconnected 16-cell cyst.
Differentiated ESCs wrap around the cystoblasts after they move away from the niche and fully
encase them until the 16-cell stage. At the 16-cell stage, ESCs are replaced by somatic epithelial
follicle cells, and the 16-cell cystoblast buds off the germarium as individual egg chamber (stage
1) (Montell, 2003). The follicle cells are produced by 2-3 SSCs located in the midway of the
germarium. Stage 1 is reached relatively late during 2nd instar development. As a consequence 2nd
instar female gonads are ~10-fold smaller than male gonads (Kerkis, 1931; Toomey et al., 2013).
Of the 16 germline cells, one differentiates into the oocyte and enters meiosis, while the other 15
become polyploid nurse cells, which provide nutrients to the oocyte. The nurse cells nourish the
oocyte by transferring cytoplasm. Stages 2–7 (between 5-7 days of larval development) are
characterized by polyploidization of the nurse cells (through endocyclic divisions), mitotic
division of the follicle cells and increases in the size of the egg chamber (Montell, 2003; Toomey
et al., 2013; Williamson and Lehmann, 1996). The oocyte begins to accumulate yolk at stage 8,
mostly provided by the cytoplasmic contents of the nurse cells. By stage 10, the oocyte occupies
half the total volume of the egg chamber. In the final few hours of oogenesis, the nurse cells
undergo apoptosis and the follicle cells produce the eggshell (Montell, 2003).
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3.2
3.2.1

Methods
Fly stocks

Flies were kept at a 12-h light/dark cycle. All crosses were performed at 22-25°C, unless stated
otherwise. The following stocks were used for this study (Bloomington Drosophila Stock Center
(BDSC) and Vienna Drosophila Resource Center (VDRC) number (#) given in parentheses):
PBac{PB}CG8368 (Exelixis at Harvard Medical School), CG8368M100 (BDSC #1306), CG8368
P{KK101144}VIE-260B (VDRC #108563), Dbp73D (DDX51, VDRC #108310), CG5033
(BOP1, BDSC #35020), CG42666 (REXO1, BDSC #33666), Nop5 (BDSC #55262), Rps3
(BDSC #31625), CG8414 (NOL9, BDSC #44435), white (BDSC #33623), PAN2 (BDSC
#53249), Dis3 (VDRC #108013), Rrp6 (VDRC #108548), CG6833 (VDRC #104314), CG6937
(NIFK, BDSC 57467), Drosha (VDRC #108026, knockdown viable), Rs1, (DDX27, BDSC
#32363), pUf68 (BDSC #25951) CG12877 (VDRC #20265, knockdown viable). The sequencing
strain (Dmel WGS sequence, BDSC #2057) was used as wild type control. Two genetic mutants
PBac{RB}CG12877e00300 and CG12877f00666 were used for knockout analysis of CG12877
(REXO1). RpS2-GFP CB02294, RpL13A CC01920, RpL10Ab CB02653 protein trap lines were
a gift from A. Spradling (Buszczak et al., 2007) and were crossed into dNEF-spC04255 and dNEFspM100 mutant backgrounds. UAS-GFP-RpL11 and UAS-RFP-RpL26 lines were a gift from P.
DiMario (Rosby et al., 2009) and were crossed with a Tubulin-Gal4 (TubGal4) driver line. For
additional genetic mapping of the C04255 and M100 mutants we used complementation mapping
with the deficiency lines Df(3L)BSC411 (BDSC #24915, cross was lethal) and Df(3L)BSC410
(BDSC #24914, cross was viable) to confirm that the region causing lethality was encompassing
the dNEF-sp genetic locus.
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3.2.2

Genetic mapping of dNEF-sp mutants

Total DNA was isolated from homozygous mutant larvae and sequencing strain control larvae
using the Roche genomic DNA extraction kit (Roche). To confirm the PiggyBac transposon
insertion in C04255, PCR fragments were amplified with specific primers within the PiggyBac
transposon and within the coding region of dNEF-sp. To identify point mutations in M100, the
entire coding region was PCR amplified and PCR products were sent for DNA sequencing
(Genewiz) and analyzed in SeqMan Pro (LaserGene).

3.2.3

Generation of transgenic dNEF-sp rescue lines

For the generation of the dNEF-sp pUAST-attB (FBmc0003002) constructs the following primers
were

used

for

amplification

of

the

dNEF-sp

ORF:

GGAATTGGGAATTCATGAAGGAACATATGTCCACCAA;

forward

reverse

5’5’-

GAGCCGCGGCCGCCTAACTTTCCATAGTCTGATTCGATC. For introduction of point
mutations in the catalytic site following primers were used (and their reverse complement):
5’-CAGGAGAACATCGATGGTCGAGATTCCATTGAGGATTCGC;
5’- CGCAGTCCTATGTTCGGCGTTGCATGTGAAATGTGTCACACGGA;
5’-CGCAGTCCTATGTTCGGCGTTGATTGTGCAATGTGTCACACGGA;
5’-CAGGAGAACATCGATGGTGCAGATTCCATT GAGGATTCGC.
Two

genomic

constructs

were

cloned

into

the

TGGGAATTCGTAACACATACCATCCATGTTG;
TGGGAATTCGGCGTCATCGCTGAGATC;

pattB

plasmid:

forward

4.7

forward

6.5

kb:

reverse:

kb:
5’5’-

GAGCCGCGGCCGCTAGTGATCCTGACCAGGGCTT. Primers were designed so that they
included the promoter region of both or one isoform, respectively. Both constructs were sufficient
for rescue of lethality. The human NEF-sp ORF was amplified from human cDNA and cloned
into

pUAS-attB

using

following

primers:
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hNEF-sp-pUAS-forward:

5’-

ATCCGAATTCATGGAGCCAGAGAGGGAAGGGA;

hNEF-sp-pUAS-reverse:

5’-

AGTGCGGCCGCTCACGAACACAGGCCTGGGCCA; GFP cDNA and FLAG/HA cDNA was
PCR amplified and cloned with NdeI into a natural N-terminal NdeI restriction site in dNEF-sp.
GFP-forward:

5’-AAACATATGGTGAGCAAGGGCGAGG;

TGGACATATGAAGCTTCTTGTACA;

GFP-reverse:

FLAG/HA-forward:

AAACATATGGACTACAAGGACGACGA;

FLAG/HA-reverse:

5’5’5’-

GCTTGGTGGACATATGTGATATCTGGTTCA. The cDNA product was inserted at the Nterminus of the cloned dNEF-sp genomic construct with NdeI restriction digest according to
standard protocols. PCR amplified inserts were cloned into the attB vector using EcoRI and Not1
restriction digest according to standard protocols. pUAS-attB and pattB DNA constructs were
sent for injection to Bestgene Inc., and using the phiC31 integrase transgenesis system (Bischof et
al., 2007), and site-specifically integrated to generate transgenic flies at the 25C7 landing site in
the attP40 strain.

3.2.4

Clonal analysis of RNAi clones

For the generation of RNAi clones UAS-shRNA-dNEF-sp/Cyo;Sb/TM6B males were crossed to
yw hsFlp;Sco/Cyo;UAS#Red47a#1tub<+GFP<Gal4/TM6B females, and embryos were heat
shocked after 24 hrs egg laying at 37°C for 1 hr. Non-TM6B 3rd instar larvae were dissected for
clonal analysis.

3.2.5

In vivo shRNA knockdown

UAS-shRNAs were crossed to Sp/Cyo;TubGal4/TM6B. Second instar larvae were collected after
72 hrs and dissected for immunostaining and RNA in situ hybridization. UAS-GFPRpL11/Cyo;TubGal4/TM6B was crossed to the shRNA lines above and 2nd instar larvae were
further processed for RNA-sequencing or dissected for immunofluorescent staining as described.
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3.2.6

Immunofluorescence and microscopy

Adult flies and 2nd or 3rd instar larvae were dissected in PBS at room temperature. Tissues were
fixed in 4% paraformaldehyde/PBS solution for 30 min at room temperature and permeabilized
with PBS/Triton-X100 0.2% for 30 min, followed by blocking with 5% normal goat serum in
PBS/Triton-X100 0.2% for 30 min at room temperature. Primary antibodies were incubated
overnight at 4°C in 5% normal goat serum in PBS/Triton-X100 0.2%, tissues were washed at
least 3x 10 min in PBS/Triton-X100 0.2% before they were incubated for 1-2 hrs with AlexaFluor
secondary antibodies (1:500), Hoechst dye (1:1000), and Alexa-Phalloidin dye (1:300) in 5%
normal goat serum in PBS/Triton-X100 0.2%. Tissues were washed in PBS/Triton-X100 0.2%
for 45 min and mounted with VectaShield mounting media. Images were taken with a Zeiss LSM
710 confocal microscope.

3.2.7

RNA in situ hybridization

Larvae were dissected in PBS and tissues fixed in 4% paraformaldehyde/PBS solution for 1 hr at
4°C. Tissues were permeabilized in PBS-Triton-X100 0.2% for 30 min before incubation with
hybridization buffer (75 mM Tris-HCl pH 8.5, 50% (v/v) formamide, 1 M NaCl, 1 x Denhardt’s
reagent, 250 µg/ml Baker’s yeast, 500 µg/ml salmon sperm DNA, 2.5 mM Chaps, 0.5% (v/v)
Tween-20) for 30 min at room temperature. Alexa-647-fluor- or Alexa-488-conjugated LNA
probes were added to the prehybridization solution at a final concentration of 20 nM and tissues
were incubated overnight at 45 °C. After hybridization, samples were washed in wash buffer I (75
mM Tris-HCl pH 8.5, 50% (v/v) formamide, 250 mM NaCl, 0.1% (v/v) Tween-20) and wash
buffer II (75 mM Tris-HCl pH 8.5, 50 mM NaCl, 0.1% (v/v) Tween-20) for 30 min each. Tissues
were incubated with PBS-Triton-X100 0.2% and Hoechst dye (1:1000) for 30 min, washed 3x 10
min with PBS-Triton-X100, and mounted in VectaShield mounting media. Images were taken
with a Zeiss LSM 710 confocal microscope. LNA probe sequences were based on the validated
127

Northern blot probes, synthesized and labeled in the laboratory by C. Bognanni (5= LNA-A,
7=LNA-G, 8=LNA-T, 6=amino-modifier-C6-PDA): 3’ETS (repetitive sequence in trailer): 5’6T7TTTGGCTACTCTT7ATAAAA6;

3’ETS-2

(specific

region

in

trailer):

5’-

6AAATT7ATGACGAGCT7TTTG6; 28S: 5’- 6TCGAATCATCAA7CAAAGGATAAGC6;
18S: 5’- 6CAA7CATATAACTACT7GCAGG6; ITS1: 5’- 6CACCATTTTACTG7CATATATCAATTCCTTCAATAAATG6.

3.2.8

Cell culture methods

S2 cells: S2 cells were maintained at 25°C in Schneider’s insect medium, supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin in 15-cm cell culture dishes.
Sf9 cells:

Sf9 cells were maintained at 25°C in supplemented Grace’s Insect Medium

(supplemented with 10% FBS, 0.1% Pluronic-F68, 100 U/ml penicillin, 100 µg/ml streptomycin)
in spinner flasks. HEK293 cells: FlpIn T-REx HEK293 were maintained as described in Chapter
2 and (Spitzer et al., 2013). Expression of NEF-sp proteins was induced by supplementing
medium with 1 mg/ml doxycycline for 16 hrs prior to any analysis.

3.2.9

Generation of stable cell lines

HEK293 cell lines: dNEF-sp, mNEF-sp and hNEF-sp were amplified from Drosophila total fly
cDNA, mouse and human testis cDNA and cloned into pENTR4 using the BP clonase
recombinase system. Drosophila dNEF-sp (CG8368) has a singular ORF, the ORFs of mNEF-sp
(2610020H08Rik) isoform NM_028129.2 and hNEF-sp (LOC81691) isoform NM_030941.2
were amplified. The resulting pENTR4 vector was subsequently recombined into the
pFRT/TO/FLAG/HA-DEST destination vectors using Gateway LR recombinase according to
manufacturer’s protocol (Invitrogen). Following primers were used: dNEF-sp-forward:
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5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAAGGAACATATGTCCACCAA;
dNEF-sp-reverse:

5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAACTTTCCA-

TAGTCTGATTCGATC;

mNEF-sp-forward:

CAGGCTTCATGAAAACATTTCACTTCCCC;

5’-GGGGACAAGTTTGTACAAAAAAGmNEF-sp-reverse:

5’-GGGGACCACT-

TTGTACAAGAAAGCTGGGTCCTAGGCCAGGGTGCGACC; hNEF-sp-forward:
5’-GTACAAAAAAGCAGGCTTCATGGAGCCAGAGAGGGAAGGGACCGA;
reverse:

hNEF-sp

5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCACGAACACAGGCCTGG-

GCCAG. Cell lines were established according to the manufacturer’s protocol for the generation
of stable cell lines using the FlpIn system (Invitrogen) (see Chapter 2).

3.2.10 T7 in vitro transcription and shRNA-mediated knockdown in S2 cells
Four primers were designed to amplify a 500 nts template, 2 forward and 2 reverse primers. To
amplify ssRNA strands into each direction the forward primer contained the T7 promoter and the
reverse lacked the T7 promoter sequence; this ensured transcription from the PCR template into
one direction only. A 500 nt segment was selected within the ORF and amplified from 100 ng
Drosophila cDNA in a 100 µl PCR reaction. For amplification of the sense strand the primer
pairs [CG8368-sense-T7, CG8368-antisense] were used, for amplification of the antisense strand
the primer pairs [CG8368-sense, CG8368-antisense-T7] were used. The PCR product was diluted
1:50 in water. 10 µl diluted PCR product were incubated in a 200 µl reaction with T7 RNA
polymerase at 37°C for 24 hrs [T7 reaction mix: 128 µl H2O, 20 µl T7 reaction buffer (400 mM
Tris-HCl pH 7.9, 10 mM spermidine, 260 mM MgCl2, Triton X-100 0.1%), 40 µl 5x NTP
(A/C/G/UTP=5/5/8/2 mM), 1 µl DTT (1 M), 1 µl T7 RNA polymerase (1U/µl)]. The T7
amplification product was purified by RNeasy Mini Kit (Qiagen). RNA strands were annealed by
incubating sense and antisense strands at 500 nM final concentration each in 10 mM Tris-HCl pH
7.5, 20 mM NaCl solution, heating them for 1 min at 95°C and letting them cool down overnight
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at

room

temperature.

Primers

used:

CG8368-sense-T7:

GCGTAATACGACTCACTATAGCAGCACGAGCGCAACGAGAAGA;
T7:
sense:

5’-

CG8368-antisense-

5’-GCGTAATACGACTCACTATAGCAGGTTCTGGATGTCGGTTAGAA; CG83685’-CAGCACGAGCGCAACGAGAAGA;

CG8368-antisense:

5’-

CAGGTTCTGGATGTCGGTTAGAA.

3.2.11 Western blot analysis
For Western blots on whole tissues approximately ~50-100 µg dissected tissues or total
larvae/flies were lysed in lysis buffer [50 mM HEPES-KOH pH 7.4, 150 mM NaCl, 0.05%
Triton-X100, complete EDTA-free protease inhibitor cocktail (Roche)] using a 1 ml tissue
grinder. Lysates were cleared by centrifugation at >12,000 g for 10 min at 4°C. Protein
concentrations of supernatants were determined by BCA assay (Pierce). 40 µg lysate was mixed
with 4x sample buffer (200 mM Tris-HCl, pH 6.8, 200 mM dithiothreitol (DTT), 8% SDS, 24%
glycerol, 0.04% bromphenol blue) and incubated for 2 min at 95°C. Samples were separated by
SDS-PAGE for 1 hr at 30 mA per gel, using standard SDS Tris base-glycine running buffer. After
electrophoresis, proteins were blotted onto nitrocellulose membranes (Hybond-ECL, GE Life
Science), pre-wetted in transfer buffer (25 mM Tris base, 190 mM Glycine, 20% MeOH, 0.05%
SDS), and semi-dry transferred (Bio-Rad) at 250 mA for 1 hr. Protein membranes were taken
through a standard immunoblot protocol followed by enhanced chemiluminescent detection
(Crescendo ECL, Millipore) using a Lumimager (Fuji, LAS-3000). For Western blots on
HEK293, S2 or Sf9 cells lysates were similarly processed either in Triton-X100 buffer [50 mM
HEPES-NaOH pH 7.4, 150 mM NaCl, 0.05% Triton-X100, complete EDTA-free protease
inhibitor cocktail (Roche)] or NP-40 buffer [50 mM HEPES-KOH pH 7.2, 150 mM KCl, 0.5%
(v/v) NP-40, 0.5 mM DTT, complete EDTA-free protease inhibitor cocktail (Roche)].
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3.2.12 Immunoprecipitations
Immunoprecipitations were carried out for Western blot analysis and mass spectrometric
identification of protein interaction partners. For a typical FLAG immunoprecipitation 1-5 ml cell
pellet of HEK293 or S2 cells was lysed in 3 volumes of lysis buffer [S2 lysis buffer: 50 mM
HEPES-NaOH pH 7.4, 150 mM NaCl, 0.05% Triton-X, complete EDTA-free protease inhibitor
cocktail (Roche), HEK293 lysis buffer: 50 mM HEPES-KOH pH 7.2, 150 mM KCl, 0.5% (v/v)
NP-40, 0.5 mM DTT, complete EDTA-free protease inhibitor cocktail (Roche)] and incubated for
30 min on ice. Lysates were cleared by centrifugation at 12,000 g at 4°C for 30 min. Per 5 ml cell
lysate 50 µl magnetic Dynabeads Protein G coupled (Invitrogen) were affinity-conjugated to 25
µl of FLAG antibody (1 mg/ml, M2, Sigma-Aldrich) in 200 µl PBS-Tween-20 0.1% at room
temperature for 30 min. The beads were washed 2x in PBS-Tween-20 0.1% and incubated with
the lysate on a rotating wheel for 1 hr at 4°C. If the immunoprecipitation experiment was
intended for mass spectrometry, prior to immunoprecipitation lysates were RNase digested with
RNase T1 at a final concentration of 1 U/µl RNase T1 (Fermentas) at 22°C for 15 min. After
immunoprecipitation, samples intended for Western blot analysis were washed 3x in wash buffer
(lysis buffer minus detergent). Samples submitted for mass spectrometry were washed 3x in IP
wash buffer [50 mM HEPES-KOH pH 7.5, 300 mM KCl, 0.05% (v/v) NP-40, 0.5 mM DTT,
complete EDTA-free protease inhibitor cocktail (Roche)] and taken through a second RNase T1
digest. In the second RNase T1 digest beads were resuspended in one bead volume (50 µl) IP
wash buffer and incubated with RNase T1 to a final concentration of 100 U/µl at 22°C for 15
min. After the second digest beads were washed 2x in IP wash buffer and affinity-bound
FLAG/HA-NEF-sp protein was eluted with FLAG-peptide in a 200x FLAG peptide elution
reaction (60 µg FLAG peptide per 50 µl beads, Sigma-Aldrich). FLAG peptide was added to IP
wash buffer in a final elution volume of 60 µl, and FLAG/HA protein was eluted on a rotating
wheel at 4°C for 1 hr. The supernatant was transferred, mixed with 20 µl 4x SDS loading dye
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(200 mM Tris-HCl, pH 6.8, 200 mM dithiothreitol (DTT), 8% SDS, 24% glycerol, 0.04%
bromophenol blue), and incubated for 2 min at 90°C. 5 µl of the elution mixture were used for
Western blot analysis. For mass spectrometric analysis 40 µl of the elution was separated on a
Nupage 4-12% Bis-Tris SDS-PAGE (Invitrogen), and the gel stained with Colloidal Blue
(Invitrogen) according to the manufacturer’s instructions. For Western blot analysis beads were
resuspended with 50 µl SDS loading dye and incubated at 90°C for 2 min. 5 µl of supernatant
was loaded onto an SDS polyacrylamide gel and separated by gel electrophoresis.

3.2.13 Antibodies
Immunofluorescent staining: The following antibodies were used (dilutions noted in
parentheses): mouse monoclonal anti-Hts (1:20, 1B1) and rat monoclonal anti-VASA (1:20)
(Developmental Studies Hybridoma Bank, Iowa), rabbit monoclonal anti-Fibrillarin (1:500,
EPR10823(B), abcam), rabbit polyclonal anti-phospho-Histone H3 (Ser 10) (1:50, Upstate),
rabbit polyclonal anti-phospho-H2Av pS137 (1:500, Rockland), Alexa-488, Alexa-546, and
Alexa-647 (Molecular Probes) fluorescence-conjugated secondary antibodies were used at 1:500
dilution.
Western blot analysis: Following primary antibodies were used (dilutions noted in parentheses):
rabbit polyclonal anti-dNEF-sp (1:1000 affinity-purified serum), rabbit monoclonal antiFibrillarin (1:1000, EPR10823(B), abcam), mouse monoclonal anti-Tubulin (DM1A) (1:1000,
Sigma-Aldrich), mouse monoclonal anti-HA (1:1000, HA-7, Sigma-Aldrich, 1:1000, Covance,
MMS-101P). Following secondary antibodies were used: HRP conjugated polyclonal goat antiArmenian hamster heavy and light chain conjugated to horseradish peroxidase (HRP) (1:5000,
Jackson ImmunoResearch), polyclonal goat anti-mouse light chain conjugated to HRP (1:2000, 1
mg/ml, Southern Biotechnology Associates, Fisher), polyclonal goat anti-mouse and anti-rabbit
conjugated to HRP (1:5000, Dako).
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3.2.14 Development of monoclonal antibodies
3.2.14.1 Standard ELISA
Sf9 baculoviral purified mNEF-sp protein (denatured) was used in standard ELISAs; as negative
control we used FMRP protein, which was also purified from Sf9 cells [gift of M. Ascano
(Ascano et al., 2012b)]. The antigen was diluted in 5.2 ml binding buffer (final concentration 1
µg/ml antigen, but concentration for general assays ranges from 0.1 µg/ml-100 µg/ml depending
on antigen, sensitivity, purity, etc.). Binding buffer: 0.1 M NaHCO3 pH 8 (8 ml 0.2M Na2CO3, 17
ml 0.2M NaHCO3, 25 ml H2O). Per well 50 µl antigen solution was plated with a multi-channel
pipette into protein-binding plates designed for ELISA (Nunc Maxisorb Immuno plates). Plates
were sealed and incubated at 4°C overnight. The residual binding solution was flicked out and
dried on paper towels, rinsed 3x with wash buffer (PBS-Tween 0.1%) and filled with 100-150 µl
blocking buffer (PBS-Tween 0.1%, 1% BSA, 0.2% azide). The plates were incubated at room
temperature for 1 hr or overnight at 4°C. Blocking solution was removed and 50-100 µl antibody
solution (1:10-1:10,000 of bleeds, for final screening bleeds were diluted 1:100 as determined by
previous test ELISAs, and 1:10 dilution of hybridoma supernatants in blocking buffer) for 1-2 hr
at room temperature. As controls following was included: (a) sera from terminal bleed (positive
control), (b) known reactive monoclonal antibody (mouse anti-FLAG, M2, Sigma) (positive
control), (c) negative pre-immune bleed (negative control), (d) fusion blank (negative control), (e)
HT fusion media negative control. Both the antigen of interest and the control antigen were
screened under these conditions. Plates were rinsed off with wash buffer 3x and incubated with
50 µl secondary antibody solution (antibody in 1:5000 dilution in blocking buffer) per well for 1
hr at room temperature (goat anti-Armenian hamster heavy and light chain conjugated to horse
radish peroxidase (HRP), Jackson ImmunoResearch, goat anti-mouse κ-chain conjugated to HRP
(1 mg/ml), Southern Biotechnology Associates, Fisher). Secondary antibody was flicked off and
the plates rinsed 4x with wash buffer. The liquid was flicked off and the plates dried on paper
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towels. For ELISA development 50 µl TMB substrate solution was added (Turbo TMB, BioFx,
Sci-Quest) and the plates were incubated for 2-10 min. 50 µl 2N Sulfuric acid was added to stop
the reaction. Plates were read on a SpectraMax 190 microplate reader (Molecular Devices) at 450
nM and analyzed using the Softmax Pro software (Molecular Devices).

3.2.14.2 Sandwich ELISAs
This assay was done to screen supernatants of hybridoma clones, identifying clones that
recognized native, folded mNEF-sp protein. Since mNEF-sp was insoluble and could only be
purified in denaturing conditions from bacterial and Sf9 baculoviral expression systems, but was
soluble in HEK293 cells, we needed this assay to screen hybridomas at a high throughput scale to
detect clones that recognized the native, folded protein, so that these clones could also be used in
immunoprecipitation assays. Blocking buffer and wash solution were the same as in standard
ELISA conditions. The capture antibody used for coating was diluted at 1 µg/ml (can range from
1-5 µg/ml per assay) in 5.2 ml binding buffer. The capture antibody should come from a species
other than the immunized animal; in this case we used rabbit anti-FLAG monoclonal antibody
(F7425, Sigma). Coating and blocking was performed as in standard ELISA. For antigen
capturing, final concentration of antigen should range between 100 ng/ml to 20 µg/ml total
protein depending on the purity of sample. In our case we used total HEK293 lysate expressing
doxycycline induced mNEF-sp protein and as negative control we coated plates with uninduced
HEK293 lysate. 50 µl FLAG/HA-mNEF-sp HEK293 cell lysate (5 µg/µl lysate concentration)
was added per well and the supernatant incubated for 1 hr at room temperature. Supernatants
were flicked out and the wells washed 3x with wash buffer. In the primary incubation step plates
were incubated with 50 µl supernatant solution (1:100 bleeds, 1:10 hybridoma supernatants, same
controls were used as in standard ELISA) per well for 1-2 hr at room temperature. Supernatants
were flicked off the plates, plates were washed 3x with wash buffer, and dried on paper towels.
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Secondary antibodies are usually used in 0.3-1µg/ml or a 1:3000 dilution of polyclonal anti-sera,
diluted in PBS-Tween 0.1% (not in blocking solution as presence of azide may interfere with the
enzymatic activity of the peroxidase). To detect binding of the hybridomas to mNEF-sp, we
selected a secondary antibody detecting Armenian hamster heavy and light chain (goat antiArmenian hamster heavy and light chain conjugated to horseradish peroxidase (HRP), Jackson
ImmunoResearch, goat anti-mouse κ-chain conjugated to HRP (1 mg/ml), Southern
Biotechnology Associates, Fisher). In our case all secondary antibodies were used in 1:3000
dilution in PBS-Tween 0.1%. 50 µl of antibody solution was added to each well and incubated for
1 hr at room temperature. The secondary antibody solution was removed by flicking off the
supernatant onto paper towels, plates were washed 3x in PBS-Tween 0.1%, dried and incubated
with 50 µl Turbo TMB solution (Turbo TMB, BioFx, Sci-Quest) per well for 10 min at room
temperature. After 10 min the reaction was quenched with 50 µl 2N sulfuric acid. Plates were
read in a SpectraMax 190 microplate reader (Molecular Devices) at 450 nm and the data analyzed
with the Softmax Pro software (Molecular Devices).

3.2.14.3 Immunoprecipitations with hybridoma supernatants
In these immunoprecipitations the goal was to determine which hybridoma clone supernatant was
able to immunoprecipitate mNEF-sp protein from doxycycline induced HEK293 cell lines. A
mixture of protein A/G agarose beads was used for the conjugation to Armenian hamster
hybridoma fusions as hamster IgGs show higher binding affinity to protein A versus G (F. WeissGarcia personal communication and online information by ThermoScientific on Protein A/G
binding characteristics). For each hybridoma supernatant 50 µl A/G beads (Pierce,
ThermoScientific) were used per immunoprecipitation. Beads were washed 2x with 1 ml PBSTween 0.1% and collected by centrifugation at 1,000 g for 1 min. Beads were resuspended in 450
µl doxycycline induced FLAG/HA-mNEF-sp HEK293 lysate (10 µg/µl, measured by BCA
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assay) and 150 µl hybridoma supernatant or 5 µl pre- or terminal bleeds were added to the bead
lysate. The lysate was incubated on a rotating wheel for 2 hrs at 4°C. As negative control beads
with lysate minus hybridoma supernatants and beads incubated with blank fusion were used. As
positive control mouse monoclonal anti-FLAG antibody was used in 1:100 dilution (1 µg/ml, M2,
Sigma-Aldrich), and 1:100 dilution of terminal bleed (5 µl). After immunoprecipitation the beads
were washed 5x with 1 ml PBS-Tween, and 40 µl 2x SDS buffer was added to yield a final
volume of ~60 µl. The suspension was incubated for 2 min at 95°C. The supernatant was resolved
by SDS-PAGE and Western blot analysis was carried out as previously described, probing for the
presence of FLAG/HA-mNEF-sp protein with mouse monoclonal anti-HA antibody (1:1000,
16B12, Covance). For probing against the mouse monoclonal FLAG antibody polyclonal goat
anti-light

chain

mouse

Peroxidase-AffiniPure

antibody

was

used

(1:2000,

Jackson

Immunoresearch lab), for probing against the hamster hybridoma fusions goat anti-Armenian
hamster heavy and light chain conjugated to horseradish peroxidase (HRP) was used (Jackson
ImmunoResearch, goat anti-mouse κ-chain conjugated to HRP (1 mg/ml), Southern
Biotechnology Associates, Fisher). Signal was detected by enhanced chemiluminescent detection
(Crescendo ECL, Millipore) using a Lumimager (Fuji, LAS-3000).

3.2.14.4 Validation of clones by Western blot analysis
In this final screen we tested the supernatant of hybridoma clones, which were positive in all
previous tests, to see whether they also could recognize mNEF-sp in Western blot analysis. 50 µg
doxycycline induced mNEF-sp HEK293 lysate (5 µg/µl lysate concentration as determined by
BCA assay), as well as uninduced HEK293 control lysate, was separated on SDS-PAGE and
transferred by Western blot onto a nitrocellulose membrane as previously described. Membranes
were stained by Ponceau S stain (Sigma-Aldrich) to assess equal transfer, and cut into pieces such
that one induced and one induced HEK293 lysate lane was side-by-side. Membranes were taken
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through a standard Western blot analysis protocol as previously described. As primary antibody
solution hybridoma supernatants were diluted 1:2 in PBS-Tween 0.1% and incubated for 1 hr at
room temperature. As positive control one strip was incubated with monoclonal mouse anti-HA
(1:1000, HA-7, Sigma-Aldrich), and with terminal bleed (1:100). Secondary polyclonal goat antiArmenian hamster conjugated to HRP (1:2000, Jackson Immuno Research) was used for
detecting signal in the hybridoma bleeds, and secondary polyclonal goat anti-mouse HRPconjugated antibody (1:5000, Dako) was used to probe against the HA monoclonal antibody
positive control. Secondary antibodies were incubated for 1 hr at room temperature, membranes
washed in PBS-Tween 0.1% for 30 min and signal detected by enhanced chemiluminescent
detection (Crescendo ECL, Millipore) using a Lumimager (Fuji, LAS-3000).

3.2.15 Development of polyclonal antibodies
Full-length 6xHis-tagged-dNEF-sp protein was purified from baculoviral Sf9 expression as
described. Polyclonal antisera were generated in two rabbits TX2078 and TX2079 (Covance). For
Western blot analysis affinity-purified TX2079 serum was used (1:1000).

3.2.16 Protein quantification
Protein concentration of cell lysates was quantified using bicinchoninic acid assay (BCA assay,
Pierce), and using a bovine serum albumin (BSA) standard curve (1, 2, 5, 10, 15, 20 µg BSA).
Absorbances were measured at A562. Protein concentrations of recombinantly purified proteins
were assessed by in-gel quantification in reference to a BSA standard curve.

3.2.17 Recombinant protein purification from E. coli
mNEF-sp was insoluble and degraded in BL21-CodonPlus(DE3)-RIL. Full-length protein could
only be co-purified under denaturing conditions with smaller degradation products. dNEF-sp and
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hNEF-sp proteins were unstable in bacteria and gave no full-length products. mNEF-sp protein
was purified from bacteria solely for antibody generation and injected into Armenian hamsters.
For injection the protein could be denatured and had to be stored glycerol-free, and after dialysis
it was snap frozen and stored at -80°C prior to injection. mNEF-sp was cloned into the
HisSUMO-pET28a bacterial expression vector (Novagen). The plasmids containing the DNA
inserts of interest were transformed into E. coli strain BL21- CodonPlus(DE3)-RIL (Stratagene)
grown in Luria-Bertrani (LB) medium supplemented with 30 mg/mL kanamycin. BL21(DE3)RIL expressing pET28a-mNFE-sp protein were grown to OD280 0.5 at 37°C before IPTG
induction at 1 mM final concentration. Induced BL21(DE3) were grown overnight at 37°C before
cells were harvested and the cell pellet flash frozen and stored at -80°C. Cells were lysed in lysis
buffer (100 mM Tris HCl pH 8, 500 mM NaCl, 5 mM MgCl2, 10 mM imidazole, 2 mM 2mercaptoethanol, 50 µg/ml lysozyme) for 30 min on ice and sonicated. The lysate was cleared by
centrifugation at 12,000 g for 30 min at 4°C. The supernatant was discarded, the pellet
resuspended in loading buffer (100 mM Tris HCl pH 8, 500 mM NaCl, 5 mM MgCl2, 10 mM
imidazole, 8M urea) and batch-purified, incubating the solution with 2 mL Cobalt resin (HisPur
Cobalt IMAC resin, ThermoScientific) for 1 hr at 4°C. The resin was washed with 12x column
volumes lysis buffer, 6x column volumes wash buffer I (100 mM Tris HCl pH 8, 500 mM NaCl,
5 mM MgCl2, 30 mM imidazole, 8M urea), 6x column volumes wash buffer II (100 mM Tris HCl
pH 8, 500 mM NaCl, 5 mM MgCl2, 70 mM imidazole, 8M urea) and eluted in 6 column volumes
elution buffer (100 mM Tris HCl pH 8, 500 mM NaCl, 5 mM MgCl2, 150 mM imidazole, 8M
urea). The protein was dialyzed in 1 L dialysis buffer (100 mM Tris HCl pH 8, 500 mM NaCl, 5
mM MgCl2, 10 mM imidazole), snap frozen and stored at -80°C.
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3.2.18 Recombinant protein purification from Sf9 cells
PCR-amplified ORFs of the Drosophila wild type and the DADAH dNEF-sp transgenic mutant
constructs (see section 3.2.3) were recombined by BP recombinase into pENTR4 and then
recombined into the pDEST10 baculoviral expression vector using the Gateway LR recombinase.
Baculoviral production and amplification was performed as described in the Bac-to-Bac Manual
(Invitrogen). Sf9 cells were used for recombinant virus production, amplification and expression
of recombinant dNEF-sp proteins. Recombinant viruses were amplified to ~2-10^8 plaqueforming units per ml titer. 1 × 10^9 Sf9 cells were infected at a multiplicity of infection (MOI) of
5 and placed back into fresh Supplemented Grace’s Insect Medium (supplemented with 10%
FBS, 0.1% Pluronic-F68, 100 U/ml penicillin, 100 µg/ml streptomycin) into a spinner flask at a
final concentration of 1 × 10^6 cells per ml medium for 3–4 days prior to collection. 5 ml cell
pellets were lysed in lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10 mM
imidazole, 10% glycerol, 0.1% Triton-X100, 1x EDTA-free Protease Inhibitor Cocktail (Roche)]
for 30 min at 4°C. The lysate was cleared by centrifugation at 19,000 g for 30 min at 4°C and
filtered through a 5-µm membrane (Pall). The supernatant was incubated with 2 ml Cobalt resin
(HisPur Cobalt IMAC resin, ThermoScientific) on a rotating wheel for 2 hrs at 4°C. The resin
was washed with 12 column volumes wash buffer-10 (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5
mM MgCl2, 10 mM imidazole, 10% glycerol) and 6 column volumes wash buffer-30 (50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 30 mM imidazole, 10% glycerol). The protein
was eluted in 6 column volumes with elution buffer-150 (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 5 mM MgCl2, 150 mM imidazole, 10% glycerol). Fractions were flash frozen in 50%
glycerol and stored at -80°C.
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3.2.19 Transient protein expression in S2 cells
ORFs of HA/FLAG-dNEF-sp wild type and HA/FLAG-dNEF-spDEDAH catalytic dead mutant
were cloned into pAc5.1/V5-His A (addgene). The dNEF-sp ORF was amplified from the pUASattB injection constructs in a 2-step PCR introducing an N-terminal HA/FLAG tag into both
mutant

and

wild

type

proteins.

(FLAG-dNEF-sp-forward:

5’-

GACTACAAGGACGACGATGACAAGATGAAGGAACATATGTCCAC; HA/FLAG-forward:
5’-TCAGAATTCATGTACCCTTATGACGTGCCCGATTACGCTGACTACAAGGAC; dNEFsp-reverse: 5’-TGCGGCCGCCTAACTTTCCATAGTCTGATTCGATCCG.) The ORF was
double digested with EcoRI and NotI following standard cloning procedures. Cells were grown in
15 cm dishes. At ~80% S2 cell confluency 15 µg HA/FLAG-dNEF-sp-wt-pAc5.1 or Ha/FLAGdNEF-spDEDAH-pAc5.1 was transfected with 30 µl TransIT-Insect transfection reagent (Mirus) in
1.5 ml serum-free medium according to the manufacturer’s instructions. Cells were harvested
after 48 hrs and expression was verified by Western blot analysis probing against the HA antigen.

3.2.20 RNA extraction and cDNA preparation
50 µg cells or 2nd instar larvae or dissected ovaries and testes where directly homogenized in 1 ml
TRIzol (Life Technologies) and total RNA was isolated according to the manufacturer’s protocol.
Poly(dT) amplified cDNA was prepared from 5 µg total RNA, using oligo(dT) amplification and
the Superscript III First Strand synthesis kit following the manufacturer’s instructions
(Invitrogen).

3.2.21 RNA and DNA phenol/chloroform extraction and ethanol precipitation
One volume of phenol/chloroform/isoamyl alcohol (25:24:1, phenol buffered at pH 4.3 for RNA,
phenol buffered at pH 7.4 for DNA) was added to one volume of an RNA/DNA solution and
vortexed vigorously for 15 sec. The phases were separated by centrifugation at 12,000 g at 4°C
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for 2 min. The upper aqueous layer was removed to a new tube and re-extracted with an equal
volume of ice-cold chloroform. The mixture was vortexed for 15 sec and the phases were
separated by centrifugation, 12,000 g at 4°C for 2 min. The upper aqueous layer was removed and
added to a new tube, and the salt concentration adjusted to a final of 0.3 M NaCl. 3 volumes of
100% EtOH were added to the solution, mixed thoroughly, and stored at -20°C for 10 min (long
RNAs/DNAs) or 1 hr/overnight (short RNAs/DNAs). RNA/DNA was precipitated by
centrifugation at 12,000 g at 4°C for 30 min. The supernatant was removed and the pellet
dissolved in 10-50 µl water.

3.2.22 NEF-sp PAR-CLIP
For small-scale PAR-CLIP tests in HEK293 cells, five 15-cm plates were grown and processed as
previously described in Chapter 2. After protein separation by SDS-PAGE, instead of gel
electroporation, crosslinked RNA-protein complexes were transferred onto a nitrocellulose
membrane (HighBond ECL, GE Healthcare Life Sciences) in a semi dry transfer system with 1x
transfer buffer (25 mM Tris base, 190 mM Glycine, 20% MeOH, 0.05% SDS) at 250 mA for 1
hr. The membrane was exposed for 1 hr on a phosphorimaging screen. For PAR-CLIP in S2 cells,
pellets expressing dNEF-sp wt and mutant and untransfected control cells were lysed in 3
volumes of Triton-X100 lysis buffer [50 mM HEPES-NaOH pH 7.4, 150 mM NaCl, 0.05%
Triton-X, complete EDTA-free protease inhibitor cocktail (Roche)] for 30 min on ice. Lysates
were cleared by centrifugation at >10,000 g for 30 min at 4°C. The remaining part of the protocol
was followed as previously described.

3.2.23 In vitro RNA nuclease assays
For 5’ end radiolabeling of oligonucleotides, 100 pmoles of RNA or DNA oligonucleotides were
incubated with 5 pmoles of γ-32P ATP and 10 units of T4 PNK (NEB) in 1 x T4 PNK buffer (70
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mM Tris-HCl pH 7.6, 10 mM MgCl2, 5 mM DTT) in a 20 µl reaction for 15 min at 37°C;
followed by addition of 1,000 pmoles of non-radiolabelled ATP and incubation for another 5 min.
To generate circular RNAs, ssRNAs were labeled as described, phenol/chloroform extracted and
ethanol precipitated, and self-ligated by incubating them with T4 Rnl1 (0.2 µg/µl) in 50 µl of
buffer containing 50 mM Tris-HCl pH 7.6, 10 mM MgCl2, 10 mM β-mercaptoethanol, 0.2 mM
ATP, 0.1 mg/ml acetylated BSA, 15% DMSO for 1 hr at 37°C. All reactions were stopped by
addition of 1 volume of stop buffer (8 M urea, 10 mM EDTA, bromophenol blue). Labeled
oligoribonucleotides were separated on a 18% polyacrylamide/ 8M urea gel at 28 W for 1 hr,
eluted with 400 µl 0.3 M NaCl solution overnight, and ethanol precipitated. Exonuclease assays
were performed in 50 mM KOAc, 20 mM Tris-OAc pH 7.9, 10 mM MgOAc, 1 mM DTT (NEB
buffer 4) in the presence of 1 pmol 5’-32P-labeled oligomers and 20 or 25 nM recombinant protein
in 50 µl total reaction volume. Samples were incubated at 25°C and 10 µl aliquots were taken at
1, 5, 10 and 30 min and mixed directly with stop mix. We used commercially available bacterial
RNase T (ExoT, NEB) (0.2U) and laboratory-purified (20 nM) C3PO [gift from M. Ascano (Tian
et al., 2011)] as exonucleolytic and endonucleolytic enzyme control. Samples were loaded on a
18% polyacrylamide/ 8M urea gel, run for 1 hr at 28 W, and exposed on a phosphorimaging
screen.

3.2.24 Northern Blot analysis
5 µg of total RNA was heated for 5 min at 65°C, snap cooled and separated the RNA on a 1.2%
formaldehyde agarose gel in MOPS running buffer (200 mM MOPS, 50 mM NaOAc, 10 mM
EDTA) for 3 hrs at 75 V. As single-stranded RNA size marker we used Ambion Millenium RNA
marker. The gel was incubated for 30 min in an alkaline solution (50 mM NaOH, 10 mM NaCl)
and neutralized for 15 min in 0.1 M Tris-HCl pH 7.0. RNA was transferred to a Zeta-Probe GT
membrane in 20x SSC (Na3Citrate 2H2O, 3M NaCl) in a downward-blotting procedure for 1.5
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hrs. Transfer efficiency was assessed with a methylene blue solution (0.04%, methylene blue
hydrate, 0.5 M NaOAc). Membranes were UV-crosslinked and incubated with 20 ml
hybridization buffer (5x SSC, 1% SDS, Dextran sulfate 10 %, formamide 25 %, 250 µg/ml
Baker’s yeast RNA) for 1 hr at 65°C. 30 pmol oligonucleotide probes were 5’end labeled as
previously described and purified using an Illustra MicroSpin G-25 column. Radioactive probes
were added to the prehybridized membrane solution for 1 hr at 65°C, and then incubated
overnight at 37°C. The membrane was washed with 2x SSC/1% SDS and 0.2x SSC/1% SDS
solutions for 30 min each at 37°C before it was exposed on a phophorimaging screen for 1 hr.
Membranes were stripped in 0.1x SSC/0.5% SDS at 85°C for 1 hr and reprobed for all probes.
Following oligonucleotide probes were used: 5’ETS: 5’-TTCGAACAATGCGAGGTCGGCAA;
ITS1 (Zhang et al., 2014): 5’-CACCATTTTACTGGCATATATCAATTCCTTCAATAAATG;
3’ETS-repeat: 5’- TGTTTGGCTACTCTTGATAAAA; 3’ETS-1: 5’-AAATTGATGACGAGC
TGTTTG; 28Sa: 5’-ACTTAGGACCGACTAACTCGTGA; 28Sb: 5’-TCGAATCATCAAGC
AAAGGATAAGC; 18S: 5’-CAAGCATATAACTACTGGCAGG; 7SL: 5’-TGGAAGGTT
GGCAGCTTCTGTAATCA.

3.2.25 RNA extraction and Illumina total RNA and mRNA-seq
2nd instar larvae or dissected ovaries and testes were directly homogenized in 1 ml TRIzol with a
tissue grinder and total RNA was isolated according to the manufacturer’s protocol. poly(A)
purification and total RNA cDNA library construction was performed using the TruSeq version
1.5 kit (Illumina). cDNA was barcoded using the Illumina Multiplexing Sample Preparation
Oligonucleotide kit and analyzed an Illumina HiSeq 2000 in a 100-base-pair (bp) single-end
sequencing run.
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3.2.26 Hydro-seq
19-nt

19.39

(5’-CGUACGCGGGUUUAAACGA)

and

CGUACGCGGAAUAGUUUAAACUGU) oligo size markers were
radioactive ATP by PNK as described.

24-nt
32

24.60

(5’-

P-5’end-labeled with

The RNA size markers contain a PmeI restriction

endonuclease recognition site (underlined). After PCR-amplification the cDNA libraries were
digested with PmeI to avoid sequencing of the size markers. Briefly, size markers were
individually radiolabeled in a 10 µl reaction containing 1 µM RNA, 10 U T4 polynucleotide
kinase and 50 µCi γ-32P-ATP (6,000 Ci/mmol) at 37 ºC for 15 min. The labeled size markers
were separated on a 15% polyacrylamide/8M urea gel, gel extracted in 0.3 M NaCl solution at
4°C overnight, and ethanol precipitated. RNA was redissolved in 10 µl water and 19-nt and 24-nt
marker were combined 1:100 in water. A known amount of calibrator RNA was added to the
experiments to follow the success of the library preparation. The calibrator oligoribonucleotides
have no match to the human or mouse genome. 0.5 fmol each of the ten following calibrator
oligoribonucleotides were added to 2 µg of total RNA. The preparation of a calibrator cocktail
requires the use of carrier oligonucleotide to prevent surface adsorption during preparation of the
dilution series in the nanomolar concentration range (11-nt oligodeoxynucleotide 11.6, 5’TCGAAGTATTC). Following calibrator RNA sequences were used (p, 5'-monophosphate): 01:
5’-pGUCCCACUCCGUAGAUCUGUUC; 02: 5’-pGAUGUAACGAGUUGGAAUGCAA; 03:
5’-pUAGCAUAUCGAGCCUGAGAACA; 04: 5’-pCAUCGGUCGAACUUAUGUGAAA; 05:
5’-pGAAGCACAUUCGCACAUCAUAU; 06: 5’-pUCUUAACCCGGACCAGAAACUA; 07:
5’-pAGGUUCCGGAUAAGUAAGAGCC; 08: 5’-pUAACUCCUUAAGCGAAUCUCGC; 09:
5’-pAAAGUAGCAUCCGAAAUACGGA; 10: pUGAUACGGAUGUUAUACGCAGC.
7 ml of carrier solution containing 500 nM 11-nt carrier of DNA oligo 11.6 was prepared in
water. (The carrier is necessary to prevent surface adsorption during dilution and storage of low
concentrations of calibrator RNA oligos.) 50 µl of a calibrator cocktail containing 1 µM of each
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calibrator RNA oligo was prepared. The calibrator cocktail was diluted 1:10 in carrier solution
resulting in a calibrator concentration of 0.1 µM each (50 µl calibrator solution plus 450 µl of
carrier). The calibrator cocktail was diluted further 1:100 in carrier solution resulting in a final
RNA oligo calibrator concentration of 1 nM each. Following pre-adenylated 3’ adapter sequences
were used (L, 3' aminolinker blocking group; rApp, 5’ terminal adenosine residue connected via a
5’, 5’-diphosphate bridge to the 5’OH of the 5’ nucleotide, which activates the adapter for
ligation): 3’ pre-adenylated RNA adapter: rAppNNNNNTCGTATGCCGTCTTCTGCTTG-L,
where NNNNN: 26.75, TCACT; 26.76, TCATC; 26.77, TCCAC; 26.78, TCCGT; 26.79,
TCCTA; 26.80, TCGAT; 26.81, TCGCG; 26.82, TCTAG; 26.83, TCTCC; 26.84, TCTGA;
26.85, TTAAG; 26.89, TAACG; 26.90, TAATA; 26.91, TAGAG; 26.92, TAGGA; 26.93,
TATCA; 26.94, TGATG; 26.95, TGTGT; 26.96, TTACA; 26.98, TTGGT. The adapters each
contain a unique pentamer barcode sequence at the 5’ end (bold and underlined) and were
preadenlyated according to a preadenylation protocol established in the laboratory. The 5’ RNA
adapter 26.68 had following sequence: 5’-GUUCAGAGUUCUACAGUCCGACGAUC. The
primers for amplification of the barcoded cDNA library used were the following: 5’ adapter
primer 44.32: 5’-AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA; 3’
adapter primer 21.929: 4’-CAAGCAGAAGACGGCATACGA.
Alkaline Hydrolysis: 0.3 µg of total RNA was subjected to partial alkaline hydrolysis in a
mixture of 10 mM Na2CO3 and 10 mM NaHCO3 for 5 min at 90°C.
Dephosphorylation: Fragmented RNA was dephosphorylated with 10 U calf intestinal alkaline
phosphatase (CIP) in dephosphorylation buffer (20 mM Tris-OAc pH 7.9, 50 mM KOAc, 10 mM
MgOAc, 100 µg/ml BSA) for 1 hr at 37°C, phenol chloroform extracted and ethanol precipitated.
Re-phosphorylation: RNA was re-phosphorylated with T4 polynucleotide kinase (PNK) in
reaction buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl2, 5 mM DTT) for 1 hr at 37°C, phenol
chloroform extracted and ethanol precipitated. The RNA was redissolved in 8.5 µl water.
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Subsequent steps were identical to a small RNA library preparation protocol previously described
in Hafner et al. (Hafner et al., 2012) and are in detail described below.
3’ adapter ligation: Re-phosphorylated RNA (in 8.5 µl water) was incubated with 8.6 µl 3’ligation mix [2 µl of 10x RNA ligase buffer without ATP (0.5 M Tris-HCl, pH 7.6, 0.1 M MgCl2,
0.1 M 2-mercaptoethanol, 1 mg/ml acetylated BSA (Sigma)], 6 µl 50% aqueous DMSO, 0.5 µl of
1 nM of each calibrator cocktail and 0.1 µl of 1:100 dilution of the 5'-32P-labeled length marker
oligoribonucleotide mix), and 2 µl 3’adapter (different adapters for different samples), and
incubated at 90ºC for 1 min to denature any RNA secondary structures. The samples were cooled
down on ice, 1 µl Rnl2(1-249)K227Q (1 µg/µl) added and incubated on ice at 4ºC overnight. As
ligation control 2 µl of the 1:100 diluted length marker was mixed with 6.5 µl of water and
processed separately. To precipitate and stop the 3’ligation reaction 3x the total volume of the
combined 3'-adapter ligation reactions of absolute ethanol was added sequentially to each tube
and the reaction transferred until all samples were pooled. Ethanol addition ensured stopping the
reaction by deactivation of Rnl2(1-249)K227Q. To the pooled samples a 3 M NaCl solution was
added in a 1/10 of the total volume to achieve a final 0.3 M NaCl concentration. The reaction was
precipitated at -20ºC for 1 hr or overnight, and the RNA pellet collected by centrifugation in a
tabletop centrifuge at 4ºC at maximum speed (approx. 14,000 g) for 30 min. The supernatant was
discarded and the pellet dried by vacuum centrifugation. The RNA pellet was dissolved in 15 µl
water per pooled library, mixed with 15 µl formamide stop mix (98.8% formamide, 1% (v/v) 0.5
M Na2 H2EDTA, pH 8.0, 0.2% Bromophenol blue), and heated at 90ºC for 1 min to denature
RNA secondary structures. The samples were loaded on a 15% polyacrylamide/8M urea gel and
separated at 28 W for 45 min. The gel was exposed on a phosphorimaging screen to visualize the
ligation product. The ligated product (at ligated size marker control length) was excised from the
gel, the ligated RNAs eluted from the gel in 400 µl 0.3 M NaCl solution by incubating the tube
overnight at 4ºC under constant agitation (on the thermomixer shaking at 11,000 rpm). The RNA
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was ethanol precipitated as previously described. The RNA pellet was vacuum dried and
dissolved in 9 µl water.
5’ adapter ligation: To the ligated product 9 µl of 5’ ligation mix was added (1 µl of 100 µM 5'adapter 26.68, 2 µl of 10x RNA ligase buffer with ATP and 6 µl 50% aqueous DMSO), the RNA
mixture was incubated at 90ºC for 1 min to denature RNA secondary structures and the reaction
immediately cooled on ice for 2 min. 2 µl of T4 RNA ligase 1 (Rnl1) (1 µg/µl, Fermentas) was
added, the reaction mixed gently and incubated for 1 hr at 37 ºC. To stop the reaction 20 µl of
denaturing formamide stop mix was added and the samples incubated for 1 min at 90ºC. Samples
were directly loaded onto a 12% polyacrylamide/8M urea gel and separated at 28W for 45 min.
The gel was exposed on a phosphorimaging screen and gel pieces of the size of the 5’ ligation
product (as assessed by the ligation control) were excised. The RNA was eluted in 400 µl 0.3 M
NaCl solution (approximately 3x the gel piece volume), 1 µl of 100 µM 3'-primer 21.929 was
added as carrier and the ligated RNAs eluted from the gel by incubating the solution overnight at
4ºC under constant agitation (on the thermomixer shaking at 11000 rpm). The RNA was ethanol
precipitated, the pellet collected by centrifugation and air dried.
Reverse transcription: Reverse transcription was performed using the SuperScript III reverse
transcriptase (Invitrogen) reaction kit. The RNA pellet was dissolved in 5.6 µl water. The control
length marker ligation product was carried forward as control. The RNA was denatured by
incubating the tube for 30 sec at 90ºC and transferring the tube to a 50ºC incubator. 8.7 µl of the
RT reaction mix were added (1.5 µl 0.1 M DTT, 3 µl 5x first-strand buffer (250 mM Tris-HCl pH
8.3, 375 mM KCl, 15 mM MgCl2, 100 mM DTT, buffer provided by the manufacturer), and 4.2
µl 10 mM each dNTPs) to each sample and incubated for 3 min at 50ºC. 0.75 µl of Superscript
III reverse transcriptase (Invitrogen) was added and the reaction incubated for 30 min at 42ºC.
After the RT reaction, the RNA template was hydrolyzed by adding 40 µl of 150 mM KOH/20
mM Tris base and incubated for 10 min at 90ºC. The solution was neutralized by addition of 40
147

µl of 150 mM HCl and the pH adjusted to a range of 7.5 (monitored on pH paper). The pH
solution should be slightly alkaline to not inhibit the subsequent PCR amplification.
PCR amplification: 10 µl of the cDNA solution, 0.5 µM of each primer (0.5 µl of each 100 µM
primer 21.929 and 44.32), 10 µl 10x dNTP mix (2 mM each dNTP), 10 µl 10x PCR buffer (100
mM Tris-HCl, pH 8.0, 500 mM KCl, 1% Triton-X100, 20 mM MgCl2, 10 mM 2Mercapthoethanol), 68 µl water and 1 µl of Taq DNA polymerase (5 U/µl) were mixed to
perform a standard 100 µl PCR with Taq polymerase. As control a no-template control PCR
reaction was performed with H2O to check for DNA contamination in the reaction mixture.
Enough master mix was prepared to have four 100 µl PCR reactions per sample (pilot PCR and
large-scale PCR). For the cDNA amplification following PCR conditions were chosen: 45 sec at
94ºC denaturation step, 85 sec at 50ºC annealing, 60 s at 72ºC polymerase extension. To
determine the number of cycles for the final library amplification a 100 µl pilot PCR was
performed. 10 µl aliquots were removed every other cycle following cycle number 10 until cycle
28 by temporarily putting the PCR cycler on hold at the end of the 72ºC step. The PCR aliquots
were mixed with 5x DNA loading dye (0.2% bromophenol blue, 0.2% xylene cyanol FF, 50mM
EDTA pH 8, 20% Ficoll type 400) and analyzed on a 2.5% agarose gel in 0.5x TBE buffer for 2
hrs at 180 V. The optimal cycle number was determined by choosing the cycle number
approximately 5 cycles below the PCR saturation threshold. Limiting the amplification cycles to
the exponential phase was important to minimize sequence-specific distortions of some sequences
amplifying better than others and leading to distortions in the RNA sequence profiles, commonly
referred to as clonal amplification. After determining the optimal cycle, 3 large scale PCR
reactions were carried out per sample, the PCR products pooled, and a 5 µl aliquot removed for
analysis on a 2.5% agarose gel. The remaining product was phenol/chloroform extracted and
ethanol precipitated by adding 30 µl 3 M NaCl solution, adding 1 volume of neutral
Phenol/chloroform/IAA and vortexing the mixture for 30 sec. The phases were separated by
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centrifugation at 14,000 g for 2 min. The aqueous supernatant was transferred to a new tube and
re-extracted with 1 volume of chloroform to remove residual phenol. The mixture was vortexed
for 30 sec and separated by centrifugation at 14,000 g for 2 min. The aqueous supernatant was
transferred to a new tube and ethanol precipitated by adding 3 volumes of 100% ethanol and
incubating the solution at -20ºC for 1 hr or overnight.

The DNA pellet was collected by

centrifugation at 14,000 g for 30 min at 4ºC. The ethanol supernatant was removed. The DNA
pellet was not air dried to prevent denaturation of DNA and directly dissolved in 20 µl PmeI
reaction mix. Denaturation and subsequent re-annealing of a complex sequence pool will result in
imperfect rehybridization and formation of DNA duplexes with internal bulges that might
compromise PmeI digestion.
PmeI digest of size marker sequences: In a final step the 19-nt and 24-nt size markers in the
samples were PmeI digested to not lead to overrepresentation of size markers in the sequencing
reaction. Per reaction following PmeI digest mix was prepared: 2 µl 10x PmeI buffer (NEB
Cutsmart buffer: 20 mM Tris-acetate pH 7.9, 50 mM Potassium Acetate, 10 mM Magnesium
Acetate, 100 µg/ml BSA, 17.5 µl of water and 0.5 µl (5 U) of PmeI (NEB). The DNA pellet was
directly dissolved in PmeI reaction mix and incubated at 37ºC for 2 hrs. The reaction mix was
mixed with 20 µl 5x DNA loading dye, loaded onto a 2.5% agarose gel and run in 0.5x TBE
buffer for 2 hrs at 180 V until 5’-adapter-3’-adpater ligation product could be sufficiently
separated from the cDNA library. The cDNA library product was excised from the gel and gel
purified using the QiaQuick gel purification kit (Qiagen). The final cDNA library was eluted in
30 µl water and submitted for Illumina sequencing.

3.2.27 RNA-seq data analysis
RNA-seq libraries were adapter extracted and aligned against the Drosophila melanogaster
genome dm3 with BWA or tophat2 (for poly(A) and total RNA-seq) in standard settings (Li and
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Durbin, 2009). Hydro-seq and total RNA-seq libraries were hierarchically aligned against
separately created indexes of different RNA classes, according to their relative abundance in the
cell: (1) rRNA, (2) tRNA, (3) snRNA/snRNA, (4) transposons, (5) miRNA and other short
ncRNAs, (6) mRNAs. Library and transcript normalized rpkm count values were calculated
separately for each alignment category and their correlation presented as scatterplots in R.
Alignments against the full 47S rRNA precursor were done using the NCBI GenBank M21017.1
reference transcript. Further downstream analysis was performed in R. Rpkm values for poly(A)mRNA –seq were calculated using cufflinks2 (Trapnell et al., 2012a) and HTSeq (Anders et al.,
2015). Differential gene expression was calculated with DEseq (Anders and Huber, 2010) and
further downstream analysis was carried out in R. Gene Ontology [using the DAVID functional
annotation database (Ashburner et al., 2000; Huang et al., 2008)] and GOrilla (Eden et al., 2009)
analyses were performed using the cuffdiff output data, selecting genes with adjusted p-values of
≤0.05.
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3.3
3.3.1

Results
The NEF-sp nuclease family has a unique structural domain organization in
vertebrates

The NEF-sp nuclease family possesses one distant S. cerevisiae homolog, the RNA exonuclease
Rex1p (RNH70). However, the homologous relationship between them is not close and the
human REXO1 family represents the main homolog by sequence conservation and evolutionary
distance. Examining the phylogenetic tree of DEDDh RNase T nucleases, NEF-sp proteins
branch off as a distinct, newly evolved protein family (Figure 3.6). NEF-sp proteins contain one
RNase T exonuclease domain, which is conserved across eukaryotes and gained at the vertebrate
level two RNA-recognition motif domains (RRMs), which are absent in invertebrates and lower
eukaryotes (Figure 3.8).

Figure 3.8 NEF-sp domain conservation across eukaryotes. Schematic domain organization of
NEF-sp proteins scaled according to protein length for human NEF-sp, mouse, Xenopus,
Drosophila and the S. cerevisiae homolog Rex1p. Protein length [in amino acids (aa)], predicted
molecular weight (in kDa), and percentage identity to the human NEF-sp protein are shown.
This structural domain combination of a catalytic RNA exonuclease domain and two
single-stranded RNA binding domains is unique across the genome (Gerstberger et al., 2014a).
The recent evolutionary acquisition of two RRM domains in NEF-sp homologs in vertebrates
might suggest an increasing requirement for affinity or specificity to recognize target RNAs.
To characterize the role of NEF-sp in RNA processing, we chose to investigate its
function biochemically and genetically in Drosophila melanogaster as this provided a tractable
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and well-established model system for gonad development. Due to the structural differences in
NEF-sp proteins at the vertebrate level we also started initial characterizations of human NEF-sp
in HEK293 cells and generated a monoclonal antibody against the mouse NEF-sp homolog for
future genetic and biochemical studies. In the following chapters I will first describe the work
performed in human cell lines on hNEF-sp and the generation of a monoclonal antibody against
the mouse homolog mNEF-sp, before I describe the full characterization of Drosophila dNEF-sp
and its in vivo phenotypes and targets.

3.3.2

Recombinant protein purification of NEF-sp and generation of stable cell lines

In order to study the in vitro RNase activities and to raise antibodies against NEF-sp proteins
several overexpression and purification strategies were pursued to generate recombinant human,
mouse and Drosophila NEF-sp proteins. We used bacterial and baculoviral expression in Sf9
insect cells (Army worm). The human isoform 1 of NEF-sp (NM_030941.2), mouse isoform 2
NEF-sp (NM_028129.2), and the Drosophila CG8368 ORFs were cloned into the bacterial
expression vector pET28a-HisSUMO with an N-terminal cleavable HisSUMO tag and into the
baculoviral pDEST10 N-terminal His6 vector using the Bac-to-Bac expression system
(Invitrogen). Bacterial expression and purification of NEF-sp proteins was not successful for
either human and Drosophila NEF-sp proteins and they were already degraded before lysis.
Expression constructs were switched to Glutathione S-transferase (GST) N-terminal tags, and
lengths of expression constructs varied, but none of the tested conditions produced stable protein,
monitored by Western blot analysis and Commassie staining. Only mNEF-sp protein was stably
expressed in bacteria, although degraded fragments of mNEF-sp protein were already observed
before lysis and co-purified (Figure 3.9 A). mNEF-sp protein was insoluble and could only be
purified under denaturing conditions. We switched to baculoviral expression of NEF-sp proteins
in Sf9 cells. In this expression system mNEF-sp protein was expressed at full length, but also
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showed unstable fragments before lysis (Figure 3.9 B). Insoluble in Sf9 cells, mNEF-sp could
only be purified under denaturing conditions. The dialyzed mNEF-sp protein purified from
bacterial and baculoviral expression was further used for injection into Armenian hamsters and
screening for monoclonal antibodies against the mNEF-sp protein. Human NEF-sp protein was
unstable in Sf9 cells in vivo and its purification was not further pursued (Figure 3.9 C).

Figure 3.9 Recombinant expression of human, mouse and Drosophila NEF-sp. (A)
Commassie gel and anti-His Western blot (anti-His) of recombinant HisSUMO-mNEF-sp protein
expressed in BL21(DE3)-RIL E. coli strain. (B) Same as in (A) for recombinant His-mNEF-sp
protein expressed with baculoviral expression in Sf9 cells. (C) Western blot analysis of Sf9
lysates with baculoviral expression of human NEF-sp and mNEF-sp protein. (D) Commassie gel
of recombinant His-dNEF-sp protein purified from Sf9 cells. (E) Western blot (anti-HA) of
HEK293 stable cell line clones expressing doxycycline-induced mNEF-sp and dNEF-sp protein.
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Drosophila NEF-sp protein could be successfully expressed and purified under native
conditions in Sf9 cells and displayed nuclease activity in vitro (Figure 3.9 D, Figure 3.23-3.24).
Lastly, using the FlpIn system, stable HEK293 cell lines expressing doxycycline inducible Nterminally FLAG/HA tagged hNEF-sp, mNEF-sp, and dNEF-sp protein were successfully
generated (Figure 3.9 E). These cell lines served as tool for testing and validating antibodies in
the hybridoma screen, for subcellular localization studies, and for PAR-CLIP RNA-crosslinking
experiments.

3.3.3

Pilot PAR-CLIP of hNEF-sp in HEK293 cells

Predominantly expressed in gonads, human NEF-sp is expressed at low levels in HEK293 cells.
Using doxycycline-inducible overexpression of FLAG/HA protein we investigated the
localization and RNA-binding activity of hNEF-sp. The human FLAG/HA-NEF-sp protein
localized to nucleoli (Figure 3.10 A). Applying 4-SU crosslinking in vivo (PAR-CLIP), I assessed
the RNA-crosslinking efficiency of hNEF-sp, visualizing the crosslinked and radioactively
labeled RNA fragments by phosphorimaging. While a crosslinking band at the expected ~100
kDa could be detected, the intensity was very low and not high enough above background to
pursue with a full cDNA library preparation (Figure 3.10 B).
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Figure 3.10 Localization and RNA-crosslinking of hNEF-sp. (A) Immunofluorescence of
doxycycline-induced hNEF-sp, and non-induced HEK293 cells as control. hNEF-sp shows
nucleolar localization. (B) Phosphor image and Western blot analysis of crosslinked,
radiolabeled, and immunoprecipitated hNEF-sp in a small-scale PAR-CLIP.
We reasoned that the observed low crosslinking efficiency may be due to either low
abundance of the in vivo targets of NEF-sp in HEK293 cells, or because RNA interactions of
hNEF-sp nuclease with its targets were highly transient or had low affinity and did not allow
sufficient crosslinking intensity.

3.3.4

Generation and characterization of a monoclonal antibody against mNEF-sp

To study the role of mammalian NEF-sp proteins in gonad development one needs a suitable in
vivo system in which knockouts can be generated and RNA targets easily isolated. Knockout
mouse embryonic stem cells for mNEF-sp exist, generated by genome-wide gene knockout
consortiums, but we needed high affinity biochemical reagents to isolate and characterize mNEFsp in vivo. Thus, we decided to raise a monoclonal antibody against the mNEF-sp protein isoform
2 (RefSeq transcript ID NM_028129.2), which could immunoprecipitate native RNA-protein
complexes of mNEF-sp. Monoclonal antibodies allow, in contrast to polyclonal antibodies,
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selective, and epitope-specific immunoprecipitation of protein-RNA complexes in vivo from cells
and tissues. Immunoprecipitation-grade antibodies are difficult to make and often researchers
resort to high affinity tags of proteins to isolate their protein of interest. The advantage of an
immunoprecipitation-grade monoclonal antibody is that it enables isolation of RBP complexes in
vivo without relying on laborious knock-in affinity tags, which may affect target and protein
complex affinity. This project was done in collaboration with the monoclonal antibody core
facility at Memorial Sloan Kettering Research Center, who isolated antibody-secreting B cells
from immunized animals and fused them with a myeloma cell line, a type of B-cell tumor. These
hybrid cells or hybridomas can be maintained in vitro and will continue to secrete antibodies with
a defined specificity. An overview of the general procedure for monoclonal antibody generation
is shown in Figure 3.11 (Greenfield, 2014).
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Figure 3.11 Outline of the stages in hybridoma production. (A) Animals are injected with an
antigen preparation. Once a good humoral response (titer) has appeared in the immunized animal
a screening procedure is developed and fusion started. The sera from test bleeds are used to
develop and validate the screening procedure. Several days before the fusion, animals are boosted
with a sample of the antigen. For the fusion, antibody-secreting cells are prepared from the
immunized animal, mixed with the myeloma cells, and fused. After the fusion, cells are diluted in
selective medium (hypoxanthine-aminopterin-thymidine medium (HAT), selection medium
usually used for selection of immortal, fused hybridomas) and plated in multiwell tissue culture
dishes. Hybridomas are ready to test beginning 1 week after the fusion. Cells from positive wells
are expanded and then single-cell-cloned. (B) Hybridoma cells grow at approximately the same
rate and tissue culture supernatants from all fusions are usually ready to screen within a few days
of one another. This makes screening the most labor-intensive part of hybridoma production.
Approximately one week after the fusion, colonies of hybrid cells are ready to screen. During the
screening supernatants of growing hybridomas are tested for the presence of the desired
antibodies. Successful fusions generally produce between 200-20,000 hybridoma colonies, on
average ~1000 colonies. Typically, the first wells are ready to screen on day 7-8 and most of the
wells need to be screened within 4-5 days. In our hybridoma generation we devised two primary
screens per week, which were followed by secondary validations each subsequent day. Positive
wells are expanded and frozen; selected colonies are chosen for further subcloning. Figure
adapted from (Greenfield).
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HisSUMO- and His-mNEF-sp protein purified from BL21(DE-3)RIL and baculoviral Sf9
cells was injected in four injections into Armenian hamsters to raise an immune response. Before
starting the hybridoma fusions, I tested humoral responses of each hamster against mNEF-sp by
standard and sandwich ELISA. In standard ELISA, response of all test bleeds was screened for
baculoviral purified His-NEF-sp protein, indicating the highest response titer for hamster 3
(Figure 3.12 A). As negative control baculoviral purified human FMRP protein was used [a gift
of M. Ascano (Ascano et al., 2012b)]. Since mNEF-sp protein could only be purified under
denaturing conditions, we reasoned that standard ELISA may predominantly over-represent
clones that recognized epitopes of the denatured protein. However, for IP-grade hybridoma
antibodies, we needed to isolate clones, which also recognized the folded, native protein in an
immunoprecipitation-like assay. Thus, as second screen we decided to use sandwich ELISAs to
screen the test bleeds and select clones, which recognized FLAG-bound, HEK293 doxycyclineinduced, native mNEF-sp protein. This assay also had the advantage that mNEF-sp had a
different affinity tag than the injected protein, thus clones recognizing the His tag were excluded.
By sandwich ELISAs hamster 2 test bleeds showed the highest response for mNEF-sp, and we
decided to use hamster 2 for clonal fusion (Figure 3.12 B).
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Figure 3.12 Results from different screens for mNEF-sp immunized hamsters. (A) Standard
ELISA using Sf9 purified recombinant mNEF-sp and FMRP antigen as negative control. Bleeds
were tested in serial dilution, shown here 1:10,000 dilution. Tested in ELISA with mNEF-sp: prebleed (orange), test bleed 1 (TB1, red), test bleed 2 (TB2, blue), test bleed 3 (TB3, green).
Control with FMRP: pre-bleed (brown), TB1 (yellow), TB2 (light green), TB3 (black). (B)
Sandwich ELISA: coated with rabbit monoclonal anti-FLAG, incubated with doxycycline
induced mNEF-sp HEK293 cell lysate and incubated with 1:50 dilution test bleeds: TB3 (dark
blue) and pre-bleed (light blue). (C) Western blot analysis (anti-HA) on immunoprecipitated
FLAG/HA-mNEF-sp inducibly expressed in HEK293 cells. Shown are total lysate control (-) and
(+) doxycycline induction in lane 1 and 2. Lane 3-8 show immunoprecipitations of FLAG/HAmNEF-sp protein from doxycycline induced mNEF-sp HEK293 cells using test bleed TB3 and
pre-bleed in 1:50 dilution. mNEF-sp isoform NM_028129.2 runs at ~50 kDa.
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Test bleeds of all hamsters were able to immunoprecipitate FLAG/HA-mNEF-sp from
HEK293 cells (Figure 3.12 C, shown here are hamsters 2-4).
For our screening strategy of hybridoma clones we developed a triage-screen (Figure
3.13). First, supernatants of all clones were tested in parallel in standard. Second, positive clones
were selected for further validation for their immunoprecipitation quality by sandwich ELISAs
and immunoprecipitation and supernatants were used to immunoprecipitate doxycycline-induced
FLAG/HA-mNEF-sp protein from HEK293 cells. Immunoprecipitated FLAG/HA-mNEF-sp
protein was detected by Western blot analysis against the HA peptide epitope. The hybridoma
fusion cultures were tested from three separate pulls for their performance in the triage screen.
Only the clones that tested positive by standard ELISA were selected for sandwich ELISA and
immunoprecipitation.
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Figure 3.13 Hybridoma screening strategy. Bacterial and baculoviral purified mNEF-sp
antigen was injected into four hamsters. In the pre-screening the hamster with highest titer
response was selected. After a final boost with Sf9 purified mNEF-sp protein B cells were fused
with myeloma cells to create stable hybridoma colonies. In screen 1 hybridoma cultures were
tested by standard ELISA with denatured Sf9 purified mNEF-sp antigen. All positive hits were
tested in screen 2 by sandwich ELISA of FLAG/HA-mNEF-sp protein and in screen 3 by
immunoprecipitation with hybridoma supernatants conjugated to agarose-Protein A/G beads.
After three repeats of the triage screen positive hybridoma cultures were frozen in liquid nitrogen
and two hybridoma cultures further subcloned to isolate single clones. The subcloned colonies
went through the same triage screen and were also validated by standard Western blot analysis.
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Of the 2,376 hybridoma cultures (approximately 6,000 hybridomas), 161 tested positive
in standard ELISA, 74 of those were only positive in standard ELISA and showed no signal in
sandwich ELISA or immunoprecipitation, 23 tested positive in all three assays, 61 in standard
ELISA and immunoprecipitation, and 3 in standard and sandwich ELISA but were negative in
immunoprecipitations. Based on these results, we froze 27 hybridoma cultures and selected 2 for
further subcloning (Table 3.1, Figure 3.14).
Table 3.2: Summary of screened hybridoma cultures.
Screen
Cultures screened
Hybridomas
Standard ELISA (+)
Standard ELISA (+), sandwich ELISA (+), IP (+)
Standard ELISA (+), sandwich ELISA (-), IP (-)
Standard ELISA (+), sandwich ELISA (+), IP (-)
Standard ELISA (+), sandwich ELISA (-), IP (+)
Frozen cultures/ pools
Subcloned

Total tested
2,376
~6,000 (~2.5 per well)
161
23
74
3
61
27
2

03D01 and 23F05 were selected for further subcloning, as these showed the highest
immunoprecipitation quality, assessed by semi-quantitative Western blot analysis (Figure 3.14).
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Figure 3.14 Selected results from hybridoma screening. (A) Immunoprecipitation screening
results for a selection of hybridoma cultures from screen 3. Hybridoma supernatants are incubated
with FLAG/HA mNEF-sp lysates in 1:10 dilution and conjugated to Protein A/G agarose beads.
Shown are Western blots probing against HA peptide, to assess loading blots are reprobed for
Protein A/G bound Armenian hamster IgG. The stars indicate the two clones (23F05 and 03D01),
which were selected for subcloning. (+/-, +/-, +/-) indicates whether the clone tested previously
positive in (1) standard ELISA, (2) sandwich ELISA, and (3) immunoprecipitation assay. The
plus behind the brackets indicates how strong the overall response was. (B) (i) Semiquantification of Western blot signal from (A) for immunoprecipitated mNEF-sp protein
normalized over anti-Armenian hamster IgG signal (light blue), (ii) further normalization of the
signal in (i) over the final test bleed response. Selected colonies for subcloning are marked with a
star. (C) Same as (A) for a selection of subclones. (D) Validation of subclones recognizing
FLAG/HA-mNEF-sp in Western blot analysis (hybridoma supernatants are used in dilution 1:10).
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3.3.5

Generation and characterization of a polyclonal antibody against dNEF-sp

We decided to raise a polyclonal antibody against the Drosophila melanogaster dNEF-sp protein.
This allowed quantification of the protein in vivo, but was more time efficient and since I had
generated an in vivo FLAG/HA-dNEF-sp transgenic fly (see section 3.3.7) we did not rely on a
dNEF-sp-specific immunoprecipitation-grade antibody. Recombinant dNEF-sp protein, purified
from Sf9 cells, was sent for injection into two rabbits (Covance). Anti-sera responses against
dNEF-sp were tested in HEK293 cells expressing doxycycline inducible FLAG/HA-dNEF-sp
(Figure 3.15). Sera were highly potent and could be used in 1:20,000 dilution to specifically
detect the antigen in 40 µg lysates (shown here are dilutions 1:5,000). To minimize background
detection of other insect proteins, the polyclonal sera were further affinity-purified with
recombinant dNEF-sp protein and the resulting eluate used in 1:1000 dilution for Western blot
analysis of Drosophila lysates.

Figure 3.15 Characterization of a polyclonal antibody against dNEF-sp. Recombinant
baculoviral Sf9 purified His-dNEF-sp protein was injected into two rabbits to generate a humoral
response. Specificity of bleeds was validated with doxycycline-inducible dNEF-sp HEK293 cell
lines. (A) Response of pre-bleed, test bleed 1 (TB1), and test bleed 2 (TB2) for rabbit 2078 tested
on doxycycline-induced FLAG/HA-dNEF-sp HEK293 total cell lysates and FLAGimmunoprecipitated protein. (B) Same as in (A) for rabbit 2079.
3.3.6

Immunoprecipitation of the mNEF-sp homolog in testis

I tested the supernatants of the subcloned for immunoprecipitation of mNEF-sp protein from
mouse liver and testis lysates. Unlike the known RefSeq isoform predictions, I detected a specific
protein band at ~80-90 kDa in testis lysates. This putative testis-specific isoform was in the
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expected size range of NEF-sp proteins from other organisms. mNEF-sp (official gene name
2610020H08Rik) has currently two annotated isoforms in the RefSeq NCBI annotation. Isoform
2 is predicted to be 479 amino acids long and did not have a predicted RRM domain by Pfam and
SMART structural domain predictions, while isoform 1, 445 amino acids long, possessed one
RRM domain instead of two (Figure 3.16 A).

Figure 3.16 Immunoprecipitation of mNEF-sp from testis and liver lysates. (A) mNEF-sp
isoforms defined by Ensembl and RefSeq. RNase T domains (red), and RRM domains (green) are
highlighted. (B) Hybridoma supernatant clone 23F5-E7 was used for immunoprecipitation (IP) of
mNEF-sp from liver and testis. Immunoprecipitated mNEF-sp was probed detected by Western
blot (WB) with clone 23F5-A7. (C) Genome Browser representation of RNA-seq read alignments
from liver and testis at the mNEF-sp locus (2610020H08Rik).
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NEF-sp proteins across mammals and vertebrates are usually ~700 amino acids long and
have a molecular weight of ~90 kDa (including rat). Hence, the deviance in size of the mouse
homolog predicted by RefSeq seemed surprising, but we decided at the start of the project to
work with isoform 1 as this appeared to be the closest related homolog (Figure 3.16 A). Given the
unexpected immunoprecipitation results, we re-examined other genome annotations and detected
recent updates of the Ensembl genome consortium, which included a new, longer isoform of
mNEF-sp that was consistent with our biochemical results. This additional isoform (isoform 3)
was 759 amino acids long, contained two predicted RRM domains C-terminal to the RNase T
domain and had a predicted molecular weight of 86.5 kDa (Figure 3.16 B). By domain structure,
weight and protein length, it was closest to other mammalian NEF-sp proteins. This isoform
remains currently not listed in the RefSeq genome annotation, but it is supported by Uniprot data.
To confirm whether the observed protein band could correspond to the longest predicted isoform,
I analyzed published adult mRNA-seq data from mouse testis and liver and assessed read
abundances for the different isoforms (You et al., 2015) (Figure 3.16 C). Isoform 3 was highly
abundant in adult testis but not expressed in the liver. Together, given the RNA-seq and
immunoprecipitation data, we concluded that isoform 3 is the dominant isoform of mNEF-sp in
testis and based on our results we revised our homology annotation for NEF-sp proteins in Figure
3.8 to include the longest isoform of mNEF-sp as the representative isoform.
This section concludes the studies on the mammalian homologs of NEF-sp. Much of this
work was done in parallel to the work on Drosophila melanogaster dNEF-sp. Because of the
complexity and time needed for each organism, I decided to shift my focus entirely on the full
characterization of the physiological function and targets of dNEF-sp for the remaining part of the
project.
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3.3.7

Characterization of Drosophila dNEF-sp genetic mutants

The dNEF-sp (CG8368) gene is located on the 3rd chromosome in Drosophila melanogaster
(Figure 3.17 A). One genetic mutant, C04255, contained a PiggyBac (PB) transposon insertion
into the 5’ UTR of isoform CG8368-a and the first intron of isoform CG8368-b and was
previously generated by the Harvard Exelixis collection (location of the PB insertion is shown in
Figure 3.17 A). I confirmed the correct location of the PB by PCR using a transposon-specific
primer in the forward and a gene-specific primer in the reverse direction (Figure 3.17 B).
Homozygous mutants were lethal during second instar larval development. We confirmed that
lethality was due to mutations in the cytogenetic region 65B3-65C1, (~135 kb) by crossing
C04255 to the deficiency lines Df(3L)BSC410 (deletion of 64E7;65B3, 3L:5770673;3L:6490185)
and Df(3L)BSC411 (deletion of 65A2;65C1, 3L:5975960;3L:6625626-6625629). Crosses of
C04255 to Df(3L)BSC411, which had a 650 kb segment deleted encompassing the dNEF-sp gene
locus, were lethal, while complementation of C04255 to the Df(3L)BSC410 deficiency line,
containing a deletion overlapping with Df(3L)BSC411 except for a 135 kb region, did not affect
viability. Next, we screened a number of previously generated ethyl methanesulfonate chemical
mutagenesis lines deposited in the Drosophila Bloomington Stock center (DBSC), which had
mutations in the 65C-65D cytogenetic band, but had previously not been further genetically
mapped (Anderson et al., 1995). Complementation of C04255 with one of the mutants, M100,
was lethal, suggesting that this mutant also caused loss-of-function of dNEF-sp. Similar to
C04255, M100 homozygous mutants were lethal at the second instar larval stage. Crosses to the
genetic deficiency lines gave the same results as above. Sequencing of M100 within the coding
region of dNEF-sp identified two missense mutations in the ORF; one of the mutations, a
glutamate to lysine substitution (E497K) located four amino residues away from the conserved
catalytic histidine in the RNase T domain presumably causes the loss-of-function of dNEF-sp
(locations of nucleotide substitutions shown in Figure 3.17 A).
168

Figure 3.17 Characterization of dNEF-sp mutants. (A) Genomic map of the dNEF-sp gene,
mRNA isoforms, and protein. The RNase T domain is highlighted in green, catalytic DEDDh
residues are shown in orange, the location of the nucleotide substitutions in mutant M100 and the
resulting amino acid changes are shown in red. The PiggyBac insertion is shown for dNEF-sp
mutant C04255 (blue). (B) Verification of PiggyBac transposon insertion in mutant C04255 into
the predicted site at the dNEF-sp locus. (C) Expression of dNEF-sp mRNA in mutants M100,
C04255, and wild type 2nd instar larvae. (D) dNEF-sp protein levels in mutants and wild type 2nd
instar larvae. Loading controls are tubulin and the nucleolar snoRNP component Fibrillarin (Fib).
Genotypes are highlighted in blue (C04255, dNEF-spPB) and red (M100, dNEF-spE497K). dNEF-sp
Genotypes: heterozygotes: dNEF-spM100/TM6B and dNEF-spC04255/TM6B; homozygotes: dNEFspM100/dNEF-spM100 and dNEF-spC04255/dNEF-spC04255, wild type: sequencing strain.
Finally, to generate transgenic flies, I cloned the full-length ORF of dNEF-sp into the
pUAS-attB plasmid and, in addition, generated four genomic pattB rescue constructs. Two of
these genomic rescue constructs contained the genomic dNEF-sp region including either a 3 or
1.7 kb promoter region and the genomic region 1 kb region downstream of the 3’UTR. In
addition, I created two genomic, N-terminal tagged dNEF-sp rescue constructs by inserting GFP
or FLAG/HA-tags into the 3 kb genomic construct at the start of the dNEF-sp ORF, the N169

terminus of dNEF-sp protein. The pUAS-attB and pattB constructs were send for injection and
were specifically inserted at 25C7 cytogenetic site on the second chromosome using the phiC31
integrase transgenesis system (Bischof et al., 2007). All genomic dNEF-sp transgenic lines
rescued lethality of dNEF-sp mutants and produced adult flies in both mutants. Expression of the
dNEF-sp ORF alone (pUAS-attB-dNEF-sp) under the actinGal4 driver also rescued lethality.
Poly(A) mRNA-seq of homozygous mutants and wild type 2nd instar larvae showed that in
C04255 mutants mRNA levels were close to depleted, while in M100 mutants mRNA levels were
similar to wild type (Figure 3.17 C). Western blot analysis of protein levels in homo- and
heterozygous mutants and wild type controls showed that heterozygous mutants had protein
levels similar to wild type larvae. In contrast, homozygous C04255 mutant protein levels were
undetectable by Western blot analysis, while M100 mutants had consistently higher protein
levels, suggesting some posttranscriptional compensation mechanism of M100 homozygous
mutants to produce more dNEF-sp protein, which nevertheless is not functional (Figure 3.17 D).

3.3.8

dNEF-sp is a nucleolar/nuclear protein and translocates to the cytoplasm during
terminal differentiation in testis development

In contrast to the mRNA abundances, dNEF-sp protein was predominantly expressed in both
male and female gonads in adult flies, but also expressed highly during early embryogenesis. To
investigate the localization of dNEF-sp, I studied the in vivo localization of GFP-dNEF-sp in the
transgenic GFP-dNEF-sp fly rescue, expressing GFP-dNEF-sp under its endogenous promoter. In
Drosophila testis GFP-dNEF-sp was expressed in GSCs and mitotic cells, as well as during
terminal spermatocyte differentiation (Figure 3.18 B). In mitotic gonialblasts and GSCs dNEF-sp
was localized to the nucleolus. In contrast, dNEF-sp abundance was highest during terminal
spermatocyte differentiation, where it localized in the cytoplasm and was concentrated
predominantly to the individualization complexes, localizing in a distinct pattern in opposite
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polarity to the actin cones (Figure 3.18 B). This pattern was unique to dNEF-sp and unlike other
rRNA biogenesis and ribosomal proteins, and may suggest an active role for dNEF-sp during
terminal differentiation. In ovaries dNEF-sp was highly expressed throughout the tissue in the
germarium in GSCs and cystoblasts, and highest expressed in the nuclei of oocytes, nurse cells,
and follicle cells (Figure 3.18 C). dNEF-sp expression was not restricted to gonads and was
ubiquitously expressed at low level in the nucleolus and nucleus of somatic tissues (Figure 3.18
D).
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Figure 3.18 dNEF-sp is predominantly expressed in the gonads. (A) Expression of dNEF-sp
and the nucleolar marker Fibrillarin (Fib) assessed by Western blot analysis on total 40 µg tissue
lysates. (B-D) In vivo localization of GFP-dNEF-sp. Shown are GFP-dNEF-sp (green), phalloidin
(PL, magenta or red), 1B1 in testes (red) and Vasa in ovaries (red), and DNA (Hoechst, blue).
Localization of GFP-dNEF-sp is also shown in gray scale images. (B) Localization of dNEF-sp in
testis. Shown are (i,i’) whole testis, (j,j’) hub region with GSCs, and (k,k’) mitotically dividing
gonialblasts, (l,l’,m,m’) the individualization complex during terminal differentiation with
punctate localization of dNEF-sp in the leading edge of the actin cones. (C) In vivo localization of
GFP-dNEF-sp in ovaries. (i,i’) dNEF-sp is localized to the nuclei of the oocyte, nurse cells and
somatic follicle cells. (j,j’) Localization of dNEF-sp in nuclei of GSCs and gonialblasts in the
germarium (red arrow in j’). (D) GFP-dNEF-sp is predominantly expressed in nucleoli in somatic
tissues. Expression for (i,i’) salivary glands, (j,j’) foregut, (k,k’) eye lobe and imaginal discs.
Genotypes: GFP-dNEF-sp/Cyo; Sb/TM6B.
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3.3.9

Homozygous mutants show gonad developmental defects

dNEF-sp homozygous mutant larvae were developmentally delayed by 24-48 days, but organs
looked generally morphologically normal in somatic tissues compared to wild type larval tissues
at the same developmental stage. We reasoned that defects in dNEF-sp mutants would most
strongly accumulate in the tissues of highest expression, i.e. during testis development, and
therefore decided to investigate early phenotypes in homozygous mutant testes during 2nd instar
larval development, their latest developmental stage before death. By confocal microscopy
mutant gonads were smaller in size and arrested in the first or second mitotic divisions (as
assessed by the level branching of connected fusomes in mitotic cells) and they also had fewer
cells compared to wild type 2nd instar male gonads (Figure 3.19 A). These results demonstrated
that dNEF-sp was required for testis development and that dNEF-sp mutants were arrested in
early mitosis.

Figure 3.19 dNEF-sp mutant gonads are developmentally arrested. (A) Second instar larval
male gonads. (i,i’) dNEF-spC04255/dNEF-spC04255 homozygous mutant (j,j’) wild type. DNA is
shown with Hoechst dye in blue, the 1B1 fusome marker in green. 1B1 staining is separately
shown in grayscale images. (B) Schematic representation of the mitotic developmental program
in Drosophila testis development. GSCs asymmetrically divide to produce one stem cell daughter
cell and one gonialblast cell. The gonialblast migrates from the hub and undergoes 4 mitotic
divisions. Stages of mutant and wild type 2nd instar larval gonad development are highlighted in
red. Genotypes: dNEF-spC04255/dNEF-spC04255, wild type: sequencing strain.
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3.3.10 Developmental arrest in testes and ovaries of actinGal4 rescued dNEF-sp adult
mutants
To investigate gonad developmental defects in adult flies, I rescued the lethality in somatic cells
by transgenic expression of UAS-dNEF-sp under the actinGal4 driver in both mutants. The UAS
promoter works inefficiently in the germline (Brand and Perrimon, 1993), thus actinGal4 UASdNEF-sp rescued flies effectively lack dNEF-sp expression in germ cells. I examined mutant
adult testes and ovaries after 3, 7, and 14 days (Figure 3.20).

Homozygous adult mutant testes

showed phenotypic variation. Severely affected testes were arrested in mitosis, and instead of
being confined to the hub, mitotic cells were spread throughout the entire organ (Figure 3.20 A).
Phosphorylation of histone H3 levels showed that mutant testes did not enter meiosis (Figure 3.20
B). Furthermore, H2Av phosphorylation levels, a marker of DNA double-stranded breaks,
indicated that also genomic stability was affected in mutant testes (Figure 3.20 C). In Drosophila
males do not undergo meiotic recombination, thus double-stranded DNA breaks are entirely due
to genomic instability. Over time, fewer cysts went through mitosis and testes became
morphologically thinner (Figure 3.20 D-E).
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Figure 3.20 dNEF-sp mutant adult testes arrest in mitosis. (A-E) dNEF-sp mutants are lethal,
but transgenic expression of dNEF-sp in the soma rescues this lethality and permits the recovery
of adult flies that lack dNEF-sp in germ cells. These flies display defects in growth and the cellcycle progression gonads. Shown are Phalloidin (green), Hoechst (blue), individual marker (red).
Individual developmental markers are shown separately in grayscale images. Genotypes of
rescued mutants: actin-Gal4/UAS-dNEF-sp, dNEF-spC02455/dNEF-spM100. (A) dNEF-sp mutant
testes are thinner and show continuous mitotic divisions with the fusome branching throughout
the entire testicular tube (1B1). (B) Serine 10 phosphorylated histone H3 (PH3) marks meiotic
divisions. Mutant testes show fewer meiotic nuclei. Wild type testes enter meiosis as detected by
the 32 PH3-stained meiotic nuclei. (C) Histone H2Av phosphorylation (H2Av) is a marker for
double-stranded DNA breaks, genomic instability and apoptosis (Fernandez-Capetillo et al.,
2004; Kotova et al., 2011). H2Av phosphorylation levels are increased in mutant testis compared
to wild type, indicating an increase in genomic instability in dNEF-sp mutants. (D-E) 1B1 and
Fibrillarin (Fib) stainings after 7 and 14 days in wild type, genomic rescue of dNEF-sp mutants
(full rescue) and actinGal4 UAS-dNEF-sp rescued mutants (germ cell loss). dNEF-sp mutants
show progression in mitosis beyond the hub throughout the entire testis (1B1, green) and the
nucleolar marker Fib (red) shows continuous staining, also marking mitotic cells. Genotypes:
mutant: actinGal4/UAS-dNEF-sp, dNEF-spM100/dNEF-spC04255; genomic rescue: 1.5kb-dNEF-sp,
dNEF-spM100; wild type: sequencing strain.
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Homozygous mutant females were sterile and had rudimentarily developed ovaries.
Morphologically, the oocyte was placed correctly and expression of the germ cell marker Vasa in
mutants was the same as in control wild type ovaries. H2Av phosphorylation, a marker of dsDNA
breaks, did not show any difference to wild type, indicating that genomic integrity of mutant
ovaries was not compromised as observed for mutant testes. However, mutant oocytes did not
fully develop, leading to homozygous females having >10 fold smaller, rudimentarily developed
ovaries. Ovaries displayed egg-chamber degeneration and arrested at stage 4-6 of oocyte
development. Moreover, complete GSCs loss occurred over time, indicating that dNEF-sp was
essential for germ cell development (Figure 3.21 A-B). We recognized that the presented ovarian
phenotypes resembled previously described ovarian defects for loss-of-function of the ribosomal
protein RpS2 (Cramton and Laski, 1994) (Figure 3.21 C), suggesting that dNEF-sp might also be
involved in a ribosome-related process.
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Figure 3.21 dNEF-sp mutant adult ovaries are growth arrested. (A, B) Mutant ovaries are
smaller than wild type and arrest at developmental stage 4-6. Organization of oocytes and nurse
cells are positioned normally, expression of the germ cell marker Vasa (red) is normal, no
physical deformities are observed, but oocyte and nurse cell growth is impaired and cells become
apoptotic at stage 4-6. (A) Mutant and wild type ovaries after 3 days. Mutant ovaries are 10-100fold smaller and degenerate, entering apoptosis at stage 4-6. Vasa (red) expression and position of
oocyte, as well as the number of nurse cells are normal compared to wild type. (B) Loss of egg
chambers becomes more severe over time; ovarioles contain only the germarium and stage 1 egg
chambers. (C) Ovarian phenotype for the string-of-pearls (RpS2) gene characterized by Cramton
et al. (Cramton and Laski, 1994) shows similarity to the dNEF-sp loss-of-function phenotype.
Genotypes: mutant: actinGal4/UAS-dNEF-sp, dNEF-spM100/dNEF-spC04255; wild type: sequencing
strain.
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In summary, the mutant phenotypes suggested a pivotal role of dNEF-sp in early gonad
development, but they did not address why high dNEF-sp protein levels were observed in later
stages post meiosis during terminal differentiation of spermatocytes. Since neither the biological
role nor the molecular mechanisms were known for dNEF-sp, I focused my attention for the
remaining study on the early gonadal and somatic roles of dNEF-sp in order to elucidate the
essential function of dNEF-sp in general RNA metabolism.

3.3.11 The catalytic RNase T domain of dNEF-sp is required for viability in vivo
The predicted DEDDh RNase T exonuclease domain in the NEF-sp protein family is highly
conserved across organisms and requires a divalent metal cation for activity (Zuo and Deutscher,
2001) (Figure 3.22 A). To test whether the catalytic activity of NEF-sp was essential for viability,
I genetically complemented C04255 and M100 mutants with UAS-dNEF-sp transgenic flies, for
which different catalytic residues were mutated to alanine in the RNase T domain. All catalytic
residues were required for survival and none of the tested constructs, which contained a single or
double alanine mutation, could rescue lethality (Figure 3.22 B). Substitution of the catalytic
histidine residue (H) to an arginine (R), an amino acid change present in the mouse NEF-sp
homolog, rescued homozygous larvae to 3rd instar, suggesting that substitution to arginine gave
still partially active dNEF-sp protein. Therefore, we concluded that mNEF-sp is most likely a
functional RNA exonuclease, despite a substitution of the catalytic histidine to arginine. The
results demonstrated that the RNA exonuclease activity of dNEF-sp, and not a secondary protein
association, was essential for survival.
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Figure 3.22 Multiple sequence alignment of conserved NEF-sp active site residues. (A)
Scheme of the structural domain organization of NEF-sp proteins across yeast, D. melanogaster,
Xen. laevis, human and mouse and Clustal Omega alignment of the conserved RNase T domain.
Conserved catalytic acidic residues (DEDD) are highlighted in orange, the general base histidine
residue is highlighted in yellow. (B) Viability test rescuing lethality of mutants with actin-Gal4
UAS-dNEF-sp constructs with substituted residues in the catalytic side.
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3.3.12 dNEF-sp displays single-stranded RNase activity in vitro
To verify the catalytic activity of dNEF-sp in vitro, I purified the recombinant full-length dNEFsp protein and the catalytic dead mutant (dNEF-spDADAH, section 3.3.2) and carried out DNA and
RNA oligomer cleavage assays. Cleavage assays were carried out for both wild type and mutant
full-length proteins with 18mer sequences. dNEF-sp showed selective 3’-5’ exonucleolytic
degradation of RNA, while DNA was not degraded (Figure 3.23 A). RNA cleavage of dNEF-sp
displayed preference for pyrimidine bases (C and U) over purine bases (A) (Figure 3.23 D-F). As
previously characterized for other DEDDh RNase T nucleases, RNA cleavage activity of dNEFsp was dependent on the presence of divalent cations (Mg2+) in the active site and the reaction
was inhibited in the presence of EDTA (Figure 3.23). Cleavage assays with circularized RNAs
demonstrated that dNEF-sp could not endonucleolytically process circularized ssRNA (Figure
3.24 A-B).
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Figure 3.23 RNase in vitro assays show specificity of dNEF-sp for ssRNA. In vitro RNA
exonuclease assays of recombinant wild type and DADAH mutant dNEF-sp protein. RNase
activity of the recombinant nucleases was tested for a selection of 5’-32P-labeled RNA and DNA
18-mer oligo(deoxy)ribonucleotides at 20-25 nM enzyme concentration in a time series (0-30/60
min). Control = no enzyme added, control EDTA = dNEF-sp wt protein in presence of EDTA (50
mM). (A) Activity of dNEF-sp wild type and mutant protein for poly-adenosine RNA and DNA
substrate at 20 nM enzyme concentration. (B) Same as in (A) for poly-cytosine RNA and DNA
substrates. (C) Same as in (A) for poly-uridine and poly-thymidine. (D) Quantification of the
degradation of substrates at 25 nM protein concentration measured in (E) and (F). Intensity
measurements are normalized to the intensity of the 1 min time point for each experimental
condition. (E) Comparison of nucleolytic activity of dNEF-sp wild type and mutant protein at 25
nM concentration for poly-cytosines versus poly-adenosine-cytosine oligomer. (F)
Exonucleolytic activity of dNEF-sp wild type and mutant protein for poly-uridine and polyadenosine RNA and DNA oligomers. DNA is not a processed substrate, dNEF-sp DADAH
mutant is inactive, addition of EDTA inhibits enzymatic activity of wild type dNEF-sp protein
(control EDTA).
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Figure 3.24 dNEF-sp has no endonucleolytic activity. (A-B) In vitro RNA nuclease assays of
recombinant wild type and DADAH mutant dNEF-sp protein and commercial RNA exonuclease
T (ExoT, NEB). RNase activity of the recombinant nucleases was tested for a selection of 5’-32Plabeled RNA and DNA 18-mer single-stranded and circularized oligo(deoxy)ribonucleotides at
20-25 nM enzyme concentration in a time series of 0-30 min. (A) (i) Activity of dNEF-sp wild
type and mutant protein for circularized poly-adenosine RNA and at 25 nM enzyme
concentration. (ii) Same as in (i) for circularized poly-cytosine RNA substrates. (iii) Same as in
(i) for circularized poly-uridine oligomers. (B) High-resolution sequencing gel for the comparison
of nucleolytic activity of dNEF-sp wild type and mutant protein, as well as the RNA
endonuclease C3PO as control (gift of M. Ascano) at 20 nM concentration for poly(C) ssRNA,
ssDNA and circularized RNA 18mers. Final concentration of substrate is 100 nM per reaction.
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3.3.13 The 3’ ETS of the 47S rRNA precursor accumulates in dNEF-sp mutants
To identify processing defects of dNEF-sp targets in the homozygous mutants in vivo we
employed next generation sequencing of total RNA isolated from wild type and dNEF-sp genetic
mutant larvae. The localization of dNEF-sp to the nucleolus, as well as the mutant phenotypes
observed in adult ovaries, suggested a role in rRNA biogenesis. Previous literature on the family
member RNH70 (Rex1p) indicated that the S. cerevisiae nuclease was involved in the processing
of a variety of noncoding RNA substrates, including tRNAs, snRNAs, and snoRNAs (Copela et
al., 2008; Ozanick et al., 2009; Piper and Stråby, 1989; Piper et al., 1983; 1987; van Hoof et al.,
2000). Thus we considered that, if dNEF-sp was a functional homolog of Rex1p, dNEF-sp could
process small nuclear noncoding RNAs. In addition, the selective upregulation of dNEF-sp in
gonads indicated a gonad-specific specific role, putatively in germline-specific noncoding RNA
metabolism such as the piRNA pathway (Siomi et al., 2011).
To analyze differential expression of long and short coding and non-coding RNAs, and
also to investigate highly structured transcripts, we combined the poly(A) mRNA-seq and total
RNA sequencing (Illumina TruSeq) protocols with an established small RNA cloning protocol
(Hafner et al., 2012), for which we included an alkaline hydrolysis step to fragment total RNA
prior to library preparation (“Hydro-Seq”) (developed by D. Briskin, M. Brown, T. Farazi, T.
Tuschl, Methods 3.3). The latter RNA-sequencing method allowed us to investigate nuclear
noncoding RNAs not covered by conventional RNA-seq protocols. tRNAs, snRNAs and
snoRNAs have a size range between ~100-150 nt length, but current RNA sequencing
methodologies, such as the Illumina TruSeq protocol, are optimized for size ranges between 200300 nts and do not appropriately cover RNAs of smaller sizes. Therefore, to capture small
noncoding RNAs between 20-100 nts, we needed read coverage of shorter RNAs. Using alkaline
hydrolysis, we include a fragmentation step of total RNA, selecting RNA of 20-30 nt-long
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segments, before proceeding with adapter ligation and library preparation of small RNAs as
previously described (Hafner et al., 2012).
I analyzed gene expression of abundant noncoding RNAs by annotating all sequence
reads in a hierarchical fashion, starting from the most abundant RNAs (rRNAs) to the less
abundant

ones

(in

descending

order:

1=

rRNA,

2=tRNA,

3=snRNA/snoRNA,

4=transposon/repeats, 5=miscRNA (miRNAs, other ncRNAs). Detecting differential expression
of rRNA genes can be challenging, as rRNA sequences are highly heterogeneous and lie within
repetitive regions of the genome (Kominami et al., 1981; Sylvester et al., 1986; Tautz et al.,
1988). As a result current genome annotation databases, such as Flybase, RefSeq or Ensembl, are
poorly curated and incomplete in their rRNA annotations. In addition, expression changes within
regions of the large rRNA precursor transcript can be difficult to detect in the presence of the
highly abundant, mature rRNAs. Failing initially to detect differential expression changes in
rRNAs, we decided to create our own rRNA alignment index by selecting annotated Drosophila
melanogaster rRNA sequences on NCBI and Flybase and blast them against the NCBI nucleotide
database, thereby adding sequence-related insect rRNA sequences from the NCBI nucleotide
database (Altschul et al., 1990). Hierarchical alignment against the most abundant RNAs showed
specific upregulation of dNEF-sp mutants for rRNAs, one snoRNA cluster, and few transposons
(Figure 3.25 A).
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Figure 3.25 RNA-sequencing reveals accumulation of the ribosomal precursor 3’ETS in
dNEF-sp mutants. (A) Hydro-seq scatterplots for different abundant noncoding RNAs. (i) NCBI
and BLAST created rRNA sequences (ii) annotated tRNAs with +/- 20 nt extensions, (iii) Flybase
annotated snRNAs and snoRNAs, (iv) Flybase annotated transposons. Mutant C04255 (dark
orange), mutant M100 (bright orange), wild type control (black). (B-C) Log2 fold changes of read
coverage and log10 read coverage along the 47S rRNA precursor. Mutant C04255 (dark orange),
mutant M100 (bright orange), wild type control (grey), dNEF-sp genomic rescue (dark blue). (B)
(i) Hydro-seq fold changes and coverage. (ii) Total RNA-seq fold changes and coverage. (C) (i)
Total RNA-seq fold changes and coverage for adult actinGal4 UAS-dNEF-sp rescued mutant
testes. (ii) poly(A) RNA-seq fold changes and coverage for adult actinGal4 UAS-dNEF-sp
rescued mutant ovaries. (D) Total RNA-seq scatterplots for long abundant noncoding RNAs.
Mutant C04255 (dark orange), mutant M100 (bright orange), wild type control (black). (i) rRNA
reference, (ii) Flybase transposon annotation. Genotypes: heterozygotes: dNEF-spM100/TM6B and
dNEF-spC04255/TM6B; homozygotes: dNEF-spM100/dNEF-spM100 and dNEF-spC04255/dNEF-spC04255,
wild type: sequencing strain.
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Using the new reference index I could detect more than 10-fold upregulation of specific
rRNA regions within the 3’ETS of the 47S precursor [Figure 3.25 A(i)]. When visualizing the
read coverage along the full 47S rRNA precursor transcript, I detected, reproducibly across
datasets, a significant 200-1000 upregulation of the 3’ ETS in mutants (Figure 3.25 B).
Visualization of the fold changes along the complete precursor at each nucleotide position
revealed that fold change differences were highest closest to the mature 3’ end of 28S (200-1000
fold), and smallest at the 5’ end of the 47S precursor (4-fold). In wild type 2nd instar larvae the
intergenic region between the 28S rRNA 3’ end and 18S rRNA 5’ end was close to undetectable
with 0-5 reads on average along the entire region. In mutants the intergenic region was fully
covered with several hundred reads directly downstream of the 3’ end of 28S, which slowly
decreased towards the 5’ETS [Figure 3.25 B (i)]. The continuous decrease in 3’ETS coverage
downstream of the 28S mature rRNA end supported an exonucleolytic trimming process instead
of a precise cleavage event within the 3’ ETS intergenic region. We also noticed a smaller
increase (4-fold) in the ITS1 and 5’ETS regions, which we attributed to an accumulation of the
47S precursor. As expected, the processing defects were also observable by Illumina total RNA
sequencing, however read coverages were less contiguous, most likely due to the presence of
extensive secondary structures not resolved by the Illumina protocol, a higher number
mismatches against the reference sequence due to sequencing errors in longer reads and
nucleotide polymorphisms [Figure 3.25 B (ii)]. Despite a role of the yeast REX1 family member
in 5S rRNA exonucleolytic trimming (Piper et al., 1983), we did not detect any differences in
abundance or 3’ end length of 5S rRNAs for dNEF-sp mutants.
Gene expression of other abundant noncoding RNAs, such as tRNAs (extended by +/-20
nts), snoRNAs/snRNAs, transposon transcripts and annotated short noncoding RNAs (ncRNAs.
e.g. miRNAs, piRNAs) did not show any significant differences in the relative abundance, except
for one snoRNA cluster Me28S-G1083 and a few transposon groups (Copia, Cr1a, R1A1), which
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were upregulated in mutants. The Me28S-G1083a-d C/D box snoRNA family of four snoRNAs is
a conserved snoRNA family in humans (SNORD80) and S. cerevisae (snR60) (Yoshihama et al.,
2013). The Drosophila Me28S-G1083a-d (FBgn0082935) cluster is located in the Nop60b gene
and predicted to methylate 28S rRNA at position G1083 (Huang et al., 2005; Riccardo et al.,
2007; Yoshihama et al., 2013). While the Me28S-G1083a-d cluster was expressed at low levels in
wild type larvae (~100 library normalized read counts), it was reproducibly ~15-30 fold higher
expressed (~1,500-3,000 library normalized read counts) in dNEF-sp mutants. However, although
this was consistently observed for both mutants, we did not observe a similar upregulation after
RNAi knockdown of dNEF-sp (next section). We also detected upregulation of a number of
transposons, most notably Copia, which we also found to be upregulated in RNAi knockdowns of
other rRNA processing factors (next section). We conclude that these are upregulated in response
to cellular stress or rRNA processing defects.

3.3.14 In vivo RNAi knockdown of dNEF-sp and Ddx51 accumulate extended 3’ETS
precursors
To test whether 3’ ETS extension was specific for dNEF-sp or whether upregulation could also be
observed for other rRNA biogenesis factors, I selected a number of transgenic RNAi fly lines
with genomically integrated short hairpin RNAs (UAS-shRNAs) and expressed these
constitutively under the TubGal4 driver. Only transgenic lines for which knockdown was lethal at
the 1st or 2nd instar larval stage were selected. This served as an internal control that shRNA
knockdown was strong enough to cause a physiological effect on rRNA processing. The choice of
this in vivo system was important, as in a previous dsRNA-mediated knockdowns of dNEF-sp in
S2 cells (>10 fold depletion) I could not detect the accumulation of the 3’ETS in the rRNA
precursors after 3 days incubation and cell viability was not affected (Figure 3.26 A). Tin contrast
to the cell culture system, in vivo shRNA knockdown of dNEF-sp and other known rRNA
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biogenesis factors resulted in 1st or 2nd instar larval death, confirming their essential function in
vivo. Thus, screening for loss of viability ensured that the shRNA knockdown was strong enough
to accumulate pre-RNA processing defects.
To compare pre-rRNA processing defects resulting from loss-of-function dNEF-sp with
the loss of other rRNA biogenesis components, I selected rRNA biogenesis factors characterized
to be involved in the processing at different sites of the rRNA precursor (e.g. pre-18S, -5.8, -28S
maturation). The following pre-rRNA processing factors were chosen, which did not possess
RNA nuclease activity: CG5033 (homolog of mammalian BOP1 and yeast ERB1, required for
processing of the 32S precursor to give mature 28S rRNA (Strezoska et al., 2000), CG8414
[homolog of mammalian NOL9, involved in 5’-3’ 5.8S rRNA trimming (Heindl and Martinez,
2010)], CG6937 [homolog of mammalian NIFK and yeast NOP15, involved in ITS1 processing
(Tafforeau et al., 2013)], RpS3 (ribosomal protein, associates with early pre-90S ribosomal
complexes), nop5 [homolog of mammalian NOP58, the box C/D snoRNP methylase, required for
18S rRNA processing, accumulates the large 47S, and the 18S 34S and 30S precursors (Dragon et
al., 2002; Tafforeau et al., 2013; Wu et al., 1998)]. In addition, we chose a number of RNA
nucleases, such as the RNA exosome catalytic 3’-5’ exonucleolytic subunits, Dis3 and Rrp6,
known to trim 5.8S precursor 3’ ends (Briggs et al., 1998), and two members of the DEDDh RNA
nuclease family CG8414 (homolog of mammalian REXO4), and CG42666 (homolog of
mammalian REXO1 and closest homolog to yeast Rex1) (Figure 3.26 B-F). In vivo shRNA
knockdowns of the other two Rex family members in Drosophila melanogaster, CG12877
(homolog of yeast Rex1p) and CG10214 (mammalian REXO2 homolog, yeast Rex2p) were
viable (either because of insufficiently strong knockdowns or nonessentiality of the gene) and
excluded from the analysis. Furthermore, the homologs of the two characterized protein factors
involved in mammalian 28S rRNA 3’ETS end processing, DEAD box helicases DDX51
(Drosophila homolog Dbp73D) and DDX27 (Drosophila homolog Rs1) were also chosen
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(Kellner et al., 2015; Srivastava et al., 2010). For both genes shRNA knockdowns were lethal. As
negative controls the non-essential RNase T-class PAN2 3’-5’ exonuclease, involved in poly(A)
deadenylation, and the Drosophila non-essential white gene were chosen.
Accumulation of the 3’ ETS was specific for dNEF-sp and Dbp73D (Figure 3.26 F). We
did not detect processing defects for Rs1 under the tested conditions (Figure 3.26 G). None of the
other rRNA biogenesis factors showed extended 3’ETS, but they did display accumulation at
different sites or changes in overall abundance, which in some cases were easier to detect by
Northern Blot than RNA-seq (Figure 3.26 B-G, Figure 3.28). None of the tested RNA
exonucleases, including the RNA exosome components Dis3 and Rrp6 had an effect on 3’ETS
removal (3.26 H). Under the tested conditions we also could not detect any involvement of the
paralogous DEDDh RNA exonucleases (CG42666, CG12877) in 3’ETS trimming (Figure 3.26
H). For all tested factors, including dNEF-sp, we could not detect significant differential
expression of tRNAs, snRNAs, snoRNAs, or small noncoding RNAs (Figure 3.26 B).
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Figure 3.26 Total RNA-seq and Hydro-seq of RNAi knockdowns of rRNA processing
factors show a unique function of dNEF-sp in 3’ETS removal. (A) dsRNA-mediated
knockdown of dNEF-sp in S2 cells. (i) Western blot of dsRNA knockdown in S2 cells. dNEF-sp
is depleted >10 fold, the star marks an unspecific protein band which serves as internal loading
control. (ii) Hydro-seq log2 fold changes of the 47S precursor for dNEF-sp knockdown and
control. (B-E) In vivo RNAi mediated by UAS-shRNA expression under the TubGal4 driver for
dNEF-sp and selected ribosomal biogenesis genes. (B) Log10 Hydro-seq scatterplots for different
abundant noncoding RNAs for dNEF-sp and selected ribosomal processing and control genes. (i)
NCBI and BLAST created rRNA sequences (ii) annotated tRNAs with +/- 20 nt extensions, (iii)
Flybase annotated snRNAs and snoRNAs, (iv) Flybase annotated transposons. shRNA
knockdown of dNEF-sp (orange), mutant M100 (bright orange), PAN2 control (black), RpS2
(dark blue), nop5 (light blue), CG81414 (homolog of human NOL9, red), splicing factor pUf68
(control, grey), CG6833 (homolog of human REXO4, light green), CG5033 (homolog of human
BOP1, violet), CG42666 (homolog of human REXO1), plotted in correlation to shRNA
knockdown of the white gene as control (white). (C-D) Log2 fold changes of read coverage over
shRNA knockdown of white (control) across the 47S ribosomal precursor and log10 read
coverage. (C) Hydro-seq fold changes and coverage for the same genes and color code as in (B).
(D) Total RNA-seq fold changes and coverage for dNEF-sp (orange), RpS3 (dark blue), nop5
(light blue), CG6937 (NIFK), pUF68 (grey), CG6833 (light green), CG42666 (dark green). (E)
Total RNA-seq scatterplots for long abundant noncoding RNAs for shRNA knockdowns shown
in (D). (i) rRNA reference, (ii) Flybase transposon annotation, plotted in correlation to shRNA
knockdown of white (shRNA w). (F-H) Total RNA-seq scatterplots for rRNAs (in log10 scale),
log10 coverage along the 47S rRNA precursor with magnified 28S-3’ETS border, and log2 fold
change difference plots along the 47S rRNA precursor for a number of shRNA in vivo
knockdowns under the TubGal4 driver. For all D. melanogaster genes the human homolog is
given in apprentices. (F) rRNA biogenesis factors: dNEF-sp (orange), Dbp73D (DDX51) (red),
nop5 (NOP58) (blue), CG6937 (NIFK) (green), control white (black), control sequencing strain
(grey). (G) dNEF-sp (orange), Rs1 (DDX27) (red), CG5033 (BOP1) (blue), RpS3 (green),
CG8414 (NOL9), control white (black), control sequencing strain (grey). (H) dNEF-sp (orange),
Dis3 (red), Rrp6 (blue), CG6833 (REXO4), CG12877 (REXO1), control white (black), PAN2
(grey). Genotypes: UAS-shRNA/Cyo, TubGal4/+ or +/Cyo, TubGal4/UAS-shRNA. (I) Left
panel: mRNA-seq levels (in rpkm) of white and other gene knockdowns under the TubulinGal4
driver. Known genes involved in rRNA biogenesis or belonging to RNA exonuclease families
were selected and compared to mRNA expression levels of dNEF-spE497K and dNEF-spPB
mutants. All selected knockdowns (except for white, PAN2, selected controls, and drosha) caused
death at the first or second developmental larval stage. Right panel: Relative repression of genes
in the respective knockdowns compared to control white shRNA knockdown larvae.
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Upregulation of a number of transposons was observed in knockdowns of dNEF-sp and
other rRNA biogenesis factors. Most upregulated were the transposons Copia, INE1 and accord.
Environmental stress is known to activate transposons such as Copia, and the expression may be a
consequence of cellular stress or increased genomic instability induced by defects in rRNA
biogenesis (Capy et al., 2000; Strand and McDonald, 1985).

3.3.15 Loss-of-function of dNEF-sp does not affect mRNA expression
To investigate changes in mRNA metabolic pathways in dNEF-sp loss-of-function mutants I
conducted differential gene expression analysis from mRNA-seq data of knockdowns of dNEF-sp
(3 biological replicates) and the white gene (2 biological replicates). This had the advantage that,
in contrast to mRNA-seq comparisons of the genetic mutants C04255 and M100, these had the
same genetic background in all experiments and therefore less expression noise compared to
control conditions. dNEF-sp expression was downregulated 10-fold in dNEF-sp knockdowns in
all three biological replicates (control ~20

rpkm, dNEF-sp RNAi ~2 rpkm). dNEF-sp

knockdowns displayed less than 250 genes differentially expressed genes as assessed by different
differential gene expression analysis methods (cuffdiff and DEseq/HTSeq) (Anders and Huber,
2010; Trapnell et al., 2012b). Only 223 genes showed significant differential expression (q value
≤ 0.05); of these 121 were upregulated while 102 were downregulated compared to white controls
(Figure 3.27 A). Most enriched Gene Ontology and REACTOME pathways for upregulated genes
were involved in cellular stress, immune and humoral response, and DNA repair (Ashburner et
al., 2000; Croft et al., 2014). Most significantly, the components of the nonhomologous end
joining (NHEJ) dsDNA repair pathway, the MRN complex [including Rad50, meiotic
recombination 11 (mre11), and Nibrin (Nbs) (Ciapponi et al., 2006; van den Bosch et al., 2003)],
as well as replication protein A 70 (RpA-70/Ku70), and Ku80 (XRCC5 homolog) (Fell and
Schild-Poulter, 2015) were upregulated ~6-fold in mutants (Figure 3.27 D). Of the 102
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downregulated genes most annotated ones were involved in cuticle/chitin production pathways,
lipid digestions, as well as a number of (metallo-)peptidases were enriched.

Figure 3.27 Differential mRNA expression upon dNEF-sp knockdown in Drosophila second
instar larvae. (A) MA plot (log2 ratios over log10 mean average between the groups) of mRNA
gene expression for dNEF-sp over white knockdown calculated with cuffdiff (Trapnell et al.,
2012a). (B) Upregulated in mutants, enriched pathways in Gene Ontology pathway analysis. (C)
GOrilla analysis of differentially expressed genes in dNEF-sp knockdown 2nd instar larvae (Eden
et al., 2009). (D) Components of the nonhomologous healing and end joining (NHEJ) dsDNA
damage repair pathway are upregulated by mRNA-seq more than 4-fold in dNEF-sp knockdown
2nd instar larvae. Shown are the mRNA expression of NHEJ components in rpkm for the control
white (black) and dNEF-sp (grey) shRNA knockdowns (left panel), and their relative fold change
expression in mutants over wild type (right panel).
In conclusion, surprisingly few protein-coding genes were differentially expressed in
mutants versus wild type larvae. These were involved in pathways related to energy supply,
cytotoxic stress response and dsDNA repair (Figure 3.27 B). This data agreed with our previous
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finding that dsDNA breaks increased in mutant testes (Figure 3.20). The majority of proteincoding genes, including genes involved in ribosomal biogenesis, did not change in their
expression. Thus, we concluded that loss-of-function of dNEF-sp does not globally influence
mRNA expression pathways and interpret the observed expression changes as a result of a
general cell stress in response to deficient rRNA biogenesis, increased genomic instability, and
deficient energy supply.

3.3.16 Northern Blot analysis shows rRNA precursor intermediates accumulate with a
distribution of sizes
RNA-sequencing gave an unbiased view of genomic targets and allowed the detection of
processing defects. However, in its two-dimensional information content it is difficult to estimate
the accumulation of different intermediates and precursors of different sizes as seen in rRNA
biogenesis. To address the size distribution of the 3’ETS misprocessed transcripts I carried out
Northern blot analysis on total RNA isolated from 2nd instar larvae to (1) confirm the defects
detected by RNA-seq and (2) to gain further insights into the size distribution of the rRNA
precursors. Probes specific to the 3’ETS showed a specific signal for homozygous larvae in both
mutants. Misprocessed rRNA precursors showed a range of products between ~6 and 9 kb in size
(by ssRNA size ladder), and around 2.5 kb. These corresponded to the full size 7.3 kb precursor
and the 4.6 kb precursor intermediate b (containing ITS1, 5.8S, ITS2, and 28S) and the mature
28Sb rRNA (2.3 kb) (Long and Dawid, 1980) (Figure 3.28 A,B). Insect rRNAs contain a
hydrolytic cleavage site in the center of 28S rRNA that generates two 28S fragments, 28Sa and
28Sb, which run at similar electrophoretic mobility as 18S rRNA (Jordan, 1975) (Figure 3.2).
Confirming the RNA-seq results, misprocessed intermediates did not have a defined size, but
displayed a continuous size range. Fragments with length of the ~28Sb rRNA were longer in
length, above the correctly processed mature 28Sb rRNA.
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Figure 3.28 dNEF-sp mutants accumulate a distribution of rRNA precursor intermediates.
Northern Blot analysis of rRNA precursors in mutant 2nd instar larvae. (A) (i) Location of
Northern blot probes are shown on the 47S pre-rRNA precursor in the 5’ETS, ITS1, mature 18A
and 28S rRNA, 3’ETS (unique sequence, labeled 3’ETS specific), 3’ETS (repetitive sequence
within the 3’ETS, labeled 3’ETS repeat); (ii) sizes of different 28S rRNA precursors (A to C). (B)
Northern Blot of both genetic mutants of dNEF-sp, RNA is loaded from homozygotes (-/-),
heterozygotes (-/+) and wild type control 2nd instar larvae. Blot was stripped and reprobed for all
probes. (C-D) Northern Blots of shRNA-mediated knockdowns of known ribosomal RNA
processing genes [CG6937 (MKI67IP), nop5, RpS3, CG8414 (NOL9)], known factors involved
in 28S pre-RNA 3’ maturation: Dbp73D (DDX51) and Rs1 (DDX27). Also tested is total RNA
isolated from shRNA knockdowns of the RNA exosome nucleases Rrp6 and Dis3. In (C) shRNA
knockdowns are also compared with the genetic loss-of-function dNEF-sp mutants (homozygous
M100 and C04255). shRNA knockdown of the white gene and the polyA mRNA-specific
DEDDh RNA exonuclease Pan2 serve as controls. Genotypes: heterozygotes: dNEFspM100/TM6B and dNEF-spC04255/TM6B; homozygotes: dNEF-spM100/dNEF-spM100 and dNEFspC04255/dNEF-spC04255, wild type: sequencing strain. shRNA knockdowns: UAS-shRNA/Cyo,
TubGal4/+ or +/Cyo; TubGal4/UAS-shRNA.
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From the processing patterns it remains unclear whether 28S rRNA processing
continuous at the 5’ end keeping the extended 3’ETS trailers until the final step or whether the 2.3
kb fragments of 28Sb rRNA is the result of an early hydrolytic cleavage of the misprocessed
precursor. Because of the hydrolytic cleavage of insect 28S rRNA one cannot unequivocally
exclude either, however, we found that this effect was specific for dNEF-sp and not observed for
Dbp73D RNA helicase, the Ddx51 homolog involved in 28S rRNA processing (Figure 3.28 C),
which may suggest that 28S rRNA processing can partially continue to the 28Sb product.
As detected by RNA-seq, processing defects were several fold stronger for the transposon
insertion line C04255 compared to the EMS point mutant M100. Furthermore, probes specific to
ITS1 revealed the accumulation of 4.6 kb precursors. In mammals and yeast, maturation of the 5′
end of the 5.8S rRNA is coordinated with formation of the 3′ end of the 25S/28S rRNA and both
events are coupled (Henras et al., 2014). The accumulation of the ITS1 (Figure 3.28 B-C) and
ITS2 suggest a partial coupling of 5’ end 5.8S and 3’ end 28S formation in Drosophila similar to
U8 snoRNA-mediated processing described in Xen. laevis (Peculis and Steitz, 1993).
Comparison of pre-rRNA processing defects in shRNAs knockdowns for the panel of
rRNA biogenesis factors and dNEF-sp showed a similar accumulation of extended 3’ETS
precursors in the shRNA mediated knockdown of dNEF-sp. Notably, by Northern Blot analysis
some defects on pre-rRNA processing were easier to detect than in a two-dimensional
representation resulting from the RNA-seq analysis. Perhaps in a tiling array-like method,
selecting short regions within the rRNA precursors and mapping RNA-seq read abundances
against these will allow comparisons of the relative rRNA precursor ratios. Accumulation of
intermediates was observed for all tested biogenesis factors, confirming that knockdown of the
selected proteins led to pre-rRNA processing defects (Figure 3.28 C). Furthermore, Dbp73D also
displayed a range of accumulated 3’ETS extended precursors at 9 kb, confirming an early role of
Dbp73D in 3’ETS removal (Figure 3.28 C). In contrast to dNEF-sp, accumulation of
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intermediates of 6 and 2.5 kb were not observed for Dbp73D knockdowns, suggesting that dNEFsp and Dbp73D action are not coupled and some defective precursors can be further processed in
dNEF-sp mutants.

3.3.17 dNEF-sp crosslinks to RNA in vivo
To investigate whether dNEF-sp binds RNA in vivo, I designed several transient transfection
constructs of dNEF-sp with a mutated catalytic domain and an N-terminal HA/FLAG-tag, which
allowed immunoprecipitation of the tagged protein using a monoclonal anti-FLAG antibody.
Colloidal blue staining could detect immunoprecipitated and FLAG-eluted HA/FLAG-dNEF-sp
protein (Figure 3.29 A). Immunoprecipitation of 4-SU labeled RNA-protein complexes followed
by RNA radiolabeling (PAR-CLIP) showed that dNEF-sp protein immunoprecipitated
crosslinked RNA (Figure 3.29 B). A second endogenous and highly abundant protein in S2 cells,
recognized by FLAG monoclonal antibodies, was also immunoprecipitated and displayed an
RNA crosslinking band (Figure 3.29 B). Currently, large-scale PAR-CLIP and protein mass
spectrometry experiments are underway to identify bound RNA fragments and protein complexes
by next generation sequencing and quantitative mass spectrometry. In addition to confirming the
direct binding of NEF-sp to the 3’ETS and identifying additional RNA targets transcriptomewide, PAR-CLIP analysis will elucidate the consensus binding motif required for dNEF-sp to
recognize its targets. Overall, our analysis will characterize the interactions of dNEF-sp with its
targets and protein partners and define the molecular complex during ribosome biogenesis.
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Figure 3.29 dNEF-sp crosslinks RNA in vivo. Immunoprecipitation of HA/FLAG-dNEF-sp
mutants and untransfected S2 cells as control. (A) Colloidal Blue staining of FLAGimmunoprecipitated and FLAG peptide- eluted dNEF-spDEDAH protein and control untransfected
S2 cells. Residual antibody eluted is marked with a star. An unknown protein of ~50 kDa is
known to immunoprecipitate with FLAG antibody from S2 cells (Miyoshi et al., 2013). (B) (i)
Western blot of FLAG immunoprecipitates crosslinked S2 cell lysates expressing dNEF-spDADAH
mutant protein and untransfected S2 cells. (ii) Phosphorimage of RNA-radiolabeled FLAG
immunoprecipitates from (i).
3.3.18 dNEF-sp mutant cells accumulate unprocessed 3’ETS in the nucleolus and display
increased nucleolar size
While examining second instar larval tissues we noticed an increased nucleolar size in
homozygous mutant gut cells. In agreement with this observation a previous screen for regulators
of nucleolar size in S2 cells had found that dNEF-sp knockdown increased nucleolar size 2-fold
(Neumuller et al., 2013). To measure the extent to which nucleolar structure was affected in
dNEF-sp deficient cells in vivo, we used clonal expression of RNAi mediated by shRNA
knockdowns. shRNA knockdown of dNEF-sp under the hsFlp-tubGal4 driver resulted in 4-fold
increase of the nucleolus in NEF-sp knockdown cells (Figure 3.30 A).
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Figure 3.30 Loss-of-function of dNEF-sp increases nucleolar size in Drosophila 2nd instar
larvae. (A) hsFlp-mediated shRNA knockdown of dNEF-sp in mid gut cells of 2nd instar larvae.
Cells expressing UAS-shRNA against dNEF-sp also express UAS-Red47. (i) Confocal 3-color
image of mutant and wild type mid gut cells. Mutant cells are red (RFP), the nucleolus is marked
with Fibrillarin (Fib, green), the nucleus stained with Hoechst dye (blue). (i’) Nuclear staining
with Hoechst shows increased nucleolar size (absence of Hoechst) for shRNA mediated RNAi
knockdown cells (marked with red arrows). (j) Quantification of the ratio of nuclear/nucleolar
area size for wild type and mutant cells in mid gut cells. Wild type cells usually have a ratio Area
(nucleus)/ Area (nucleolus) 8:1, while mutant cells display a ratio of 2:1, i.e. in mutant cells the
nucleolus occupies half of the nucleus and is ~4 times larger than in wild type cells. (B)
Fluorescent RNA in situ hybridization probing against the repeat sequence in the 3’ETS (red) in a
dNEF-sp mutant background expressing RpS2-GFP (green). Hoechst dye is shown in blue. In
homozygous mutants the unprocessed 3’ETS is retained in the nucleolus, which increases in size.
In heterozygous mutants (viable, no phenotypes), no unprocessed 3’ETS can be detected and
nucleolar size is unchanged. Genotypes: (A) hsFlp; UAS-shRNA dNEF-sp (P{KK101144}VIE260B)/Cyo, UAS#Red47a#1 tub<+GFP<Gal4/TM6B. (B) homozygotes: RpS2-GFP/Cyo, dNEFspC04255/dNEF-spC04255; heterozygotes: RpS2-GFP/Cyo, dNEF-spC04255/TM6B.
Since the Northern Blot results indicated aberrant 28S fragments close to the size of
mature 28S rRNA, we were curious to see whether loss-of-function of dNEF-sp resulted in
misprocessed 28S rRNAs being exported to the cytoplasm or whether these aberrant 28S
precursor transcripts were retained in the nucleolus. Therefore, to assess 3’ETS export we
synthesized in situ LNA probes specific to a repeated sequence within 3’ETS, which allowed a
natural amplification of the signal. RNA fluorescent in situ hybridization (RNA FISH)
experiments showed specific signal of the extended 3’ETS region only in homozygous mutants,
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where it was exclusively confined to the nucleolus, while no signal was detected in heterozygous
larvae. Hence, aberrant 3’ETS-extended 28S rRNA precursors were not exported from the
nucleolus. The increase in nucleolar size may therefore be the result of the accumulation of
incorrectly processed 3’ETS fragments (Figure 3.30 B).

3.3.19 Loss-of-function of dNEF-sp impairs ribosome export
In order to determine whether misprocessing also affects ribosome export we combined a RpS2GFP reporter line with our mutant backgrounds (Buszczak et al., 2007). Heterozygote flies, which
were essentially wild type in viability and phenotype, displayed predominantly cytoplasmic
localization of the GFP-tagged ribosomal proteins (Figure 3.31). In contrast, homozygous
mutants showed nuclear/nucleolar retention of RpS2-GFP and retention of RpL13A-GFP,
although nucleolar retention of Rpl13A was only found in few mutant cells. Nucleolar retention
of RpS2-GFP most strongly accumulated in foregut cells, but was also observed in other tissues,
such as salivary glands and fat cells (Figure 3.31 A-C). RNA FISH against the 3’ETS showed that
the 3’ETS strongly accumulated in these tissues (Figure 3.31 D-F). In addition to an increased
nucleolus, overall cell morphology was also deformed and nuclei were larger relative to the cell
body (Figure 3.31 D). In all tissues, processing defects of the 3’ETS affected export of the small
ribosomal subunits (RpS2-GFP) and showed stronger nucleolar staining of 18S rRNA (Figure
3.31 D-E). RNA FISH against mature 28S rRNA did not show, apart from a larger nucleolar size
in homozygous mutants, significant nucleolar accumulation in mutants (Figure 3.31 F). Together
with the data on RpL13A, these results suggested to us that the observed phenotypes of 3’ETS
misprocessing took place early in rRNA biogenesis, thereby affecting the export of the small
ribosomal subunit first.
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Figure 3.31 Ribosome export is impaired in dNEF-sp mutants. (A-B) RpS2-GFP protein trap
in the dNEF-sp mutant backgrounds shows nucleolar/nuclear retention of RpS2-GFP in
homozygous mutants. In heterozygous mutants (no phenotypes, viable) RpS2-GFP is exported to
the cytoplasm. Shown are RpS2-GFP (green) and DNA staining (Hoechst, blue). (A) (i,i’) dNEFspC04255/dNEF-spC04255, fat body; (j,j’) dNEF-spC04255/TM6B, fat body. (B) (i,i’) dNEFspM100/TM6B, salivary glands; (j,j’) dNEF-spM100/dNEF-spM100, salivary glands. (C) In vivo
localization of RpL13A-GFP in the C04255 dNEF-sp mutant background shows
nucleolar/nuclear retention of RpL13A-GFP in homozygous mutants for some cells, foregut. (DE) RNA FISH of the 3’ETS (red) and mature 18S rRNA (green) in foregut cells in homozygous
and heterozygous C04255 mutants. 18S rRNA shows nucleolar accumulation, the misprocessed
3’ETS RNA is not exported. Cells show increased nucleolar size and altered nuclear and overall
cell morphology. (F) RNA FISH of the 3’ETS (red) and mature 28S rRNA (green) shows nuclear
retention of the 3’ETS, but unaltered distribution of mature 28S rRNA.
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28S rRNA is incorporated into the large ribosomal subunit and the small and large subunits
are exported in separate pathways, with the small subunit undergoing export more rapidly (Figure
3.1). In light of our data, we interpret the observed nucleolar retention of the small ribosomal
subunit that either removal of 3’ETS takes place early on in rRNA biogenesis and thus faulty
processing affects early biogenesis or, alternatively, that accumulation of defective 3’ETS
precursors sends a negative feedback to halt export of the small ribosomal subunit.

3.4
3.4.1

Discussion
3’-5’ exonucleolytic trimming of the 3’ETS of 47S pre-rRNA is a conserved
mechanism across lower and higher eukaryotes

In this chapter I identified and characterized the DEDDh 3’-5’ RNA exonuclease dNEF-sp and
showed that it is involved in the exonucleolytic trimming of the 3’ETS rRNA precursor. I
characterized the function of dNEF-sp in vivo and in vitro and showed that 3’ETS removal is an
essential process in Drosophila melanogaster. In absence of dNEF-sp and other factors required
for 3’ETS removal, such as Dbp73D (DDX51), misprocessed rRNA precursor transcripts
accumulate in the nucleolus and impair ribosome export to the cytoplasm. Through an unbiased
RNA sequencing approach, profiling small and large noncoding RNAs, we investigated abundant
noncoding RNAs transcriptome-wide and studied targets and regulatory effects of dNEF-sp and
other ribosomal RNA processing factors. I found that dNEF-sp is unique in its role of removing
the 3’ETS in Drosophila melanogaster. The conserved expression and nucleolar localization of
the Drosophila and human NEF-sp homologs may imply a conserved function of NEF-sp
proteins in higher eukaryotes. Contrary to previous models of 28S rRNA 3’ end maturation, we
find that 3’-5’ exonucleolytic trimming is an essential process during 28S rRNA biogenesis in
higher eukaryotes. dNEF-sp is the enzyme responsible for 28S rRNA 3’ end trimming and
generation of mature 28S rRNA ends in Drosophila melanogaster. In S. cerevisiae the distant
211

homolog of NEF-sp, Rex1p, generates the mature 28S rRNA 3’ end by exonucleolytically
trimming the 28S rRNA precursors after co-transcriptional cleavage of Rnt1p that releases the
37S rRNA precursor [Figure 3.31 A (i)]. Future studies of the human and mouse NEF-sp
homologs, which have been briefly started here, will be needed to answer the role of NEF-sp in
mammalian rRNA biogenesis, its tissue-specific expression, and how its domain divergence from
lower to higher eukaryotes has evolved to recognize its RNA targets. Furthermore, biochemical
purifications of the protein complex of NEF-sp are the next steps to yield a molecular
understanding of the recruitment and processing factors involved in 3’ETS removal and to
delineate the precise mechanism of release of the 47S rRNA precursor.
In higher eukaryotes, a direct endonucleolytic cleavage is thought to occur, in which
cleavage is guided by the C/D box snoRNA U8 (Peculis, 1997). The enzymatic factor catalyzing
such cleavage has not been characterized so far and the mammalian and the Drosophila homologs
of Rnt1p, Drosha, do not have a role in 3’ETS cleavage (Chong et al., 2008; Smibert et al., 2011).
The DEAD box helicase Ddx51 has previously been shown to be required for correct 3’ end
processing by unwinding and releasing U8 snoRNA from 5.8S-28S-binding (Srivastava et al.,
2010) [Figure 3.31 A (ii)]. In agreement with the mammalian Ddx51 function, we find that the
function of the Drosophila homolog Dbp73D is conserved and knockdown of Dbp73D displays
3’ETS processing defects similar to dNEF-sp [Figure 3.31 A (iii)].
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Figure 3.32 Current view of 28S rRNA 3’ end maturation in S. cerevisiae, humans, and
Drosophila. (A) Schematic comparison of 28S rRNA 3’ end maturation in S. cerevisiae, human
and Drosophila. (i) In S. cerevisiae Rnt1p endonucleolytically cleaves the 3’ETS and releases the
37S precursor transcript. Rex1p trims the residual 3’ETS overhangs to generate the mature 3’ end
of 28S rRNA. (ii) In humans and other mammalians, as well as in Xenopus laevis, a homologous
endonucleolytic cleavage reaction by the Rnt1p homolog DROSHA has not been identified, and
cleavage or processing factors maturing the 3’end of 28S rRNA remain uncharacterized. U8
snoRNA is known to basepair to 28S rRNA and guides a proposed direct endonucleolytic
cleavage reaction at the 3’ end of 28S rRNA. The DEAD box helicase DDX51 is required for
unwinding of U8 snoRNA and release of the rRNA precursor. DDX27 has been implicated in
3’ETS end definition and knockdowns of DDX27 display precursors, which extend beyond the
defined end of the 3’ETS. (iii) In Drosophila melanogaster, a conserved U8 snoRNA homolog
has been identified. This study shows that the DDX51 homolog Dbp73D is functionally
conserved and knockdowns display, like the mammalian DDX51 protein, extended 3’ETS
precursors in D. melanogaster. Loss-of-function dNEF-sp mutants accumulate extended 3’ETS
rRNA precursors, showing that dNEF-sp exonucleolytic processing is a required step in 28S
3’end maturation in D. melanogaster. (B) RNA secondary structure of the mature 3’ end of
human and Drosophila 28S rRNA show that the nucleotides at the mature 3’ end differ, however
secondary structure remains conserved. Figure adapted from (Anger et al., 2013).
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Our study provides a fresh perspective on 28S rRNA biogenesis in higher eukaryotes.
Previous works suggested a model in which a precise endonucleolytic cleavage event at the 28S3’ETS transition released the mature 3’ end of 28S rRNA, guided by U8 snoRNA. However, our
data clearly supports a model that requires exonucleolytic trimming to generate mature 3’ends of
28S rRNAs, similar to S. cerevisae. The conserved base-pairing interactions of U8 snoRNA may
ensure the required specificity to define the mature 28S rRNA end. In support of such a
mechanism, in vivo transcripts have been found to readily extend beyond the T1 site in Xenopus
laevis and previous work found that endonucleolytic cleavage was followed by rapid
exonucleolytic trimming to generate the 40S precursors (Labhart and Reeder, 1986). Processing
at the cleavage site of mature 28S 3’ ends (T1) in Xenopus laevis (the mature 28S 3’ end site) also
takes place in vitro in fractions of impure albumin serum, suggesting that the nucleolytic reaction
requires little or none sequence specificity to generate the mature 28S 3’ ends (Labhart and
Reeder, 1986). Given the heterogeneity and lack of conservation of 3’ETS sequences across
organisms (Figure 3.31 B), an exonucleolytic mechanism may also be preferred over an
endonucleolytic cleavage, which requires specific base pair recognition and conservation.

3.4.2

The role of tissue-specific levels of rRNA biogenesis factors

dNEF-sp exhibits high tissue specificity, which is conserved across metazoans. Every cell needs
to synthesize rRNAs abundantly and general pre-rRNA processing factors involved in cleavage
and maturation of rRNAs usually do not show regulated gene expression across tissues. Thus the
restricted expression of one of its essential rRNA processing factor is mechanistically unexpected
and points towards tissue-specific regulation of rRNA biogenesis.
Posttranscriptional gene regulation of rRNA modifications in different cell types and
tissues is known to lead to cell-type specific variations in processing pathways and rRNA
intermediates. Heterogeneity of rRNA modifications and changing ratios of 5.8SS/L rRNA in
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different cell types are among the reported examples (Lafontaine, 2015; Mullineux and
Lafontaine, 2012). Furthermore, tailoring translational efficiency of ribosomes to specific mRNA
targets by tissue-specific incorporation of ribosomal proteins (or in response to cytosolic stress)
has also recently been reported (Kondrashov et al., 2011; Vesper et al., 2011; Zhang et al.,
2015b). However, tissue-specific regulation of rRNA biogenesis remains currently unknown.
The tissue-specific expression of dNEF-sp may suggest (1) a tissue-specific
regulation/function or targets of dNEF-sp or (2) 28S rRNA 3’ end maturation requires the
involvement of other nucleases, which have overlapping specificities. In our study we have not
found tissue-specific RNA targets of dNEF-sp. Maturation of the 3’ETS through several RNA
exonuclease with some overlapping specificity would allow tissue-specific regulation of 28S
rRNA maturation through e.g. signaling pathways that modulate activity of rRNA biogenesis
factors. Thereby they can directly influence posttranscriptional processing steps in rRNA
biogenesis according to the demands of the specific cell type or tissue. However, in this study, we
could not identify any overlapping specificities of NEF-sp and its family paralogs, or other 3’-5’
RNA exonucleases, such as those of the RNA exosome Rrp6 and Dis3, which have been
described in 5.8S 3’ end maturation. In conclusion, we find that, at present, the role of dNEF-sp
in 3’ETS maturation of 28S rRNA is unique.
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4 Conclusion
In this short chapter I aim to provide a brief summary and highlight unanswered questions this
work raises. In chapter 2, I studied characteristics of PTGR from a genome-wide perspective. The
central role of PTGR in cellular metabolism can be appreciated by considering the large number
of proteins interacting with RNA. Over 1,500 of the 20,500 unique human proteins are directly
contributing to PTGR. RBPs form many distinct families with few members and human RBPs
can be grouped into ~1,100 paralogous families related by greater than 20% sequence identity.
The complexity of PTGR was established early in evolutionary time scales. The earliest
common ancestor of metazoans had a set of ~200 RBPs (Kerner et al., 2011), and of the ~1,100
human RBP families ~600 families have homologs in yeast. Consistent with their high degree of
conservation, most RBPs (98%) do not display highly tissue-specific expression, but they are
abundant and make up to 25% of the expressed transcripts encoding for cellular proteins.
Interestingly, dysregulation of ubiquitous and general components in PTGR often shows highly
tissue-specific phenotypes; for instance defects involving mRBPs are most frequently associated
with neurological diseases, especially of the peripheral nervous system.
Given that the common RBD folds have been characterized and the majority of RBPs do
not fall into large families, novel RBPs are most probably singular or have recently evolved
RNA-binding activity independent of their family. This makes RBP prediction challenging and
leaves experimental approaches as the most suitable strategy for their identification. Genomewide experimental methods such as covalent RNA-protein cross-linking coupled with highthroughput sequencing to identify RNA target sites, or combined with mass spectrometric
approaches to identify proteome-wide RBPs cross-linked to RNAs, will advance these efforts
towards the elucidation of novel RBP and with increasing sensitivity of these experimental
approaches, the number of RBPs is likely to grow. Based on our current collective data and recent
experimental genome-wide studies, which added less than <50 novel RBPs to our census, we
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believe that most RBPs or their homologs (>95%) have been identified and we will see fewer
novel discoveries in the future. Even at present though, the precise biological functions and RNA
targets for the majority (>50%) of the known human RBPs have not been characterized. For
example, rRNA and tRNA-biogenesis components and their targets are often inferred by
homology, as well as many of the proteins with canonical RBDs have not been characterized in
humans. Some of the RNA regulatory processes, such as noncoding RNA maturation pathways,
control of RNA transport, the role of RNA modifications, sensing of intracellular RNA, RNA as
structural component for genome organization (Ding et al., 2012) or regulation (Cech and Steitz,
2014), as well as mechanisms of RNA/RNP clearance, remain poorly understood. Thus, the main
challenges in the field are the characterization of these processes and the mechanisms leading to
human disease.
Much of the dynamics and the integration of co-regulatory functions of RBPs in PTGR
regulation remain to be elucidated. We are still in the process of profiling the targets and binding
affinities for most RBPs. In the future, with a more detailed knowledge of targets and coregulated expression of RBPs in developmental processes, we can begin to study their integration
into different regulatory pathways, and ask questions on how for example signaling pathways and
innate immunity are connected to RNA metabolism and neuroplasticity (Figure 2.11).
Stoichiometries and time scales strongly determine regulatory outcome, thus studying dynamic
assembly processes in RBP regulation will be important to understand the final outcome in gene
expression control.
Through in silico investigation of novel PTGR factors I identified and characterized two
unknown proteins, the RG/RGG-rich RBP FAM98A and the conserved 3’-5’ RNA exonuclease
NEF-sp. Our findings shed light on one of the members of the poorly characterized DEDDh
RNase T exonuclease class and investigated in detail the mechanism of 3’ETS 28S rRNA
maturation in higher eukaryotes. We show here that 28S rRNA undergoes exonucleolytic
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trimming, a process conserved from yeast to higher eukaryotes. Still the question remains how the
pre-rRNA precursor transcript is released from RNA Pol I in higher eukaryotes: is a separate
endonucleolytic cleavage required or is transcription termination, followed by rapid
exonucleolytic trimming, sufficient to release the precursor transcript? The latter would explain
the absence of a homologous enzymatic function of the Rnt1p homolog Drosha. The evolution of
a distinct RNA endonuclease, which carries out 3’ETS nucleolytic cleavage in higher eukaryotes,
but not in S. cerevisiae, seems unlikely for a highly conserved mechanism such as rRNA
biogenesis. Perhaps an intrinsic nucleolytic mechanism of the Pol I complex, in combination with
other protein factors, could carry out an equivalent cleavage reaction.
Our work also raises the question of the tissue-specific requirement for high levels of
NEF-sp in germ cells. NEF-sp could either function in gonad-specific regulation of rRNA
biogenesis or serve an additional gonad-specific function in different noncoding RNA regulatory
pathways. In addition, the distinct subcellular localization of dNEF-sp during terminal
differentiation points to a specific role of NEF-sp in the final stages of spermatid differentiation.
Given the structural differences between the Drosophila and vertebrate NEF-sp proteins,
the characterization of NEF-sp in higher organisms will be important to understand its function
and conservation. NEF-sp is a relatively newly expanded RNA nuclease family that evolved from
an old RNase T family. What is the role of the newly evolved RRM domains? None of the other
DEDDh RNA exonuclease members or any other RNA exonucleases share structural similarities
with NEF-sp proteins, making it a unique enzymatic protein family. Furthermore, how are the
domain differences between invertebrates and vertebrates explained and how does that alter target
recognition? It remains to be asked whether substrates are directly recognized through the RBDs
of NEF-sp or whether NEF-sp is recruited by additional regulatory factors.
Finally, it is likely that 3’ETS exonucleolytic trimming is executed by several RNA
exonucleases, as redundancies in exonucleolytic trimming have been observed for several pre218

rRNA substrates, such as e.g. 5’exonucleolytic trimming of 5.8S pre-rRNA through Rrp17 and
Xrn1 (Oeffinger et al., 2007).
Another interesting aspect of this project has been to understand the role of RNA
exonucleases regulating pre-rRNA maturation. As one of the earliest steps in rRNA maturation,
3’ETS exonucleolytic trimming regulates rRNA production. In contrast to one specific RNA
endonucleolytic event, the utilization of a number of RNA exonucleases allows for a complex
posttranscriptional control of rRNA processing. The control of a number of exonucleases to carry
out this processing step allows for fine-tuning of rRNA biogenesis in response to cellular needs.
This may also have implications for dysregulated rRNA biogenesis in human diseases. Hence, the
study of tissue-specific processing in rRNA biogenesis and its regulation in different
developmental processes opens up an interesting field of PTGR in the future.
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5 Appendix of Tables
Table 5.1 Canonical RNA-binding domains
Domain
RRM
KH
DEAD
dsrm
zf-CCCH
zf-C2H2_jaz
zf-CCHC
zf-RanBP
zf-nanos
Zf-U1
LSM
SAP
YTH
SAM
La
PWI
PABP
S1, S1-like
SMN
PUA
Surp
PAZ
Piwi
CSD
Agenet
TUDOR
PUF
TROVE
THUMP

Description
RNA recognition motif, single-strand RNA (ssRNA)-binding (Cléry et al., 2008)
KH-homology domain, ssRNA-binding (Grishin, 2001; Lunde et al., 2007)
DEAD and DEAH box helicase motif, unwinds RNA (and DNA) (Rocak and Linder, 2004)
Double-stranded dsRNA binding motif (Lunde et al., 2007)
Zinc finger motif type C-x8-C-x5-C-x3-H, ssRNA-binding (Krishna et al., 2003; Lunde et al., 2007)
JAZ dsRNA-binding protein zinc-fingers, dsRNA-binding (Krishna et al., 2003; Lunde et al., 2007)
Zinc knuckle, C-x2-C-x4-H-x4-C, ssRNA-binding (Krishna et al., 2003; Lunde et al., 2007)
RNA-binding Ran-binding-protein-like zinc finger (Krishna et al., 2003; Lunde et al., 2007)
Zinc finger domains found in the eukaryotic proteins RBP families Nanos and Xcat-2 (Krishna et al.,
2003; Lunde et al., 2007)
Zinc finger motif found in several U1 small nuclear ribonucleoprotein C (U1-C) proteins (Krishna et
al., 2003; Lunde et al., 2007)
LSM (Like Sm) domain is found in snRNP complexes, bind A/U rich regions (Wilusz and Wilusz,
2005)
(SAF-A/B, Acinus and PIAS) motif, RNA/DNA-binding domain (Aravind and Koonin, 2000)
YTH (YT521 homology) domain, ssRNA-binding, conserved aromatic residues within the ß-stands of
the YTH domain similar to RRM, PUA, and OB-fold structures (Zhang et al., 2010)
Sterile alpha motif, 4-5-helical bundle of two orthogonally packed alpha-hairpins, ssRNA-binding
(Kim and Bowie, 2003)
La protein RBD; alpha/beta fold that comprises a winged-helix motif, ssRNA-binding (Kenan and
Keene, 2004)
~80 amino acid module with PWI tri-peptide located in N-terminal region, found at the N or C terminus
of RBPs, generally found in association with RRM and RS RBDs (Szymczyna et al., 2003)
C-terminal domain in polyadenylate-binding protein, involved in homodimerization (Derry et al., 2006)
S1 ssRNA-binding domain, found in ribosomal proteins, similar to cold shock domain (Lunde et al.,
2007)
Survival of motor neuron gene (SMN) contains a Tudor domain (SMN domain), which facilitates
SMN-Sm protein interaction in the assembly of spliceosomal uridine-rich small nuclear
ribonucleoprotein (Selenko et al., 2001)
Pseudouridine synthase and archaeosine transglycosylase domain often found in RNA modification
enzymes and ribonucleoprotein complexes, ssRNA-binding (Pérez-Arellano et al., 2007)
Commonly found in splicing factors, ssRNA-binding domain, alpha-helical (Kuwasako et al., 2006)
Piwi Argonaut and Zwille (PAZ) domain, posttranscriptional silencing domain, binds siRNAs (Meister,
2013)
Piwi domain (P-element induced wimpy testis), posttranscriptional silencing domain, dsRNA guide
hydrolysis of ssRNA (Meister, 2013)
Cold-shock domain, ssRNA/ssDNA binding (Mihailovich et al., 2010)
Tudor-like domain found in FMRP and other RBPs, putative RBD, tandem Agenet-like domains
preferentially recognize trimethylated peptides in a sequence-specific manner, four-stranded
antiparallel beta sheet (Adinolfi et al., 2003; Maurer-Stroh et al., 2003)
Tudor domain, found in Tudor proteins, Tudor proteins are in complexes with RBPs (Siomi et al.,
2010)
Tandem repeat of eight domains, ssRNA-binding domain (Wang et al., 2001; Zamore et al., 1997)
TROVE (Telomerase, Ro and Vault) domain is a module of ~300-500 residues that is found in TEP1
and Ro60 the protein components of three ribonucleoprotein particles (Bateman and Kickhoefer, 2003)
Thiouridine synthases, methylases and pseudouridine synthases, α/β fold, RNA-binding
(Aravind and Koonin, 2001b)
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Table 5.2 Pfam RNA-binding and RNA-related domains
Index
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

Pfam Domain
RRM_1
DEAD
zf-CCCH
RRM_6
KH_1
RRM_5
GTP_EFTU
dsrm
zf-CCHC
LSM
GTP_EFTU_D2
HA2
G-patch
IBN_N
RnaseA
SAP
TUDOR
KOW
MMR_HSR1
zf-C2H2_jaz
RNase_T
MIF4G
NTF2
PAM2
PAZ
RBM1CTR
zf-RanBP
Anticodon_1
CSD
GTP_EFTU_D3
HGTP_anticodon
Piwi
R3H
RNase_Zc3h12a
Ribosomal_L7Ae
S1
Xpo1
tRNA-synt_2b
Exo_endo_phos
La
Nol1_Nop2_Fmu
PAP_assoc
RNase_PH
W2
tRNA-synt_1
tRNA_SAD
zf-C2H2
zf-met
APOBEC_N
A_deamin
MA3
RAP
RNase_PH_C
Surp
tRNA_anti-codon
Brix
DZF
FtsJ
PARP
PWI
Tap-RNA_bind
YTH

Count
178
62
45
43
38
35
21
21
20
19
17
17
15
14
13
13
13
12
12
12
11
10
9
9
9
9
9
8
8
8
8
8
8
8
8
8
8
8
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
6
5
5
5
5
5
5
5

Index
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
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Pfam Domain
PRP1_N
PRP21_like_P
PRP3
PRP8_domainIV
PTS_2-RNA
Paf67
Pept_tRNA_hydro
Pescadillo_N
PolyA_pol
Pox_MCEL
ProRS-C_1
Prp18
Prp19
Prp31_C
RAI1
RAM
RNA_GG_bind
RNA_POL_M_15KD
RNA_bind
RNA_pol
RNA_polI_A34
RNA_pol_I_A49
RNA_pol_N
RNA_pol_Rpb1_1
RNA_pol_Rpb1_2
RNA_pol_Rpb1_3
RNA_pol_Rpb1_4
RNA_pol_Rpb1_5
RNA_pol_Rpb1_R
RNA_pol_Rpb2_1
RNA_pol_Rpb2_3
RNA_pol_Rpb2_4
RNA_pol_Rpb2_5
RNA_pol_Rpb2_6
RNA_pol_Rpb2_7
RNA_pol_Rpb4
RNA_pol_Rpb5_C
RNA_pol_Rpb5_N
RNA_pol_Rpb6
RNA_pol_Rpb8
RNase_H
RNase_H2-Ydr279
RNase_H2_suC
RNase_HII
RNase_P_p30
ROKNT
RRF
RRM_4
RRP7
RRS1
RTC
RTC_insert
RVT_1
Ribonuc_L-PSP
Ribonuc_P_40
Ribonucleas_3_3
Ribonuclease_T2
Ribosomal_L12
Ribosomal_L13e
Ribosomal_L14e
Ribosomal_L15e
Ribosomal_L17

Count
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127

tRNA-synt_2
AF-4
Beta-Casp
CAF1
CRM1_C
DND1_DSRM
Dus
EFG_IV
IF4E
Lactamase_B
OAS1_C
PABP
PIH1
PIN_4
PUA
PseudoU_synth_2
RF-1
Ribosomal_L30
S4
SUI1
THRAP3_BCLAF1
tRNA-synt_1b
tRNA-synt_2c
2OG-FeII_Oxy_2
AKAP95
Ago_hook
CBF
CBFNT
Calreticulin
DUF2414
DUF2465
DcpS_C
EST1_DNA_bind
FXR1P_C
FYTT
Fox-1_C
IF-2B
LSM14
LUC7
MBD
Methyltransf_31
Nop
Nucleoplasmin
PAP_RNA-bind
PseudoU_synth_1
PurA
RIG-I_C-RD
RIO1
RMMBL
RNB
RS4NT
Ribonuc_2-5A
Ribosomal_60s
Ribosomal_L1
Ribosomal_L10
Ribosomal_L16
Ribosomal_L18e
Ribosomal_L3
Ribosomal_S10
Ribosomal_S18
Ribosomal_S4e
RrnaAD
S1-like
SMN
Sas10_Utp3

5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
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Ribosomal_L18ae
Ribosomal_L19
Ribosomal_L19e
Ribosomal_L20
Ribosomal_L21e
Ribosomal_L21p
Ribosomal_L23eN
Ribosomal_L27
Ribosomal_L27e
Ribosomal_L28
Ribosomal_L29
Ribosomal_L29e
Ribosomal_L31e
Ribosomal_L32e
Ribosomal_L32p
Ribosomal_L33
Ribosomal_L34
Ribosomal_L34e
Ribosomal_L35Ae
Ribosomal_L35p
Ribosomal_L36
Ribosomal_L36e
Ribosomal_L37
Ribosomal_L37ae
Ribosomal_L37e
Ribosomal_L38e
Ribosomal_L40e
Ribosomal_L41
Ribosomal_L5
Ribosomal_L50
Ribosomal_L5_C
Ribosomal_L6
Ribosomal_L6e
Ribosomal_L6e_N
Ribosomal_L9_N
Ribosomal_S13
Ribosomal_S13_N
Ribosomal_S16
Ribosomal_S19
Ribosomal_S19e
Ribosomal_S21
Ribosomal_S21e
Ribosomal_S24e
Ribosomal_S25
Ribosomal_S26e
Ribosomal_S27
Ribosomal_S28e
Ribosomal_S30
Ribosomal_S3Ae
Ribosomal_S3_C
Ribosomal_S6
Ribosomal_S6e
Ribosomal_S7e
Ribosomal_S8
Rpp20
Rpr2
Rrp15p
Rsm1
RtcB
S10_plectin
SAP18
SART-1
SBDS
SBDS_C
SF3a60_bindingd

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192

SpoU_methylase
Suf
TAP_C
THUMP
TruB_N
UPF0020
Utp12
cwf21
eIF-1a
eIF-5a
tRNA-synt_1c
tRNA-synt_His
tRNA_m1G_MT
zf-RNPHF
zf-U1
zf-nanos
AARP2CN
AKAP7_NLS
AXH
Aconitase
Aconitase_C
Alba
B3_4
Bin3
CPSF_A
Caprin-1_C
Clp1
CwfJ_C_1
CwfJ_C_2
Cwf_Cwc_15
DALR_1
DCP1
DRY_EERY
DUF1387
DUF1897
DUF2051
ECR1_N
EF1_GNE
EST1
Endonuclease_NS
FDF
FDX-ACB
FRG1
Fcf1
Fibrillarin
GCD14
GUCT
Gar1
HABP4_PAI-RBP1
HEXIM
HnRNPA1
IF-2
INT_SG_DDX_CT_C
L51_S25_CI-B8
LsmAD
MRP-S27
MT-A70
Mago_nashi
Met_10
NOP5NT
NOT2_3_5
NUC153
Nop25
Nop52
PAT1

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
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SF3b1
SF3b10
SHQ1
SHS2_Rpb7-N
SIP1
SLBP_RNA_bind
SNase
SR-25
SRA1
SRP14
SRP19
SRP40_C
SRP72
SRP9-21
SURF6
SUV3_C
Sen15
Seryl_tRNA_N
Slu7
Snurportin1
Sof1
Spt4
Ssu72
Sua5_yciO_yrdC
Symplekin_C
THOC7
TRM13
TYW3
Telomerase_RBD
Thg1
Tho2
Thoc2
Transformer
Transposase_22
Trm112p
U1snRNP70_N
U3_assoc_6
U3snoRNP10
U5_2-snRNA_bdg
U6-snRNA_bdg
UPF0086
UPF0113
UPF1_Zn_bind
UTP15_C
Upf2
Urb2
Urm1
Utp11
Utp13
Utp21
Vault
WGG
Wyosine_form
XendoU
eIF-3_zeta
eIF3_N
eIF3_subunit
eIF3g
efThoc1
mRNA_cap_C
mRNA_cap_enzyme
mTERF
rRNA_processing
tRNA_Me_trans
tRNA_U5-meth_tr

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257

PDCD9
PRP38
PRP4
PTH2
PUF
RNA_pol_L_2
RNase_P_Rpp14
RRM_3
ResIII
Ribonuclease_3
Ribosom_S12_S23
Ribosomal_L11
Ribosomal_L11_N
Ribosomal_L13
Ribosomal_L14
Ribosomal_L18p
Ribosomal_L2
Ribosomal_L22
Ribosomal_L22e
Ribosomal_L23
Ribosomal_L24e
Ribosomal_L28e
Ribosomal_L2_C
Ribosomal_L30_N
Ribosomal_L39
Ribosomal_L4
Ribosomal_L44
Ribosomal_S11
Ribosomal_S14
Ribosomal_S15
Ribosomal_S17
Ribosomal_S17e
Ribosomal_S2
Ribosomal_S27e
Ribosomal_S4
Ribosomal_S5
Ribosomal_S5_C
Ribosomal_S7
Ribosomal_S8e
Ribosomal_S9
SID-1_RNA_chan
SM-ATX
SRP54
SRP54_N
SRRM_C
SYF2
Smg4_UPF3
SpoU_sub_bind
TGT
TRM
TROVE
Translin
TruD
Tudor-knot
Utp14
XRN_N
eIF-3c_N
eIF-5_eIF-2B
eIF2A
eIF2_C
eRF1_1
eRF1_2
eRF1_3
rRNA_proc-arch
tRNA-synt_1c_C

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
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tRNA_bind_2
tRNA_int_end_N2
tRNA_int_endo_N
tRNA_synt_1c_R1
tRNA_synt_1c_R2
z-alpha
zf-C3H1
zf-C3HC
zf-CCHC_2
zf-FPG_IleRS
zf-TRM13_CCCH
2OG-FeII_Oxy
2_5_RNA_ligase
3_5_exonuc
5_3_exonuc
5_3_exonuc_N
ANTAR
APOBEC_C
APO_RNA-bind
ASCH
Agenet
Arb1
Arb2
AviRa
B2
BDHCT
BRK
BTV_NS2
CAT_RBD
CM1
CM2
CPDase
CRS1_YhbY
DALR_2
DEAD_assoc
DUF1325
DUF1669
DUF1866
DUF446
DbpA
EIAV_Rev
Ebola_NP
EndoU_bacteria
Endonuclea_NS_2
Fibrillarin_2
FlbT
FmrO
GAD
GIIM
GidB
HA
Helicase_Sgs1
IF2_N
Init_tRNA_PT
KH_3
KH_4
KH_5
L31
Lactamase_B2
Leu_Phe_trans
MKT1_C
MKT1_N
MRL1
MRP
MetRS-N

1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322

tRNA-synt_1d
tRNA-synt_1e
tRNA-synt_1g
tRNA-synt_2d
tRNA_bind
tRNA_int_endo
zf-CCCH_2
zf-U11-48K
AAR2
AD
ARS2
AdoMet_MTase
Arg_tRNA_synt_N
B5
BOP1NT
BUD22
Btz
Bud13
Bystin
CMS1
CNPase
CPL
CPSF73-100_C
CWC25
Cgr1
DAP3
DBP10CT
DBR1
DCP2
DHHA1
DKCLD
DNA_RNApol_7kD
DRIM
DUF1604
DUF1693
DUF1917
DUF2040
DUF2356
DUF2363
DUF2638
DUF2650
DUF382
DUF947
DcpS
EF1G
EF_TS
EIF4E-T
EIF_2_alpha
EMG1
EXOSC1
Ebp2
Endonuclease_5
Es2
FTO_CTD
FTO_NTD
Fcf2
Fip1
GEMIN8
GIDA_assoc_3
GLE1
GN3L_Grn1
GatB_Yqey
Gcd10p
Gemin6
Gemin7

2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
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Methyltrans_RNA
Mtr2
N-Term_TEN
NRDE-2
NSP10
NSP13
Nab2
Nab6_mRNP_bdg
Nol1_Nop2_Fmu_2
Nsp1
Nup35_RRM
Nup35_RRM_2
PAZ_siRNAbind
PIN
PIN_2
PIN_3
PNPase_C
PORR
PP_M1
Pet127
Phe_tRNA-synt_N
PolyG_pol
Pox_ATPase-GT
Pox_Rap94
Pox_mRNA-cap
Pox_polyA_pol
ProRS-C_2
ProSAAS
Queuosine_synth
RIX1
RMF
RNA12
RNA_Me_trans
RNA_bind_2
RNA_helicase
RNA_lig_T4_1
RNA_ligase
RNA_polI_A14
RNA_pol_3_Rpc31
RNA_pol_A_CTD
RNA_pol_A_bac
RNA_pol_I_TF
RNA_pol_L
RNA_pol_Rbc25
RNA_pol_Rpa2_4
RNA_pol_Rpb1_6
RNA_pol_Rpb1_7
RNA_pol_Rpb2_2
RNA_pol_Rpb2_45
RNA_pol_Rpc34
RNA_pol_Rpc4
RNA_pol_Rpc82
RNA_pol_Rpo13
RNA_pol_delta
RNA_replicase_B
RNaseH_C
RNase_E_G
RNase_P_pop3
RPM2
RRM
RRM_2
RSD-2
RSS_P20
RVT_2
RdRP

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387

Glu-tRNAGln
HAT
HGTP_anticodon2
HRDC
HVSL
HnRNP_M
INTS2
INTS5_C
INTS5_N
IPPT
Img2
Isy1
KH_2
Kin17_mid
Lactamase_B_4
Las1
Lsm_interact
MIF4G_like
MIF4G_like_2
MPP6
MRP-63
MRP-L27
MRP-L28
MRP-L46
MRP-L47
MRP-L51
MRP-S22
MRP-S23
MRP-S24
MRP-S26
MRP-S28
MRP-S31
MRP-S32
MRP-S33
MRP-S35
MRP_L53
MTS
Maelstrom
Mago-bind
Methyltransf_15
Methyltransf_8
Methyltrn_RNA_3
Mitoc_L55
Mpp10
Myb_Cef
NMD3
NOB1_Zn_bind
NOC3p
NOG1
NOGCT
NUC129
NUC173
NUC205
NUDIX_2
NUFIP1
NUFIP2
Noc2
Nop10p
Nop14
Nop16
Nop53
Not1
Not3
Npa1
Nrap

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
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RdRP_1
RdRP_2
RdRP_3
RdRP_4
RdRP_5
RdgC
Rho_N
Rho_RNA_bind
Ribonuclease
Ribonuclease_BN
Ribonuclease_P
Ribosomal_L25p
Ribosomal_L31
Ribosomal_L9_C
Ribosomal_S20p
Ribosomal_S22
Ribosomal_S23p
Ribosomal_S30AE
Ribosomal_S3_N
Ribosomal_S4Pg
Rif1_N
RimK
RimM
RnaseH
Rsm22
S1-P1_nuclease
SEN1_N
SPOUT_MTase
Se-cys_synth_N
SelA
SelB-wing_1
SelB-wing_2
SelB-wing_3
She2p
SnAPC_2_like
SpoU_methylas_C
Stb3
Suppressor_P21
THP2
TPP1
TSNR_N
TilS
TilS_C
Trm56
TruB-C_2
TruB_C
U3_snoRNA_assoc
Utp8
UvrD-helicase
VAR1
Val_tRNA-synt_C
Vmethyltransf
Vmethyltransf_C
WT1
XS
cwf18
dsRNA_bind
eIF3_p135
eIF_4EBP
eIF_4G1
mRNA_triPase
nsp7
nsp8
nsp9
rRNA_methylase

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

388
389
390
391
392
393
394
395
396
397
398
399
400

OB_RNB
P68HR
PC4
PHAT
PHF5
PMC2NT
PNPase
POP1
POPLD
PPR
PRO8NT
PROCN
PROCT

1
1
1
1
1
1
1
1
1
1
1
1
1

788
789
790
791
792
793
794
795
796
797
798
799
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tRNA-Thr_ED
tRNA-synt_1f
tRNA-synt_2e
tRNA_NucTran2_2
tRNA_NucTransf2
tRNA_anti
tRNA_anti-like
tRNA_deacylase
tRNA_lig_CPD
tRNA_lig_kinase
tRNA_synt_2b
tRNA_synt_2f

0
0
0
0
0
0
0
0
0
0
0
0

Table 5.3 RBP census
Supplementary table S3 at:
http://www.nature.com/nrg/journal/v15/n12/full/nrg3813.html#supplementary-information
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Table 5.4 Most abundant RBDs in the human proteome
Domain
RRM
RG/RGG
DEAD
zf-CCCH
KH
GTP_EFTU,
GTP_EFTU_D2,
GTP_EFTU_D3
dsrm
zf-CCHC
LSM
OB_NTP_bind
HA2
G-patch
IBN_N
SAP
TUDOR
RnaseA
zf-C2H2_jaz
MMR_HSR1
KOW
RNase_T
MIF4G
zf-RanBP
NTF2
PAZ
RBM1CTR
PAM2
Xpo1
S1
HGTP_anticodon
tRNA-synt_2b
Piwi
CSD
Ribosomal_L7Ae
RNase_Zc3h12a
Anticodon_1
R3H

Description
RNA recognition motif, single-strand RNA (ssRNA)-binding
RG/RGG box repeats are arginine glycine rich low complexity regions, may bind RNA or act as
protein-protein interaction domains in shuttling
DEAD and DEAH box helicase motif, unwinds RNA (and DNA)
Zinc finger motif type C-x8-C-x5-C-x3-H, ssRNA-binding
KH-homology domain, ssRNA-binding
GTP-elongation factor family, proteins usually consist of 3 structural domains, 2 oligonucleotide
binding domains (D2 and D3) and a GTP-binding domain
Double-stranded RNA binding motif
Zinc knuckle, C-x2-C-x4-H-x4-C, ssRNA-binding
LSM (Like Sm) domain is found in snRNP complexes, bind A/U rich regions
Oligonucleotide/oligosaccharide-binding (OB)-fold, found in DEAD-box helicases in association with
HA2 domain, regulates helicase activity through RNA binding
Helicase-associated domain, found in RNA helicases
G-patch domain, ~48 amino acids with 6 conserved glycines, found in RBPs
Importin-beta N-terminal domain, RNA transport or RBP transport proteins
(SAF-A/B, Acinus and PIAS) motif, RNA/DNA-binding domain
Tudor domain, found in Tudor proteins, Tudor proteins are in complexes with RBPs
RNase A domain, ssRNA endonuclease
JAZ dsRNA-binding protein zinc-fingers, dsRNA-binding
50S ribosome-binding GTPase domain, found in RBPs
KOW (Kyprides, Ouzounis, Woese) motif, found in a variety of ribosomal proteins
RNase T ssRNA exonuclease domain
MIF4G [Middle domain of eukaryotic initiation factor 4G (eIF4G)], RNA- (and DNA-) binding
RNA-binding Ran-binding-protein-like zinc finger
Nuclear transport factor 2 (NTF2) domain, found in RNA export factors
Piwi Argonaut and Zwille (PAZ) domain, posttranscriptional silencing domain, binds siRNAs
C-terminal region found in hnRNPs
PABP-interacting motif PAM2, found in RBPs
exportin 1 domain, RNA transport or RBP transport proteins
S1 ssRNA-binding domain
Anticodon binding domain, found in aminoacyl-tRNA synthetases
tRNA synthetase class II core domain (G, H, P, S and T), core catalytic domain of tRNA synthetases
Piwi domain (P-element induced wimpy testis ), posttranscriptional silencing domain, dsRNA guide
hydrolysis of ssRNA
cold-shock domain, ssRNA/ssDNA binding
domain found in ribosomal proteins L7Ae/L30e/S12e/Gadd45
ssRNA endonuclease domain found in Zc3h12a proteins, member of the NYN domain family
tRNA anticodon-binding domain, found in tRNA synthetases
R3H domain, R-x3-H conserved core, binds ssRNA/ssDNA
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Table 5.5 TF census
Supplementary Table S4 at:
http://www.nature.com/nrg/journal/v15/n12/full/nrg3813.html#supplementary-information
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